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ABSTRACT 
Constipation is the second most commonly self-reported gastrointestinal symptom. On 
the basis of anorectal physiological investigations and colonic transit studies, a sub- 
group of patients with severe intractable symptoms, but without organic disease, will be 
found to have slow transit constipation (STC). STC is a condition of gut dysmotility 
which predominantly affects young women, and may result in surgical intervention with 
variable, often unsatisfactory results. The aetiology remains elusive. 
New aetiological hypotheses for STC were examined following full clinical and 
pathophysiological. characterisation of a large cohort of 130 patients referred to our 
institution over the last 10 years. Aspects of nerve and muscle dysfunction were studied. 
A new scoring system demonstrated some ability of multiple symptoms to discriminate 
STC from other fonns of constipation. Detailed clinical and gastrointestinal 
physiological studies confirmed the heterogeneity of STC patients. Some significant 
physiological differences were detectable between clinically defined sub-groups of 
patients and refuted previous assumptions based on smaller numbers. Detailed 
neurophysiological studies, including quantitative peripheral sensory and autonomic 
testing, provided evidence of a small fibre neuropathy in a proportion of patients with 
STC. Mutational screening of some early-onset cases for a possible congenital 
pathogenetic mechanism, based on the observation that some STC patients had relatives 
with Hirschsprung's disease demonstrated that mutation of 2 important genes now 
implicated in this disorder were not a frequent cause of STC. Serum 
immunoprecipitation assays showed that anti-neuronal ion channel autoantibodies may 
have an as yet unrecopised role in the development of STC in a small proportion of 
acquired cases. An inclusion body myopathy was identifiable in colonic tissue of 
patients with STC, and this appeared to arise secondary to denervation. Further 
knowledge of the single or multiple pathogenetic mechanisms leading to this clinical 
condition may allow more rational or directed therapies aimed at the correction of the 
disease process or processes themselves. 
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INTRODUCTION, LITERATURE 
1 
REVIEW AND AIMS 
1.1 CONSTIPATION 
1.1.1 DEFINITION 
Con. sti. pat. ion [Latin. constipatio a crowding together]. Confinement of the bowels: a 
state of the bowels in which the evacuations are obstructed or stopped (Burchfield & 
Robert, 1987). 
A symptom is a term that people use to describe a sensation or bodily function that 
they perceive as abnormal. Constipation is a symptom reported by patients who 
believe that there is a disturbance of the events that they perceive to comprise normal 
defaecation. As such, patients may associate a wide variety of symptoms with the 
term constipation, including those apparently directly related to defaecation e. g. 
infrequency of bowel action, loss of urge to defaecate, straining, incomplete, painful 
or unsuccessful evacuation, or more diverse symptoms such as abdominal pain, 
bloating or nausea. Without agreement over what constitutes normality or abnormality 
in terms of the type or frequency of symptoms reported by patients, clearly the 
definition of constipation is highly subjective. In practice, patients present when their 
personal situation is unsatisfactory. 
Attempts have been made to define constipation by objective criteria (Drossman et al., 
1982; Whitehead et al., 1991; Thompson et al., 1992). An international workshop 
(Whitehead et al., 1991) defined constipation as the presence of fewer than 2 bowel 
movements per week on average for at least 12 months, or the presence of 2 or more of 
the following complaints for at least 12 months: 
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- Straining on at least 25% of bowel movements when not taking laxatives. 
- Feeling of incomplete evacuation after at least 25% of bowel movements when 
not taking laxatives. 
- Stools less frequent than 3 per week without laxatives. 
A simpler, but also acceptable definition may be that proposed by Drossman et al. 
(Drossman et al., 1982): "two or fewer bowel movements per week and / or straining at 
stool more than 25% of the time". 
1.1.2 EPIDEMIOLOGY OF CONSTIPATION AND COST 
Constipation is the second most commonly self-reported gastrointestinal symptom, 
affecting between 2-34% of populations studied (Drossman et al., 1982; Sonnenberg & 
Koch, 1989; 'AUtehead et al., 1991; Camilleri et al., 1994). The lack of consistency in 
the description of constipation may be responsible for such vast discrepancies in 
estimation of prevalence and epidemiological factors associated with constipation 
(Sonnenberg et al., 1994a). When definitions such as those outlined above are 
employed, the prevalence is probably about 2% (Sonnenberg & Koch, 1989). At all 
ages, there appears to be an increased rate of physician visits by women, while, for both 
sexes, visits increase with age (Sonnenberg & Koch, 1989). 
Most of the economic costs incurred for constipation relate to this high frequency of 
occurrence rather than its medical severity. Annually, constipation results in at least 2.5 
million visits to healthcare professionals in the United States, the largest proportion of 
which are physicians (Sonnenberg & Koch, 1989). Eighty-five percent of patients 
receive at least one prescription for a medication, most commonly laxatives. Based on 
United States' data, the average direct cost ($73) and indirect cost ($6) of constipation 
per patient per year led to a total cost in 1985 of over $350 million (Sonnenberg et al., 
1994a). If the costs of self-prescribed medication and evacuation aids (estimated to be 
used by 12% of the population) had been added to this figure, the total would have 
exceeded $650 million per year. This figure is increasing: in 1994, over $725 million 
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were spent in the United States on laxatives alone (Wald, 1999). 
1.1.3 CAUSES OF CONSTIPATION 
There are a wide range of causes of constipation (Table 1.01a), and numerous methods 
of their classification. In general, patients can be divided into those whom routine 
clinical practice (clinical / radiological / endoscopic examination with routine 
biochemical tests) defines a cause, leaving a sub-group of patients with intractable 
symptoms but no definable organic pathology. This second group constitutes what is 
sometimes referred to as "idiopathic constipation" in recognition of the absence of a 
defined cause, and represents a major part of a group of gastrointestinal conditions 
loosely termed "functional bowel disease". This group itself may also be subdivided on 
the basis of specialist investigations (Table 1.01b). 
1.2 SLOW TRANSIT CONSTIPATION (STC) 
1.2.1 DEFINITION 
Slow tTansit constipation is a physiological description based on the observation in a 
proportion of patients with severe constipation that there is a reduction in the rate of 
progress of colonic intraluminal contents as demonstrated by transit studies (below). 
The disorder encompasses patients with idiopathic constipation (the majority), as well as 
some with a defined systemic cause. The condition is probably synonomous with 
"chronic intestinal stasis" first described by Arbuthnot Lane at the turn of the century 
(Lane, 1908 & 1909), and possibly with some subsequent descriptions of atonic bowel 
(Trumble, 1934; Trumble, 1935; White et al., 1940). 
Whilst disturbances of transit do occur with megacolon and megarectum, the tenn slow 
transit constipation is used for patients with a nonnal calibre colon (Preston et aL, 
1985b; MacDonald, 1993). 
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Table 1.01 
a. Classification of defined structural or systemic causes of constipation 
GASTROINTESTINAL CAUSES 
Colorectal Mechanical obstruction 
Megacolon or megarecturn 
Benign and malignant 
neoplasms, other strictures: 
e. g. inflammatory 
Hirschsprung's disease 
Idiopathic 
Neurological or other 
Anorectal Anal atresia or malformation 
Hereditary internal anal sphincter hypertrophy 
Anal stenosis 
Rectal prolapse 
Large rectocele 
Solitary rectal ulcer syndrome 
EXTRAGASTROINTESTINAL CAUSES 
Endocrine / 
metabolic 
Neurological 
PsyChological 
Drugs 
Hypothyroidism 
Hypercalcaemia 
Porphyria 
Degenerative CNS diseases 
Spinal lesions 
Damage to sacral parasympathetic nerves 
Autonomic neuropathy 
Severe endogenous depression 
Eating disorders 
Opiates 
Antidepressants 
Anticholinergics 
Anticonvulsants 
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b. Classification offunctional disorders causing constipation 
Simple constipation Lifestyle exercise 
("reversible") mobility 
Diet fibre 
hydration 
Outlet obstruction 
Ineffective straining 
Normal transit 
constipation 
Idiopathic slow 
transit constipation 
Dynamic structural rectocele 
abnormalities intussusception 
Idiopathic outlet obstruction anismus 
Failure of coordinated 
abdominal / diaphramatic contraction 
to raise intrapelvic pressure 
tt constipation predominant 
irritable bowel syndrome " 
(i colonic inertia " 
The fact that a diagnosis of STC is entirely dependent on the results of a single 
physiological observation cannot be over-stressed. Such a definition might in reality be 
guilty of pigeonholing patients with multiple pathologies into a single group, either for 
descriptive convenience or to aid clinical decision making. Of particular concern are 
observations made in man and experimental animals that painless rectal distension can 
inhibit proximal intestinal motility and transit (Pearcy & Van Liere, 1926; Youmans & 
Meek, 1937; Kreulen & Szurszewski, 1979; Youle & Read, 1984; Kellow et al., 1987; 
Klauser et al, 1989; Brugere et al., 1991; Boj6 & Cassuto, 1992; Wingate, 1993; Gue et 
al., 1995). Conversely, the cut-offs used to denote abnormality on transit estimation 
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might simply select for the severe end of a continuous spectrum of biologically similar 
patients, placing these into one group, whilst excluding others. Nevertheless, the 
assumption that STC represents a separate clinical entity is now so well accepted in the 
literature and clinical practice, that for the purposes of current studies, including those 
within this thesis, it has been regarded as afait accompli. 
1.2.1.1 Slow transit constipation: a group disorder 
It is well recognised that heterogeneity of clinical presentation exists amongst patients 
with STC (Preston & Lennard-Jones, 1986; Waldron et al., 1988; MacDonald, 1993). 
In the majority of patients, symptoms arise de-novo in childhood, and these have been 
labelled chronic and idiopathic (Preston & Lennard-Jones, 1986; Waldron et al., 
1988). A proportion of patients with intractable slow transit constipation present in 
later life. Some of these patients will have no obvious trigger for their complaint 
(Waldron et al., 1988), whereas others follow events such as hysterectomy (Roe et al., 
1988; Vierhout et al., 1993) or childbirth (MacDonald et al., 1997). STC has similarly 
been demonstrated in patients with endocrine (Iber et al., 1993; Maleki et al., 1998), 
CNS (Devroede et al., 1979; Weber et al., 1987; Beuret-Blanquart et al., 1990; 
Keshavarsian et al., 1995; Leduc et al., 1997; DeLooze et al., 1998) and connective 
tissue diseases (Basilisco et al., 1993). The terrn STC therefore probably encompasses 
a range of disorders, grouped for convenience by the finding, in a normal calibre large 
bowel, of a definable, measurable abnormality i. e. prolonged transit time. Whilst the 
clinical end-point is almost indistinguishable between patients with STC (MacDonald, 
1993), heterogeneity, including that of aetiology, is likely to exist, and STC should be 
probably be considered as a "group disorder". 
1.2.1.2 Transit studies 
Methods used to measure gut transit may be classified as radiological, calorimetric, 
particulate, chemical, and isotopic (Hinton et al., 1969). Historically, bismuth 
subnitrate and barium sulphate have been used as radiological markers (Hurst, 1919, 
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Barclay, 1936), insoluble coloured powders and coloured glass beads (Alvarez & 
Freelander, 1924) as particulate markers, barium, chromium and copper compounds 
as chemical markers (Alvarez & Freelander, 1924), and "Cr-labelled sodium 
chromate as an isotope marker (Hansky & Connell, 1962; Hinton et al., 1969). 
Radioopaque marker studies 
The first description of methodology, employing radioopaque polythene cylindrical 
pellets, was that of Hinton et al. (Hinton et al., 1969) who measured the disappearance 
of 20 such markers from the gut and their appearance in the stool by serial 
radiographs. They were able to establish that this marker was not absorbed, and was 
completely recoverable in the stool. Transit rate of the markers was thought 
comparable to that of food residue because of similar density of the markers to stool, 
and there was no evidence to suggest that the markers affected gut activity (a criticism 
made of previous methodologies). In addition, they determined a normal range for 
males, who passed the first marker by 3 days,, and 80% of the markers by 5 days. 
Nonnal ranges for both men and women have subsequently been determined, with 
abnormal transit defined as retention of more than 20% of markers on a single plain 
radiograph at 5 days (Bassotti et al., 1988; Evans et al., 1992; Roberts et al., 1993) 
(Figure 1.01a). 
The study of marker retention with a single abdominal radiograph allows the 
distinction between those patients in whom the transit is normal and those in whom it 
is prolonged (Hinton et al., t969; Evans et al., 1992; Roberts et al., 1993). Attempts 
have been made to extend the technique to assess segmental colonic transit times 
using a series of abdominal radiographs following a single ingestion of markers 
(Arhan et al., 1981), as first described by Martelli et al. (Martelli et al., 1978). The 
method has been simplified and the radiation exposure of daily X-ray films reduced 
by giving either different shaped (Metcalf et al., 1987), or even simpler, identical 
markers (Chaussade et al., 1989) on three successive days, and taking an X-ray on the 
4" day after ingestion. The utility of such studies in the determination of the pattern of 
colonic transit has been shown in healthy volunteers (Metcalf et al., 1987), but 
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Figure 1.01 (a) Radio- 
opaque marker study of a 
patient with STC. All 50 
markers (shapes) are 
retained at 96 hours. 
18 h -, 24 h 
42 h 48 h 
Figure 1.01 (b) I"In-DTPA 
radloisotpe scintigraphy. Normal 
healthy control with complete 
isotope excretion by 48 hours, and 
a patient with STC, in which 
isotope progresses slowly around 
the whole colon with no focal areas 
of hold-up. 
18 h 
66 h 
24 h 
72 h 
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remains contentious for patients with constipation (van der Sijp et al., 1993). In 
particular, because mass movements are infrequent events in patients with 
constipation (Bassotti et al., 1988; see below), a large number of frequent serial 
radiographs would be required to adequately monitor segmental transit, and would be 
unacceptable with respect to radiation exposure (van der Sijp et al., 1993). 
Isotope transit studies 
Radioisotopes are well suited to the study of regional transit in constipated patients 
because they allow unlimited numbers of observations at a low radiation dose. Whilst 
the use of isotopes (radionuclides) to study intestinal transit were first described using 
"Cr-labelled sodium chromate in 1962 (Hansky & Connell, 1962), the first 
description using 1111n DTPA was made in 1986 by Kreksky et al. (Krevsky et al., 
1986). This, and subsequent studies (Kamm et al., 1988; Krevsky et al., 1989), 
installed the radionuclide directly into the large bowel by intubation of the caecum. 
Subsequently, this methodology has been replaced by oral administration of the 
radionuclide (Roberts et al., 1993; van der Sijp, 1993; McLean et al., 1995; Maurer & 
Krevsky, 1995). In normal subjects, approximately 70% of radioisotope is excreted by 
48 hrs (Krevsky et al., 1986), with total excretion by approximately 70 hours (Roberts et 
al., 1993). In contrast the majority of patients with STC show significant slowing of 
isotope progression at 48 hours with minimal faecal elimination occuring in the duration 
of the study (96 hours) (Roberts et al., 1993) (Figure 1.01b). 
1.2.2 EPIDEMIOL 0GY 
It is estimated that patients referered for specialist investigation for severe intractable 
symptoms constitute approximately 1% of all patients with constipation (Camilleri et 
al., 1994). Large published series indicate with appropriate physiological testing, that 
approximately 15-30% of this group will be found to have STC (Pemberton et al., 
199 1; de Graaf et al., 1996; Surrenti et al., 1995; Nyam et al., 1997; Glia et al., 1998). 
Since the overall prevalence of constipation may be between 2% and 34% (see 
above), this gives an estimated prevalence of STC of approximately 3-100 / tOO, 000. 
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STC predominantly affects women, comprising 70-100% of published series (Read et 
aL , 1986; Preston et aL, 1986; Chaussade et aL , 1989). 
1.2.3 CLINICAL FEATURES AND ROUTINE INVESTIGATIONS 
The clinical history elicits any triggering events (e. g. pelvic surgery). The long duration 
of symptoms usually noted at presentation reflects the nature of onset, which is in the 
majority of patients in early childhood or teenage years. The main symptoms usually 
include difficulties with defaccation itself, and abdominal pain and bloating. Whilst 
generally there has been poor correlation between specific symptoms and the presence 
of slowed colonic transit as compared with other causes of constipation (Grotz et al., 
1994), patients with STC often report a loss of defaecatory urge with a marked 
infrequency of bowel opening, with many days, or even weeks between successive 
bowel actions. In addition, a high proportion complain of general malaise and lassitude, 
and some have upper gastrointestinal symptoms such as nausea. These symptoms have 
commonly come to dominate the patient's life and greatly impair its quality (Preston 
and Lennard-Jones, 1986). Patients with STC often give a past history of previous pelvic 
and abdominal surgery, and a family history of constipation is present in about half of 
cases (Chaussade et al., 1989). Most patients with STC will have tried several laxatives 
with little or short-lived benefit, and several will have tried high doses of powerful 
stimulant laxatives. 
Abdominal examination may reveal faecal loading, or gaseous distension, but this and 
examination of the pelvis by digital rectal examination and sigmoidoscopy are usually 
unremarkable. Abdominal plain X-ray and barium studies may show a long redundant 
colon (Brummer et al., 1962) and the latter will exclude megabowel (Preston et aL, 
1985b). It is customary to perform routine blood tests to exclude an endocrine or 
metabolic cause of constipation, although these are rarely present. 
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1.2.4 MANAGEMENT 
1.2.4.1 Current therapies for STC 
Non-surgical treatment 
In the first instance, patients should be given reassurance and advice that dangerous 
disease has been excluded, and attention should be made to lifestyle, fluid intake, and 
dietary alterations as well to psychological or behavioural aspects. 
Laxatives are effective for some patients especially in the short-term, but long- 
duration high dose stimulant laxatives should be used with caution because of the 
unproven, but potentially deleterious effect on the colon (see section 1.6.6). Bulking 
agents (bran, ispaghula, sterculia) are usually not effective in severe idiopathic 
constipation. Stool softeners (arachis oil, docusate sodium, liquid paraffin, given as an 
enema) may be of value in assisting evacuation of stool. Stimulant laxatives induce 
secretion and propulsive movements in severely constipated patients (Kamm et al. , 
1992), and fall into 3 groups: anthranoids e. g. senna, aloe and danthron; polyphenol 
derivatives e. g. phenolphthalein, bisacodyl and sodium picosulphate, and 
miscellaneous compounds e. g. docusate sodium (also a stool softener). Another group 
of compounds are the osmotic laxatives (mannitol, lactulose, magnesium salts etc. ), 
which increase the fluid content of the stool and facilitate expulsion of the bolus by 
lubication and softening. 
Biofeedback, a form of behavioural therapy, has been used for a long time to 
strengthen the pelvic floor in patients with faecal incontinence (Engel et al., 1974). 
More recently, it has been utilised in patients with obstructed defaecation with 
variable success rates from 8- 100% (Rieger et al., 1997; Gilliland et al., 1997). 
Inappropriate pelvic floor contraction in many of these patients during attempted 
defaecation formed the original focus for behavioural therapies, and most groups have 
restricted the use of biofeedback to patients with normal transit and paradoxical 
puborectalis contraction during straining (Wexner et al., 1992; Karlbom et al., 1997). 
35 
PhD Thesis 2000 
Such therapy may however be equally effective in symptom reduction for patients 
with STC (Chiotakakou-Faliakou et al., 1998), and may even normalise measured 
transit time (Koutsomanis et al., 1994). Indeed, the St Mark's group (Chiotakakou- 
Faliakou et al., 1998) use biofeedback as a first-line treatment for all patients 
presenting with intractable constipation (Michael Kamm; personal communication). 
Psychotherapy has been shown to have a role in the treatment of normal-transit 
constipation (IBS) (Camilleri, 1999), and may have been a contributory factor in the 
success of some trials of behavioural therapies such as biofeedback, especially for 
pelvic floor disorders. In STC, the role of psychogenic factors is small in comparison 
with these pathophysiological groups (Wald et al., 1989; Grotz et al., 1994; see 1.6.7 
for detail). No specific data exist to confirm or refute the effect of psychotherapy for 
STC patients and treatment is generally directed at possible modification of the 
disordered transit itself (Wald et al., 1989). 
Surgeryfor slow colonic transit 
Because most medical lines of management are relatively ineffectual, surgery may be 
contemplated. Since the beginning of the century, surgery for STC has been loosely 
based on a concept of the pathology (colonic stasis) (Albuthnot Lane, 1908; Albuthnot 
Lane, 1909). Colectomy and ileorectal anastomosis has remained the treatment of choice 
for STC in preference to other surgical options, such as limited resection (Preston et al., 
1984a). The outcome from such surgery is highly variable, with widespread variability 
in satisfaction rates, incidences of post operative complications and functional outcome. 
In a review performed by the author (Knowles et al., 1999), 32 studies (1981-1998) 
which had fulfilled the entry criteria of (1) publication in the English language, (2) 
description of outcome of : ý! 10 patients with STC, (3) excision of all or part of the 
colon, with restoration of bowel continuity by primary anastomosis, i. e. subtotal or 
segmental colectomy, were analysed. Overall documented patient success / satisfaction 
rates varied greatly from 39% (Hawagewa et al., 1999) to 100% (Pemberton et al., 
1991). Post-operative morbidity rates from small bowel obstruction (with or without re- 
operation) varied from 2% to 71% (median 18%), and resulted in re-operation in 0% to 
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50% of patients (median 14%). Functional outcome measures were often poorly 
documented, and were also highly variable. Poor functional outcome related principally 
to the incidence of diarrhoea: range 0- 46% of patients (median 14%), incontinence: 
range 0- 52% (median 12%), recurrent constipation: range 0- 33% (median 7%), and 
abdominal pain: range 0- 90% (median 39%). As a result of poor functional outcome, 
permanent ileostomy was formed in up to 28% of patients (Hasegawa et al., 1999), 
(median 5%, range 0- 28%). It is now generally agreed that surgery for STC should 
probably only be considered in a highly selected group of patients who fulfil certain 
clinical and physiological criteria (Pfeiffer et al., 1996; Knowles et al., 1999) 
1.2.4.2 Novel therapies for STC 
The search continues for pharmacological agents that might be able to regulate colonic 
motility. Initial enthusiasm for the known enterokinetic erythromycin (Minocha et al., 
1995), has been tempered by its failure to have a prokinetic effect on distal colonic 
motility (Bassotti et al., 1998). The prostaglandin analogue, misoprostol has been shown 
to be of some value (Soffer et al., 1994), and continues to be used, especially in the 
U. S. A (Arnold Wald; personal communication), although side-effects are a problem 
(Roarty et al., 1997). Other recently considered agents have included cholecystokinin- 
like peptides, and opioid antagonists (see section 1.6.5), neither of which have shown 
great future promise (BrieJer et al., 1999). 5-hydroxytryptamine (5-HT) agonists 
continue to receive much attention. Cisapride, a gastrointestinal motility stimulant and 
5-HT4 receptor agonist, accelerates colonic transit and is beneficial in a subset of 
constipated patients (Longo et al., 1995), but its effects are only moderate and therefore 
it is not considered a standard treatment (Muller-Lissner, 1995). Novel, more selective 
5-HT4 receptor agonists, such as prucalopride are currently undergoing evaluation. 
Prucalopride has been shown to induce propulsive contractions in a dose-dependent 
manner in dogs (BrieJer et al., 1997), accelerate transit and increase stool frequency in 
healthy subjects (Emmanuel et al., 1998), and reduce symptoms in patients with chronic 
constipation including STC (Felt-Bersma, 1999). 
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Resarch into the pharmacology of cardiac arrhythmias has focussed on drugs that affect 
voltage-gated channels involved in generating diastolic depolarisation. Ion channels 
specifically involved in the regulation of intestinal motility, especially slow-wave 
activity, have not as yet been identified, but it seems likely that such pharmacological 
modification of intestinal pacemaker activity may be possible in the future (Huizinga et 
al., 1997). The importance of interstitial cell function is discussed below, and that of ion 
channels in chapter 7. 
1.3 NORMAL COLONIC CONTRACTILE ACTIVITY 
Gastrointestinal (GI) motility is a term used to describe the mixing and propulsive 
movements of the alimentary canal, responsible for the transit, digestion and 
absorption of intraluminal food contents. In patients with STC, non-nal defaecation is 
compromised by an abnormal slowing of colonic contents (transit). Since transit is 
dependent upon the normal contractile functions of the colon, STC should be thought of 
as a motility disorder. 
In man, the contractile activity of a viscus can be measured by recording changes in 
intraluminal pressure i. e. manometry, and information regarding the ability of the 
intestine to propel its contents, inferred from this data. Whilst a variety of techniques are 
available, the most commonly employed are perfused tubes or catheter mounted strain 
gauges. Advances in the placement and positioning of new devices by colonoscopy, and 
in the use of solid state transducers linked to portable recording systems with enhanced 
memory capacities, now enable 24 hour ambulatory studies of colonic motility to be 
performed. However, the majority of studies to date have been carried out in the left side 
of the colon only, under circumstances where basal physiological conditions were not 
usually observed (non-ambulant subjects, prepared bowel) (e. g. Richie et al., 1962; 
Frexinos et al., 1985). Monitoring of proximal colonic motility has rarely been achieved 
(Soffer et al., 1989; Lemann et al., 1995), and prolonged recordings of colonic motility 
are scant (Narducci et al., 1987; Soffer et al., 1989; Crowell et al., 1991; Lemann et al., 
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1995). The reproducibility and methods used for interpretation of data produced by such 
studies still require validation. 
The term motility encompasses various patterns of motor activity in the digestive 
tract. In general, the colon can be considered to have 3 broad categories of motor 
activity, which are considered to be the motor correlates of the movements required to 
subserve the functions demanded by this organ. 
1. Individual phasic contractions Mixing (pendicular or segmental) 
(short and long duration) 
2. Organised groups of contractions 
e. g. migrating & non-migrating 
motor complexes 
3. Specialised high amplitude 
propagated contractions 
movements 
Propulsion over short distances or 
further mixing 
Mass movements / defaecation 
Normal colonic motility is characterised by a relative background quiescence with a 
general infrequency of motor events, providing an optimal environment for water and 
electrolyte absorption. Phasic contractions are the basic unit of contractile activity 
throughout the GIT. In the colon, the individual phasic contractions are of 2 types: short- 
duration (<15 secs), and long-duration (40-60 secs) (Sarna, 1991). Such contractions are 
primarily non-propagating or propagate only short distances, and these appear to 
facilitate mixing and mucosal absorption. The role of organised (periodic) groups of 
contractions in the colon (Narducci et al., 1987) is less clear than in the small intestine, 
but these probably spread faeces over a short distance, predominantly in the caudad 
direction (Sarna 1991). The colon also has specialised high amplitude propagated 
contractions (HAPCs), which are the motor correlates of mass movement waves 
(Holzknect, 1909; Richie et al., 1962; Hardcastle & Mann, 1968; Torsoll, 1971; 
Narducci et al., 1987), and which propel intraluminal contents rapidly over large 
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distances. These occur spontaneously, approximately 3-6 times per day (Narducci et 
al., 1987; Soffer et al., 1989; Crowell et al., 1991; Lemann et al., 1995), originate 
mainly in the proximal colon, and also accompany most episodes of spontaneous 
defaecation (Karaus & Sarna, 1987; Scott et al., 1995). In addition, the colon displays 
tonic contractile activity (Steadman et al., 1991). In health, phasic activity, tonic 
activity, and HAPCs increase in frequency after awakening from sleep, or eating 
(Narducci et al., 1987; Soffer et al., 1989; Crowell et al., 1991). 
1.4 THE CONTROL OF COLONIC MOTILITY 
The mechanisms that control gastrointestinal motility have been studied more 
extensively in the foregut than hindgut, and more completely in experimental animals 
than in man. Nevertheless, the following general points can be made about the control of 
human colonic motility. 
Movements of the colon have underlying patterns of contractile activity which are the 
44motor correlates" of each movement type. These motor correlates in turn have 
underlying electric events which are termed the "myoelectrical correlates" of motor 
activity. Such electrical events arise on a background of spontaneous, intrinsic "pace 
making" electric activity which is omnipresent (Figure 1.02). 
Three main control mechanisms co-operate in the regulation of the normal transit of 
contents through the gastrointestinal tract. These are 
Myogenic Control systems lying within the musculature itself 
Neural Enteric, autonomic, and central nervous system influences 
Chemical Neurotransmitters, hormones and other peptides 
Although they are often considered individually for convenience (including in the 
description below), these control systems do not act independently, but are closely 
functionally intertwined. 
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Whilst some motor events are spontaneous, many are activated by intraluminal 
distension or chemical stimuli. Such reflex events are of primary importance to the 
transit of colonic contents, and have been studied in health and disease. 
MYOGENIC CONTROL 
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1.4.1 MYOGENIC CONTROL MECHANISMS 
The muscle coat of the gut is a continuous structure made of smooth muscle. Intestinal 
muscle cells are small uninucleate, spindle shaped cells with a high surface area to 
volume ratio, and which contain the necessary organelles and filaments (actin and 
myosin) for the conversion of chemical energy into shortening. Muscle cells lie 
approximately parallel to each other forming sheet-like layers. In the colon, two layers 
are superimposed, with their cells orientated at right angles to each other to form the 
circular (inner), and longitudinal (outer) musculature. The latter is very attenuated 
except in 3 regions around the circumference (taeniae), and the circular muscle forms 
the bulk of the muscularis propria. Whilst the longitudinal muscle and circular muscle 
layers have been shown in vitro to have different myoelectric and motor activities (El- 
Sharkawy 1983; Huizinga et al., 1983), it is likely that they function as a syncytium in 
vivo (Huizinga et al., 1983), and are considered as such in this description. 
The gastrointestinal tract, when activated by intestinal contents or neural activity, 
produces local contractions lasting several seconds, each of which is followed by 
relaxation in a regular periodic manner. These contractions cause a local, partial luminal 
occlusion, which propagates in an arboral direction and moves gut contents anally. The 
frequency and propagation characteristics of the contractions are characteristic for each 
organ, and are governed by intrinsic omnipresent, electrical membrane-potential 
oscillations, the so-called "slow-waves" or electric control activity (ECA) (frequency = 
2-13 / min in human colon) (Sama, 1991). The slow-waves represent the pacemaker 
activity activity of the gastrointestinal contractile activity, and translate an excitatory, 
usually neural, stimulus into orderly peristaltic movements. 
Slow-waves are generated by specialist cells, the interstitial cells of Cajal (ICCs) 
(Thuneberg, 1982; Sanders et al., 1989; Huizinga et al., 1995; Sanders, 1996). These 
cells were first described more than 100 years ago (Cajal, 1893) as small fusiform or 
stellate cells that formed networks in gastrointestinal tissues. Subsequent work 
(Christensen et al., 1987) has established these to be unique speciallsed fibroblast-like 
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cells which lie between the axonal plexuses of the gut and the smooth muscle itself In 
the large intestine they are found particularly in relation to a dense axonal plexus which 
lies in the submucosa, immediately adjacent to the muscularis propria, (Stach's plexus 
externus extremus) (Stach, 1972), but are also found in association with the myenteric 
plexus. [An additional plexus is found within the circular muscle layer in the small 
intestine]. 
The slow-wave activity generated by ICCs controls short-duration contractions. Such 
temporally and spatially discoordinated activity, which predominates in the colon, is 
perfectly suited to fulfil the colonic motor function of mixing of intraluminal contents 
(Sarna, 1991). The significance of slow-wave activity to transit has been shown in 
murine models in which slow wave-driven peristalsis is absent (Ward et al., 1994; 
Huizinga et al., 1998). In addition to slow waves, high frequency waves are also 
generated, the so called contractile electrical complex (CEQ (frequency == 25-40 / min) 
(Sarna, 1991). These are intermittent rather than omnipresent, and probably require 
neural or chemical stimulation to be present (Huizinga and Daniel, 1986; Sarna, 1991). 
Unlike the ECA, the CEC controls long duration contractions. 
1.4.2. NE UR 0 GENIC CONTR OL ME CHA NISMS 
Neural control mechanisms are integral to the generation of propulsive activity in the 
gastrointestinal tract. Afferent nerves generate and convey, via specialised endings, 
visceral sensory information. Efferents control motility but also have modulatory roles 
in secretory and absorptive functions. 
The enteric nervous system is a collection of neurones that control the motility, 
exocrine and endocrine secretions and microcirculation of the gastrointestinal tract 
(Furness & Costa, 1987, Wingate, 1993). It can further be considered to have 2 
components: intrinsic neurones whose components are intramural, and lie in plexuses 
which consist of ganglia (clusters of tightly packed nerve cell bodies and glial cells), 
connected by intraganglionic fascicles of nerve fibres ansing principally from the 
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nerve cells, and extrinsic neurones whose cell bodies lie extra-IntestInally, though 
they may subsequently follow an intramural course. Extrinsic neurones are generally 
considered to be part of the autonomic nervous system (ANS), which is in turn 
influenced by the central nervous system ý(CNS). The hierarchy of neural control in the 
colon, like the rest of the gastrointestinal tract, may be the ENS > ANS > CNS 
(Wingate, 1993) (Figure 1.03). 
Fig 1.03: Autonomy of the ENS in the control of motility. Motor programmes are 
generated within the ENS and the contribution of extrinsic innervation is limited to 
modulation. The hatched plane represents the ganglionic layer of the myenteric 
plexus. The majority of intrinsic, post-ganglionic fibres are now known to be non- 
adrenergic, non-cholinergic (NANQ as shown. With kind permission from Wingate, 
1993. 
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The ENS exerts almost continuous spatial and temporal control of colonic contractions, 
whereas the ANS and CNS chiefly modulate ENS activity, apart from during 
defaccation, where the CNS input is transmitted directly through autonomic nerves 
(Sarna, 1991, Wingate, 1993). The ENS participates in the reflex activity which is of 
particular importance to the generation of propulsive contractile activity. 
Neural control provides the necessary stimulation, by the release of neurotransmitters, 
for the depolarisation of the muscle membrane to yield electrical complexes, which 
control propulsive contractions (Figure 1.02). Postganglionic highly branched axons 
reach the effector smooth muscle where they become beaded or varicose. 
Neurotransmitters are released from these varicosities during impulse conduction. Co- 
transmission i. e. the release of more than one transmitter from neurones (Burnstock, 
1976), is very common in the ENS, and it is likely that many of these substances have 
neuromodulatory effects on the release or actions of primary transmitters, and / or 
have trophic roles. Whilst nerves can directly stimulate smooth muscle cells, ICCs 
also function in conveying (Thuneberg, 1982), and possibly amplifying (Publicover et 
al., 1993) neural stimuli. 
The morphology, neurochemistry and function of the ENS is a complex and rapidly 
expanding subject in itself For the purposes of this thesis, neural influences on 
colonic contractile activity are only discussed in more detail with relevance to the 
pathophysiology of STC. 
1.4.3 CHEMICA L CONTR OL ME CHA NISMS 
Chemical control of intestinal motility refers to the modulation of contractile activity 
via the release of chemical substances from nerve varicosities or endocrine-paracrine 
cells. An ever expanding number of such chemicals have been isolated, which may act 
directly on smooth muscle, pre-synaptic or post-synaptic enteric neurones, 
paravertebral or prevertebral ganglia, the spinal cord, or the CNS, to stimulate or 
inhibit contractions of the gut. They may work as endocrine, neurocrine, or paracrine 
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substances to modify contractile activity. The chief substances include established 
neurotransmitters, amines, peptides and fatty acid derivatives, such as prostaglandins 
and sex steroids. Such chemical modulators of motility are discussed with respect to 
postulated alterations in their function that might underly the aetiology of STC. 
1.5 PATHOPHYSIOLOGY OF SLOW TRANSIT CONSTIPATION 
1.5.1 PHYSIOLOGICAL ABNORMALITIES INSTC 
The finding of an overall reduction in colonic transit, which defines STC, has been 
discussed. Some further information may also be attained from transit studies. It is 
possible to distinguish between a generalised colonic or distal colonic delay (Krevsky 
et al., 1989; Roberts et al., 1993), and in patients with the same pattern of transit 
disturbance, the progression of the radionuclide marker is slower in some than others 
(Kamm et al., 1988; Krevsky et al., 1989; Roberts et al., 1993; van der Sijp et al., 
1993). The significance of these observations with respect to either the pathophysiology 
of STC, or its treatment, especially in terms of choice of surgical resection remains 
unclear. 
1.5.1.1 Colonic contractile activity 
Whilst transit studies are a relatively safe and simple method of estimating colonic 
propulsive contractile function, they must be regarded as an indirect measure of such 
activity. The use of manometric techniques (1.3) has allowed the direct study of colonic 
contractile activity in patients with STC. The paucity of data in man with respect to the 
normal pancolonic measurement of contractile activity, especially in the ambulant state 
has been noted and care must be taken therefore in reaching conclusions about studies in 
patient groups. 
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Pancolonic studies 
Few publications have specifically selected constipated patients for study of pan- 
colonic motility on the basis of delayed transit (Bassotti et al., 1993; Bassotti et al., 
1994; Bassotti et al., 1998; Bassotti et al., 1999a; Bassotti et al., 1999b). These 
studies have shown a reduction in the number, amplitudeand duration of propulsive 
high amplitude waves (HAPCs) in patients with STC, although these findings had 
also been observed in constipated patients with severe idiopathic constipation in 
which the transit was not specified (Kamm et al., 1988), and also in constipated 
patients with normal transit (Bassotti et al., 1994). 
The gastrocolonic response has been shown to be impaired in patients with severe 
idiopathic constipation (Bassotti et al., 1988; Bazzocchi et al., 1990). In one study, 
the early post-prandial motor response was absent in patients with slow transit (Kamm 
et al., 1988). In contrast, no differences have been observed in the motor response to 
sudden awakening (Bassotti et al., 1999a). A reduced colonic motor response to 
intraluminal bisacodyl has been demonstrated in some patients with STC (Kamm et al., 
1988). This observation, has however been refuted by more recent studies of patients 
with severe idiopathic constipation (Kamm et al., 1992) and with proven STC, in which, 
the majority (88%) had an intact bisacodyl response (Bassotti et al., 1999b). Motor 
responses following intravenous administation of the anticholinesterase, edrophonium, 
were reduced in patients with STC (Bassotti et al., 1993). 
Rectosigmoid studies 
There have been a number of studies of rectosigmoid motility in intractable 
constipation, although few papers specifically selected only patients with STC. These 
and other studies had paradoxical findings: in some, overall motility (Waldron et al., 
1990; Ferrara et al., 1994), post prandial response (Reynolds et al., 1987; Grotz et al., 
1993; Ferrara et al., 1994; responses to awakening (Ferrara et al., 1994) and responses 
to cholinergic stimulation (Grotz et al., 1993) and intrarectal bisacodyl (Preston & 
Lennard-Jones, 1985; Shouler & Keighley, 1986) were all reduced. However, other 
studies have shown normal basal levels of rectosignioid motility (Shouler & Keighley, 
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1986; Reynolds et al., 1987; Waldron et al., 1988), and a non-nal response to cholinergic 
stimulation (Reynolds et al., 1987) or bisacodyl (Kamm et al., 1992). A reduced tone in 
the left colon has been suggested by one study (O'Brien et al., 1996). 
1.5.1.2 In-vitro physiological studies of colonic tissue 
The results of organ bath studies of colonic muscle from patients with constipation have 
been conflicting. Hoyle et al. (Hoyle et al., 1992) found little difference overall between 
the electrical properties of the circular smooth muscle of the sigmoid colon from 
patients with idiopathic STC and those of controls. Slater et al. (Slater et al., 1997) 
suggested that denervation hypersensitivity and an intrinsic myopathy were present, on 
the basis of altered carbachol responses with or without the addition of cisapride. In 
addition to the inclusion of only 5 patients, the interpretations reached by this study are 
not clear. Further in vitro studies have found alterations in the release of 
neurotransmitters to field stimulation with a reduced release of acetylcholine (ACh) 
(Burleigh et al., 1988), and increased release of inhibitory neurotransmitters (NO, ATP) 
(Mitolo-Chieppa et al., 1998). Alterations in the contractile responses to 
neurotransmitter application have similarly been demonstrated with a reduced 
contraction in response to ACh, and increased relaxation after inhibitory 
neurotransmitter application (Mitolo-Chieppa et al., 1998). 
1.5.1.3 Anorectal and pelvic floor physiological abnormalities 
Abnormalities of rectal emptying with anatomical abnormalities (Turnbull et al., 1988; 
Wald et al., 1990; Karlbom et al., 1995; MacDonald et al., 1997), rectal hyposensation 
(Read et al., 1986; Akervall et al., 1988; Waldron et al., 1988; Kamm & Lennard-Jones, 
1990), or paradoxical puborectalis contraction (Turnbull et al., 1986, Shouler & 
Keighley; 1986; Wald et al., 1990; Miller et al., 1991) have been well documented in 
patients with STC. Similarly, abnormalities of sphincteric function have been reported 
using anorectal manometry (Read et al., 1986; Wald et al., 1990). These abnormalities 
may equally be found in patients with constipation without STC (Turnbull et al., 1986; 
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Wald et al., 1990; Miller et al., 1991; Wald et al., 1993; Karlbom et al., 1995), and 
indeed, also in subjects with no evacuatory symptoms (Shorvon et aL, 1989; 
Voderholzer et al., 1997). 
1.5.1.4 Upper gastrointestinal motility 
The presence in some patients of upper gastrointestinal symptoms prompted the 
investigation of patients with STC for upper gastrointestinal motor abnormalities. 
Dysmotility is now well documented in idiopathic STC, with motor abnon-nalities 
(usually reduced overall motility) demonstrated in the oesophagus (Watier et al., 1983; 
Reynolds et al., 1987; Redmond et al., 1995; Ghosh et al., 1996) stomach (Reynolds et 
al., 1987; Van der Sijp et al., 1993; Ghosh et al., 1996; MacDonald et al., 1997), 
duodenum (Bassotti et al., 1996; Glia & Lindberg, 1998; Mollen et al., 1999), ileum 
(Panagamuwa et al., 1994) and gallbladder (Hemingway et al., 1997). The terin 
"generalised intestinal disorder" (GID) has been used to describe patients with STC who 
have extracolonic gastrointestinal dysmotility (Redmond et al., 1996) 
1.5.1.5 Extragastrointestinal physiological abnormalities 
Studies of patients with idiopathic STC have demonstrated sensory or motor 
abnormalities of the urinary tract (Abdel-Rahman et al., 1981; Watier et al., 1983; 
Bannister et al., 1988; Kerrigan et al., 1989). Evidence of autonomic dysfunction has 
been found by peripheral sweat-testing in patients with STC (Altomare et al., 1992), 
with similar abnormalities also reported in other functional gastrointestinal disorders 
(Camilleri & Fealey, 1990; Bharucha et al. 1993; Camilleri et al., 1993). 
1.5.1.6 Discussion 
The results of physiological studies in STC pose some problems in Interpretation. In the 
colon, studies demonstrating a minimal colonic motor response to intraluminal 
bisacodyl (a surface laxative) (Preston & Lennard-Jones, 1985; Shouler & Keighley, 
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1986; Kamm et al., 1988) might be indicative of an intrinsic neuronal problem, since 
this effect can be blocked by lignocaine (Hardcastle & Mann, 1968). However, the 
precise receptor, site and mode of action of this laxative remain unclear, and further 
reports have refuted this observation (Bassotti et al., 1999b). In general, both in vivo, 
and in vitro studies point towards an altered cholinergic innervation. e. g. in vivo, the 
reduced reponses to intravenous edrophonium (Bassotti et al., 1993; Grotz et al., 1993), 
and increased responses to surface application of choline esters such as bethanecol 
(Waldron et al., 1988; Slater et al., 1997). However, such responses to edrophonium 
have not been observed by all studies (Reynolds et al., 1987), and the increased 
response to choline esters, which are said to be indicative of cholinergic denervation 
supersensitivity (Cannon, 1934; Lapides et al., 1962) are at variance with the in vitro 
reduced response to surface application of ACh itself (Mitolo-Chieppa et al., 1998). 
Whether the demonstration of an altered release of neurotransmitters in response to field 
stimulation (Burleigh et al., 1988; Mitolo-Chieppa et al., 1998) supports an intrinsic 
neuronal problem is arguable (especially for ACh, which is both an intrinsic and 
extrinsic excitatory neurotransmitter). Similarly a disturbed gastrocolonic or awakening 
response could theoretically be indicative of extrinsic or intrinsic denervation, or a 
myopathy. 
1.5.2 ABNORMALITIES OF SMOOTH MUSCLE 
The important role of smooth muscle in the control of motility, as well as being the 
final effector of gastrointestinal motor activity has been described (1.4.1). In terms of 
human disease, recent advances have identified some (albeit rare) underlying smooth 
muscle structural and morphological abnormalities, which may be primary or 
secondary (see reviews: Smith & Milla 1997; Martin et al., 1999). 
Most reported myopathies are characterised by intestinal dilatation e. g. intestinal 
pseudoobstruction, although some patients may present with constipation. 
Morphological changes seen include varying degrees of fibrosis, hypertrophy or 
atrophy of muscle fibres, vacuolation of myocytes (Smith & Milla, 1997; Schuffler et 
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al., 1977; Martin et al., 1990), alteration in the irnmunohistochemical staining pattern 
of myocyte contractile proteins (Smith et al., 1992), abnormal layering of the muscle 
(Smith & Milla, 1997), and the presence of intracellular inclusion bodies (Martin et 
al. , 1990). 
In contrast, consistent myopathic findings have never been demonstrated by light 
microscopy in patients with idiopathic constipation (Dyer et al., 1969; Smith et al., 
1977; Hughes et al., 1981; Krishnamurthy et al., 1985; Kamm et al., 1988; Ghosh et al., 
1996), or STC (Pemberton et al., 1991; Benson et al., 1992; Redmond et al., 1995; Pluta 
et al., 1996). One study (Park et al., 1995) demonstrated an increased ratio of the 
circular layer to longitudinal layer of the muscularis propria in the descending and 
sigmoid colon. Similarly, in-vitro physiological studies have had conflicting results 
(Hoyle et al., 1992; Slater et al., 1997; Mitolo-Chieppa, 1998). Whilst a single 
ultrastructural study has observed some changes in patients with STC i. e. muscle cell 
degeneration in the muscularis propria and increased collagen in the longitudinal muscle 
layer (Benson et al., 1992), detailed ultrastructural studies of smooth muscle have 
generally not been performed (unlike, for instance, cases of childhood 
pseudoobstruction). Inclusion bodies have recently been reported in small numbers of 
patients with STC (Martin et al., 1999). 
1.5.3 ENTERICNEVRONAL ABNORMALITIES 
A multitude of studies have provided evidence for morphological abnormalities of 
colonic enteric neurones in patients with constipation. The number of studies in which 
there is documentation of slow transit for all patients is more limited, but their inclusion 
may be inferred in others. The results of such studies have been tabulated for 
completion, but are excluded from prolonged discussion in the text. 
1.5.3.1 Routine and silver staining (Table 1.02) 
In colonic tissue from patients with STC, routine light microscopy 
has failed to identify 
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a persistent abnormality other than melanosis coli (Redmond et al., 1996; Preston et al., 
1984b; Kamm et al., 1988), although 2 studies found variable nerve abnormalities by 
H&E staining in 3/9 (Watier et al., 1983) and 5/ 24 (Pluta et al., 1996) STC colons 
respectively. Described changes include axonal vacuolation, loss of myenteric neurones, 
and non specific plexus degeneration. 
Studies have reported morphological abnon-nalities of the colonic innervation using the 
silver staining method first described by Smith (Smith et al., 1967). A number of studies 
of patients with severe idiopathic constipation without proven STC had previously 
reported argyrophilic degeneration of the myenteric plexus, with or without associated 
Schwann cell hyperplasia (Dyer et al., 1969; Smith et al., 1977; Sninsky et al., 1984; 
Yoshioka and Keighley, 1989; Krishnamurthy et al., 1985). Notably, Krishnamurthy et 
al. (1985) in their widely-cited, semi-blinded and controlled study of 12 patients noted a 
reduction in the total number of argyrophilic neurones coupled with morphological 
abnormalities. Preston et al. (Preston et al., 1984b) suggested that there was a loss of the 
argyrophil plexus in 9/ 10 patients with STC, with associated Schwann cell hyperplasia. 
Two subsequent studies have confirmed Krishnamurthy's findings using silver staining 
in un-blinded studies of 12 and 25 colons respectively (Zenilman et al., 1989; 
Pemberton et al., 199 1). 
1.5.3.2 Immunohistochemistry and assay studies 
Neuronal associated antigens 
Pan-neuronal markers used in studies of the colon in patients with STC include 
neuron-specific enolase (NSE), protein gene product 9.5 (PGP 9.5), and the satellite 
cell marker S 100 protein. Neurofilaments, which provide the basis for silver staining 
(Gambetti et al., 198 1), are found exclusively in neurones as part of the cytoskeleton 
and therefore antibodies raised against them predominantly stain the myenteric plexus. 
Neuronal markers have been used to demonstrate a variety of conflicting findings in 
STC (Table 1.03). 
52 
C. H. Knowles 
Table 1.02: Morphological findings by routine and silver staining in patients 
with idiopathic constipation 
Author Year Number STC Mega- Melanosis Abnormalities SCH 
only colon coli Neuronal Axonal 
H&E staining only 
Hughes et al. 1981 10 n. s 0 0 N N N 
Walsh et al. 1987 19 some 2 11 N N N 
Kamm et al. 1988 44 some 0 16 N N N 
Ghosh et al. 1996 21 n. s 4 6 variable in 4 n. s n. s 
Watier et al. 1983 9 Y 0 n. s variable in 3 n. s 1 
Preston et al. 1984b 21 Y 0 5 n. s n. s n. s 
Redmond et al. 1995 34 Y 0 7 N N N 
Park et al. 1995 14 Y 0 4 N N N 
Pluta et al. 1996 24 Y n. s n. s variable in 4 2 n. s 
Porter et al. 1998 15 Y 0 1 N n. s n. S 
Silver staining 
Dyer et al. 1969 1 N 0 n. s Y 
Smith et al. 1977 4 N 2 1 n. s N 
Sninsky et al. 1984 5 n. s n. s n. s degeneration n. s n. s 
Krishmanurthy 1985 12 N 3 4 * in 10 * in 1 N 
Yoshioka 1989 13 some 8 5 * in all n. s n. s 
Preston et al. 1984b 10 Y 0 some variable loss MP in 9 Y 
Zenilman et al. 1989 12 Y 0 4 number n. s dec no N 
Pemberton et al 1991 25 Y n. s 1 in 15 n, s n. s 
Key: SCH = Schwann cell hyperplasia, N= none, n. s = not stated, dec decreased, 
inc = increased, decreased number and morphological changes, MP myenteric 
plexus. 
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Table 1.03: Morphological findings by immunostaining for neuronal associated 
antigens in patients with STC 
Author Year N Immunostain used Main results 
Park et al. 1995 14 PGP 9.5 / SIOO Normal myenteric plexus 
Porter et al. 1998 
Schouten et al. 1993 
Benson et al. 1992 
Romanska et al. 1996 
Neurotransmitters 
15 NSE 
39 NF2Fj 
12 SIOO / NSE / NF2FII 
6 NCAM 
neural supporting tissue 
small fibres muscularis propria 
Normal 
Patchy axonal loss 29/39 
T small fibres muscularis propria 
Normal 
In relation to the putative effects of an imbalance of neurotransmitters, a number of 
studies have used immunostaining, immunoassay, or both to demonstrate an alteration in 
the expression of one or more neurotransmitters (the majority of which are 
neuropeptides) or their enzyme markers in the large intestine of patients with 
constipation. Studies have been performed on neurotransmitters thought to be 
predominantly inhibitory: VIP (Dolk et al., 1990; Milner et al., 1990; Cortesini et al., 
1995; Romanska et al., 1996; Tzavella et al., 1996; Sjolund et al., 1997); NO 
(Cortesini et al., 1995; Porter et al., 1998), NPY (Dolk et al., 1990; Milner et al., 
1990; Tzavella et al., 1996; Porter et al., 1998); or excitatory: SP (Goldin et al., 1989; 
Dolk et al., 1990; Milner et al., 1990; Romanska et al., 1996; Tzavella et al., 1996; 
Sjolund et al., 1997; Porter et al., 1998), ACh (Porter et al., 1998), opioid peptides 
(Dolk et al., 1990; Romanska et al., 1996; Sjolund et al., 1997; Porter et al., 1998). 
Table 1.04 demonstrates the wide inconsistency of results with the most frequently 
studied neuropeptides (SP, VIP, NPY and 5-HT). For example, considering only 
studies with physiological selection for STC, decreased (Romanska et al., 
1996), 
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increased (Sjolund et al., 1997), and unchanged (Tzavella et al., 1996) levels of VIP 
have been demonstrated by immunoassay, and similarly, decreased (Romanska et al., 
1996), increased (Cortesini et al., 1995) or unchanged (Dolk et al., 1990; Porter et al., 
1998) VIP immunoreactivity has been shown by immunostaining. 
Table 1.04: Immunohistochemical (IHC) and immunoassay studies of 
neuropeptides in colon tissue from patients with either severe idiopathic 
constipation or proven STC. 
Author Year Blind Number STC Specimen Immuno- Immunoassay 
only site(s) histochemistry 
------- - - - ------------------- 
Substance P 
-------- ------- ------------ -------- ---------------------------- -------------------- -- -- - ---- 
Goldin et al. 1989 n. s 24 n. s rectal biopsy NP 
Milner et al. 1990 n. s 8 n. s sigmoid colon 
Dolk et al. 1990 n. s 7 Y colon levels NP 
Tzavella et al. 1996 Y 22 Y rectal biopsies NP 
Sjolund et al. 1997 Y 18 Y colon levels (AC only) 
Porter et al. 1998 n. s 15 Y colon levels & ileum NP 
UP 
Koch et al. 1988 n. s 4 Y descending colon § 
Milner et al, 1990 n. s 8 n. s sigmoid colon § 
Dolk et al. 1990 n. s 7 Y colon levels NP 
Cortisini et al. 1995 n. s 5 Y colon levels + NP 
Tzavella et al. 1996 Y 22 Y rectal biopsies NP -> 
Sjolund et al. 1997 Y 18 Y colon levels (TC only) 
T (AC only) 
Porter et al. 1998 n. s 15 Y colon levels & ileum NP 
NPY 
Milner et al. 1990 n. s 8 n. s sigmoid colon 
Dolk et al. 1990 n-s 7 Y colon levels NP 
Sjolund et al. 1997 Y 18 Y colon levels NP 
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Porter et al. 1998 n. s 15 y colon levels & ileum -> NP 
5HT 
Dolk et al. 1990 n. s 7 y colon levels -> NP 
Lincoln et al. 1990 n. s 9 y sigmoid colon -> 
TT 
Sjolund et al. 1997 Y 18 y colon levels Ts NP 
Key: n. s: not stated, NP: not performed, AC: ascending colon, TC: transverse colon, * 
descending colonic myenteric plexus only, t: circular muscle only, +: decreased in 
myenteric plexus, increased in circular muscle, $: endothelial cells of mucosa of 
descending colon only, §: muscularis propria only, 1: increase in circular muscle, no 
change in myenteric plexus. 
Changes in assayed indole levels merit comment because of increasing interest in their 
role in colonic motor activity, especially with reference to new directed enterokinetic 
therapies (see discussion below). Lincoln et al. (Lincoln et al., 1990) demonstrated a 
significant increase in the total level of indoles (sum of 5-HT and its breakdown product 
5-HIAA) in the mucosa and circular muscle (but not in the combined muscle and 
plexuses sections), of sigmoid colonic tissue from patients with STC. Differences were 
most marked for mucosal indole levels (a finding also made by Sjolund et al. (Sjolund et 
al., 1997), and may have reflected differences in enterochrornaffin cell content which 
demonstrated strong immunostaining. No consistent differences were demonstrated in 
the pattern of immunostaining for 5-HT in this study, and in one other (Dolk et al., 
1990). 
1.5.3.3 Variability of pathological findings 
The results described demonstrate the variability of pathological findings between 
studies of STC. This may have resulted from the heterogeneous mixture of patients in 
many studies e. g. chronic idiopathic vs. other causes of STC, or may have arisen as a 
result of differences in tissues studied both with respect to the level in the colon, or areas 
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of the colonic wall studied. Some variability is implicit with routine staining or 
immunohistochemical methodology when attempts are made to quantify changes in 
density of staining. Such error may also be compounded by observer bias, and it should 
be noted that few studies were documented as blind in design (Krishnamurthy et aL, 
1985; Tzavella et aL, 1996; Sjolund et aL, 1997) (see table 1.04). 
Argument still exists (see below) as to the contribution of laxatives on changes seen in 
argyrophil staining (Smith, 1968; Smith, 1973; Preston et al., 1984b), ultrastructural 
analysis (Reimann et al., 1980), and neuropeptide levels (Milner et al., 1992; Tzavella et 
al.; 1995). In addition, ageing may have had an effect on density of subsets of certain 
neurochernically coded neurones. Neuronal loss has been demonstrated with age in 
experimental animals (Gabella et al., 1989), and in the myenteric plexus of the small (de 
Souza et al., 1993), and large (Gomes et al. 1997) intestine of man. Indeed, the only 
study utilising age matched controls showed an isolated decrease in tachykinin and leu- 
enkephalin-coded neurones with an otherwise nonnal density of neural elements (Porter 
et al., 1998). Sensory neuropeptides have been shown to be lost in the obstructed human 
bladder (Chapple et al., 1992), but the question of the effect of prolonged colonic stasis 
on neuropathological findings has not been answered because no human study has 
controlled for these variables, and no animal model currently exists for STC. Study 
design in STC continues to improve, and it is anticipated that future blinded studies with 
better defined clinical groups, which are adequately controlled for age, will yield better 
quality data. 
1.5.3.4 Discussion 
A substantial proportion of studies of STC (Preston et al., 1984b; Zenilman et al., 
1989; Pemberton et al., 1991; Schouten et al., 1993) and severe idiopathic 
constipation (Yoshioka & Keighley 1989; Krishmanurthy et al., 1985) have found 
degeneration of neurones in the myenteric plexus. Krishnamurthy et al. 
(Krishnamurthy, 1985) suggested that this pathology was definitive of a single 
disorder, probably congenital, and distinct from the pathology of chronic idiopathic 
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intestinal pseudoobstruction (CIIP) (Schuffler & Jonak, 1982). Likewise, a number of 
studies highlighting variation in immunoreactivity or assay levels of a number of 
intrinsic neurotransmitters have concluded that the results are representative of 
primary intrinsic neuronal disease (Goldin et al., 1989; Dolk et al., 1990; Lincoln et 
al., 1990; Milner et al., 1990; Tzavella et al., 1996; Sjolund et al., 1997; Porter et al., 
1998). The premise of such studies is that a generalised degeneration of intrinsic 
neurones, or a disturbance in the balance of intrinsic neurones with different 
functional and neurochemical characteristics could lead to an alteration in colonic 
motility manifest as STC. Accepting the enormous variability of the findings from 
these studies, it is still difficult to equate specific changes in neurotransmitter 
immunoreactivities with the physiological findings in STC. Whilst recent attempts 
have been made to link the function of subsets of ENS neurones with their chemical 
coding, projections and morphology in normal colon (Wattchow et al., 1997; Porter et 
al., 1997), further knowledge of the role of individual subsets of neurones in local 
enteric reflex activity is probably required to understand how degenerative changes may 
contribute to the observed patterns of motility in the human colon in disease. For 
instance, the finding of increased assay levels of 5-HT in patients with STC (Lincoln et 
al., 1990), does not equate with the observations that 5-HT, acting at 5-HT3,4 receptors 
initiates peristaltic reflexes in the intestine (Grider et al., 1998), including the colon (Jin 
et al., 1999), and that 5-HT4 receptor agonists increase transit in healthy volunteers 
(Emmnauel et al., 1998) (see section 1.2.5: novel therapies). 
1.5.4 EXTRINSIC (AUTONOMIC) NEURONAL INFLUENCES 
There are 3 principal extrinsic nerve supplies to the colon derived from the autonomic 
nervous system (ANS). 
1. Pelvic nerves 
2. Vagus nerves 
3. Mesenteric nerves 
parasympathetic 
parasympathetic 
sympathetic 
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Their role in the control of normal colonic motility, and potential role in the actiology of 
STC is considered here. 
1.5.4.1 Parasympathetic dysfunction 
1.5.4.1.1 Pelvic nerve dysfunction 
Functional importance of the pelvic parasympathetic innervation of the colon 
Morphological studies of various species including man, indicate that the pelvic nerves 
innervate most or all of the colon. (Schmidt, 1933; Fukai & Fukuda, 1984; Christensen 
& Rick, 1987; Christensen, 1991), and there is no doubt as to the importance of the 
pelvic nerves in colonic motor function. In experimental animals, bilateral pelvic nerve 
section effects a fall in colonic tone and a decrease in spontaneous motor activity (Garry, 
1933; Scott & Cantrell, 1949; De Groat & Krier, 1976), with loss of mass defaecation 
and passage of pellet-like stools. Matsushima showed that high-amplitude propagated 
contractions (HAPCs), and therefore colonic "mass movements" were abolished 
following bilateral pelvic nerve section (Matsushima, 1989). Similar decreases in 
motility, which did not recover during the 6 month duration of the study, have been 
shown in the proximal colon in dogs (Ishikawa et al., 1997). Conversely, stimulation of 
the pelvic nerves causes contractions of the colon powerful enough to expel the entire 
luminal contents (Langley & Anderson, 1895; Bayliss & Starling, 1900; Elliott & 
Barclay-Smith, 1904; Gray et al., 1955; Garry & Gillespie, 1955; Hulten et al., 1969; 
De Groat & Krier, 1976). 
Pelvic nerves also provide the pathways for extracolonic and intramural reflexes 
(Wingate, 1993). Inhibition of proximal colonic motility has been shown to be invoked 
by distending the distal colon or rectum: the colo- or recto-colonic inhibitory reflex 
(Brugere et al., 1991; Pearcy & Van Liere, 1926; Kreulen & Szurszewski, 1979; Gue et 
al., 1995). Reflex inhibition of motility is not limited to the proximal colon, however, as 
painless rectal distension also inhibits contractile activity and delays intraluminal transit 
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in various organs of the upper gastrointestinal tract (Pearcy & Van Liere, 1926; 
Youmans & Meek, 1937; Wingate, 1993). 
Observations on pelvic nerve injuries in humans 
Small numbers of patients with constipation have been described following established 
neural injuries to the pelvic parasympathetic outflow. Observations were similar to those 
observed in animals with loss of mass defaecation and passage of pellet-like stools 
(Trumble, 1935), and atonic bowel with loss of peristaltic rush waves (fluorometric 
equivalent of mass movement waves) (V4-tite et al., 1940). Two subsequent studies of 
infra-conal, i. e. cauda equina injury (Devroede et al., 1979; Beuret-Blanquart et al., 
1990) have demonstrated delayed transit. Devroede and Lamarche (1974) described one 
patient who underwent resection of the nervi erigentes for multiple sclerosis related 
urinary symptoms, resulting in the immediate loss of rectal sensation and ability to 
defaecate. Subsequent physiological study demonstrated retardation of transit 
throughout the colon (Devroede and Lamarche, 1974). Similar findings have been 
demonstrated by 2 further studies (Gunterberg et al., 1976; Sun et al., 1995). 
Sacral nerve stimulation can facilitate defaecation in humans (Binnie et al., 1991; 
MacDonagh et al., 1990; Vanna, 1992), concomitant with a decrease in oro-anal 
transit time (Binnie et al., 1991). An increase in colonic motility indices, especially 
with S3 stimulation, has been demonstrated in the left and transverse colon (Vanna, 
1992). 
Relationship ofSTC to pelvic surgery and childbirth 
Many studies have demonstrated changes in bowel function after hysterectomy 
(Taylor et al., 1989; Smith et al., 1990; Heaton et al., 1993; van Dam et al., 1997) and 
a significant group of patients with proven STC have symptoms that started at or after 
pelvic surgery, particularly hysterectomy (Preston & Lennard-Jones, 1986; Waldron 
et al., 1988; Roe et al., 1988; Vierhout et al., 1993), but also after other operations 
such as tubovarian surgery (Waldron et al., 1988) and even appendicectomy (Preston 
& Lennard-Jones, 1986). Similarly, STC can follow childbirth (Waldron et al., 1988), 
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especially in patients with a prolonged second stage of labour and instrument assisted 
delivery (MacDonald et al., 1997). 
The assumption that nerve injury might follow pelvic surgery or childbirth, whilst 
gaining general acceptance (Christensen and Schulze-Delrieu, 1985; Smith et al., 1990; 
MacDonald et al., 1993), has never been anatomically proven. The possible sites of 
nerve injury during pelvic surgery have been discussed with particular reference to 
sexual (Long & Bernstein, 1959) and urinary dysfunction (Smith & Ballantyne, 1968). 
The preganglionic parasympathetic pelvic splanchnic nerves (nervi erigentes) leave the 
spinal cord in the ventral roots at levels S, -S, in humans (Gonella et al., 1987; Williams 
et al., 1989; Christensen, 1991), and pass forward as visible condensations, expanding 
into the inferior hypogastric plexuses (left and right: also known collectively as the 
pelvic plexus). In females, each plexus is lateral to the rectum, uterine cervix, vaginal 
fornix and the posterior part of the bladder, extending into the uterine broad ligament 
(Williams et al., 1989), and is presumably susceptible during hysterectomy, especially 
any nerves lying in the broad ligament which may be ligated with the uterine arteries. 
Whether a similar nerve injury can occur, possibly by mechanical stretching of nerves 
during prolonged, or even 'normal' childbirth is less clear. Certainly permanent changes 
in the pelvic floor anatomy and physiology have been observed following childbirth 
(Snooks et al., 1990; Karasick & Spettell, 1997), and similarly the effect of stretching of 
the pudendal nerves with subsequent sphincteric dysfunction is well recognised (Snooks 
et al., 1990; Sultan et al., 1993; Jorge & Wexner, 1993). No study in human or higher 
mammals has been performed to morphologically demonstrate that nerve injury occurs 
following either pelvic surgery or childbirth, but degeneration of pelvic ganglia 
posterolateral to the vagina has now been demonstrated in a simulated birth injury 
model in the rat (Lin et al., 1998). 
It should also be noted that symptoms attributed to pelvic surgery might have been 
present before surgery, but given heightened significance afterwards, as has been shown 
with urological symptoms and hysterectomy (Parys et al., 1989). Prospective study of 
IBS symptomatology (Prior et al., 1992) suggests that symptoms arise at the time of 
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hysterectomy in only 10% of patients, other patients having pre-existing symptoms, 
which were either made worse or better by surgery. Indeed, it Is possible that a number 
of patients undergoing hysterectomy do so for problems such as pelvic visceral pain that 
may have been primarily related to bowel dysfunction. 
Evidence for pelvic denervation inpatients with chronic idiopathic STC 
Since patients with STC following pelvic surgery and childbirth are clinically 
indistinguishable from the chronic idiopathic group in whom symptoms arose de-novo 
(MacDonald et al., 1993), pelvic nerve damage might be a plausible hypothesis for the 
aetiology of chronic idiopathic STC, in which similar pelvic parasympathetic 
dysfunction might occur by way of a non-traumatic, possibly degenerative process. 
In support of this hypothesis, physiological studies demonstrate many similarities 
between patients with STC following pelvic surgery or childbirth and those with chronic 
idiopathic symptoms (Abdel-Rahman et al., 1981; Baldi et al., 1982; Watier et al., 
1983; Bannister et al., 1986; Turnbull et al., 1988; Roe et al.; 1988; de Medici, 1989; 
Kerrigan et al., 1989; Kamm & Lennard-Jones, 1990; Wald et al., 1990; Smith et al., 
1990; Varma, 1992; Bassotti et al., 1994). The co-existence of bladder and rectal 
dysfunction in patients with chronic idiopathic STC (Abdel-Rahman et al., 198 1; Watier 
et al., 1983; Bannister et al., 1988; Kerrigan et al., 1989), and increased pelvic visceral 
responses to the parasympathomimetic choline esters (supersensitivity) (Watier et al., 
1983; Slater et al., 1997), as seen in patients with pelvic nerve injury (Smith et al., 
1990), is consistent with a denervation hypothesis (Cannon, 1934; Lapides et al., 1962). 
Direct study of colonic motility in patients with chronic idiopathic STC demonstrates a 
reduction in the frequency, amplitude and duration of high-amplitude propagated 
contractions (HAPCs) (Bassotti et al., 1988; Bassotti et al., 1994), and reduced tone in 
the left colon (O'Brien et al., 1996). These findings are similar to those made in 
animals following experimental pelvic denervation (above) (Garry, 1933; Scott & 
Cantrell, 1949; De Groat & Krier, 1976; Matsushima, 1989). 
Morphological findings reported in the distal colon, i. e. neuronal degeneration with 
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morphological changes and Schwann cell hyperplasia, in patients with chronic 
idiopathic STC (Krishnamurthy et al., 1985; Preston et al., 1984b; Zenilman et al., 
1989; Pemberton et al., 1991) are identical to those of patients with surgical section of 
the pelvic nerves (Devroede & Lemarche, 1974), and cauda equina injury (Devroede et 
al. , 1979). 
Pelvic nerve injury and STC: pathogenetic mechanisms 
Several mechanisms may co-operate in the pathogenesis of observed retardation of 
colonic transit. 
i) Severance of the extramural pelvic nerves has been shown experimentally to 
result in degeneration of the ascending colonic nerves in dogs and cats (Fukai & 
Fukuda, 1984; Christensen & Rick, 1987), and may involve the entire colon (Schmidt, 
1933). In the human, at least 80% of the colon might be affected by such degeneration 
(Christensen, 1991) with resultant hypomotility coincident apon a direct loss of 
parasympathetic excitatory influence. 
ii) Following degeneration of ascending colonic nerves, finther changes in motility 
might be explained by reorganisation of efferent pathways. Experimental work has 
shown that, following injury to the innervation of other pelvic organs such as the 
bladder, subsequent re-innervation of denervated parasympathetic ganglion cells by 
sympathetic nerves may contribute to the dysfunction (de Groat & Kawatani, 1989). It 
has long been recognised that the sympathetic nerves of the autonomic nervous system 
exert a tonic inhibitory influence on the colon (Lister, 1858). 
iii) Alternatively, left sided stasis may contribute to proximal slowing of colonic 
transit by reflex inhibition occurring secondary to distal distension. The recto-colonic 
inhibitory reflex has been well defined in experimental animals (Pearcy & Van Liere, 
1926; Kreulen & Szurszewski, 1979; Brugere et al., 1991; Gue et al., 1995), but has 
rarely been reproduced in man due to technical limitations (Klauser et al., 1990; Warren 
et al., 1994). Reflex inhibition of transit or motility in more proximal regions of the 
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gastrointestinal tract is well documented during rectal distension, however (Youle & 
Read, 1984; Kellow et al., 1987; BqJ6 & Cassuto, 1992; Tjeerdsma et al., 1993), and 
may explain the upper gastrointestinal findings in some patients with STC (Watier et al., 
1983; Bassotti et al., 1996; MacDonald et al., 1997; Mollen et al., 1999). 
1.5.4.1.2 Vagal dysfunction 
The vagal nerves innervate at least the proximal, and possibly all of the colon, 
although the density of innervation decreases aborad (Fukai & Fukuda, 1984). 
Experimental evidence has demonstrated that interruption of the vagi causes a 
significant decrease in contractions of proximal, middle and distal colon segments in 
monkeys in both fasted and fed states (Esser et al., 1989; Dapoigney et al., 1992), and 
that a colonic excitatory vago-vagal reflex pathway exists which is mediated by both 
cholinergic and non-cholinergic mechanisms (Dapoigney et al., 1992; Collman et al. 
1984). 
Truncal vagotomy performed with gastric drainage procedures is well known to cause 
diarrhoeal syndromes in a significant proportion of patients by a number of 
mechanisms, and can cause constipation (Hines et al., 1975). The effect of vagotomy 
on colonic motility alone in humans is not known, and no studies have been directed 
to examining a possible vagal role in the causation of idiopathic constipation. 
1.5.4.2 Sympathetic dysfunction 
Sympathetic nerve section causes an increase in colonic motility (Lister, 1858; 
Learmonth & Markowitz, 1930; Garry, 1933; De Groat & Krier, 1979). Conversely, 
stimulation of pre- and post-ganglionic extrinsic sympathetic nerve fibres (lumbar 
splanchnics and lumbar colonics) inhibits spontaneous contractions (Langley & 
Anderson, 1895; Bayliss & Starling, 1900; Garry & Gillespie, 1955; Hulten et al., 
1969), and reduces or blocks the stimulatory response from pelvic nerve stimulation 
(below) (Hulten et al., 1969; Gillespie & Khoyi, 1977; Hedlund et al., 1985). These 
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observations suggests that sympathetic nerves have a predominantly inhibitory 
influence on the gut, exerted by suppressing the parasympathetic nerve-derived 
excitatory drive. 
Since immunoassay levels or immunostaining for the sympathetic neurotransmitters 
NA, NPY, and doparnine P-hydroxylase appear to be normal (Lincoln et al., 1990; 
Milner et al., 1990; Dolk et al., 1990; Porter et al., 1998), there is little morphological 
evidence to suggest that extrinsic sympathetic denervation occurs in STC. This is in 
accord with the predominantly inhibitory role of the sympathetic innervation to the 
intestine. The role of sympathetic reorganisation, which might occur following 
parasympathetic denervation has been discussed. 
1.5.5 CENTRAL NEVRONAL INFLUENCES 
It is probable that the CNS modulates normal colonic function only under particular 
circumstances e. g. defaccation, and that the moment-to-moment control is provided 
by the ENS (Sarna, 1991; Wingate, 1993). Whether there is any continuous central 
input to the colon is still questionable. Indirect evidence that cerebral influences 
modify colonic motility may be implied from the behavioural response of mammals to 
stressful situations, such as anxiety or fear (Truelove, 1966), and the changes in 
motility observed with sleep and awakening (decreased and increased contractile 
acitvity respectively) (Narducci et al., 1987; Soffer et al., 1989). Colonic motor 
activity is enhanced after exposure to short-term mental or physical stress (Narducci et 
al., 1985; Stam et al., 1995). More direct evidence that the CNS modulates colonic 
motor activity is derived from observations that intracerebroventricular administration 
of various chemicals can influence change in colonic contractility (e. g. Bueno et al., 
1985). 
There is no conclusive physiological or morphological evidence for CNS dysfunction in 
patients with STC, but, indirect clinical evidence does exist. Epidemiologically, there 
is 
concordance of occurrence of constipation and central nervous system 
disorders 
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(Johanson et al., 1992): STC occurs in some patients with diseases of the brain and 
spinal cord e. g. spinal cord transection (Keshavarsian et al., 1995; Glickman & Kamm, 
1996); Parkinson's disease (Edwards et al., 1994), and multiple sclerosis (Weber et al., 
1987). 
In particular, it is well established that disordered defaecation can follow supraconal 
spinal cord injury (Glickman & Kamm 1995). Clearly other factors have a role in the 
association of constipation with such injuries e. g. recumbency and opiate use, but 
colonic transit is invariably delayed in patients with spinal cord transection (Devroede 
et al.,, 1979; Nino-Murcia et al., 1990; Beuret-Blanquart et al., 1990; Keshavarsian et 
al., 1995; Leduc et al. 1997; De Looze et al., 1998). A possible role for psychogenic 
influences is discussed below (1.6.7). 
1.6 PROPOSED AETIOLOGIES 
1.6.1 PRIMARYNEURONAL OR SMOOTH MUSCLE DISEASE 
The onset of STC in infancy or early childhood in some patients, which may be familial, 
suggests the possibility of a primary, possibly congenital aetiology for STC. At present, 
evidence is lacking, but the hypothesis that STC might have a genetic basis has never 
been formally tested. 
1.6.1.1 Primary neuronal dysfunction 
The neural-crest-denved precursors of the ENS migrate along defined pathways to 
colonise the bowel. Recent studies of the sequential actions of essential growth and 
transcription factors have revealed that enteric neuronal development involves a 
complex interaction of lineage-determined and microenviromental elements. The 
genetic signals that are critical for normal crest migration and differentiation have 
been identified by studying natural and targeted mutations in mice, and include the 
normal transcription of genes such as the RET proto-oncogene (Schuchardt et al., 
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1994), as well as genes encoding other neurotrophins, their receptors, and associated 
neuropoietic cytokines (Gershon, 1997; Chalazonitis et al., 1998). Hirschsprung's 
disease is an example of a human disorder caused by failure of these complex 
processes, and mutations of genes involved in neural crest development have now 
been described in this condition (Lyonnet et al., 1993; Puffenberger et al., 1994; 
Salamon et al., 1996; Hofstra et al., 1996). Candidate genes are also being 
characterised for other gastrointestinal pseudo-obstructive phenotypes (Auricchio et 
, al., 1996; Verma et al., 1997). The finding of intrinsic neuronal abnon-nalities, 
coupled with the onset in infancy or early childhood of symptoms in many patients 
(chronic idiopathic STC) might suggest that STC is a primary ENS disorder arising 
during development. 
1.6-1.2 Primary smooth muscle dysfunction 
It is conceivable that some developmental morphogenic abnormalities could result from 
defective genetic control of the complex sequential events in gut development (Pitera et 
al., 1999), although other mechanisms such as congenital viral infection or intrauterine 
vascular defects / accidents may also operate. Abnormality in any of the up-stream or 
down-stream genes involved in smooth muscle migration, maturation and programmed 
cell death could result in impairment of these functions and thereby lead to the muscle 
defects seen in some enteric myopathies. There has been much recent interest in key 
regulatory proteins, termed transcription factors that are involved in determining the 
eventual phenotype of mesenchymal cells early in development. One important class are 
the homeodomain proteins, that when mutated cause alterations in the body plan of the 
fruit fly called homeotic changes. Expression patterns of homeodomain proteins are 
critical for defining the structural blueprint of the body plan and the identity of cells in 
many organisms, from flies to humans. A number of homeobox genes are expressed in 
complex patterns in mesoderm-derived cells in the hindgut tube (Pitera et al., 1999), and 
experimental abnormalities have been shown to affect its structure (Wolgemuth et al., 
1989; Roberts et al., 1995). Whilst such gross abnormalities have been demonstrated in 
mice, a genetic component to certain human visceral myopathies is also known to exist 
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in some families with autosomal dominant and recessive (Mitros et al., 1982), and X- 
linked (Smith & Milla, 1997) modes of inheritance. A greater understanding of the 
pathogenesis of the skeletal muscular dystrophies is being rapidly achieved, particularly 
in relation to membrane associated or linked cytoskeletal proteins, and similar 
mechanisms are likely to be discovered in gut leiomyodystrophies, and possibly STC. 
1.6.2 INTERSTITIAL CELL DYSFUNCTION 
Because of their potential importance throughout the gastrointestinal tract in motility 
(section 1.4.1), abnormalities in the density and distribution of ICCs have been sought 
and described in human aganglionosis (Vandervinden et al., 1996), some cases of 
hypoganglionosis, idiopathic neonatal (Kenny et al., 1998a) and adult 
pseudoobstruction, and in high anorectal malformations with refractory constipation 
(Kenny et al., 1998b). Although germline mutations of the C-K[Tproto-oncogene were 
absent in patients tested with STC (Malik et al., 1998), and evidence for a decreased 
density or distribution of ICC in the colon of patients with STC is contradictory (Hagger 
et al., 1997; He et al., 1998), it remains feasible that a disruption in motility in humans 
could result from ICC dysfunction, as has been shown in murine models (Ward et al., 
1994; Huizinga et al., 1995; Huizinga et al., 1998). 
1.6.3 A UTOIMMUNITY 
1.6.3.1 Autoantibody mediated neuronal damage 
Antibodies against antigenic determinants on enteric nerve cells have been found in 
pseudoobstruction associated with small-cell lung carcinoma (Lennon et al., 1991). 
High levels of circulating IgG enteric neuronal antibodies were reported in small 
numbers of patients who presented with abdominal pain and constipation in late 
childhood with acquired intestinal aganglionosis, but without other neurological 
problems or neoplasia (Smith et al., 1997). Similarly, anti-myenteric autoantibodies 
have been demonstrated in progressive systemic sclerosis (scleroderma) (Howe et al., 
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1994; Eaker et al. , 1999), a disorder which can cause STC (Basilisco et al., 1993). 
Autoantibodies may also mediate the gastrointestinal manifestations of certain 
infections, for instance in patients with Chagas' disease, in which antibodies have 
been detected to myenteric neurones (Wood et al., 1982), and more recently to 
specific neuronal muscarinic receptors (Goin et al., 1999). Antibodies to entenc 
neuronal epitopes have not been investigated in idiopathic STC, and therefore remain 
an aetiological possibility. This hypothesis is supported by Lindberg et al. (Lindberg 
et al., 1999), who have recently described a lymphocytic epithelloganglionitis, i. e. 
ganglionitis accompanied by intraepithelial lymphocytosis and mild chronic mucosal 
inflammation in intestinal diseases characterised by severe motor dysfunction, 
including a group of patients with STC. 
1.6.3.2 Autoantibody mediated smooth muscle damage 
Cases of intestinal pseudoobstruction caused by an autoimmune myopathy 
characterised by a dense lymphocytic myositis, and circulating IgG-class 
autoantibodies against smooth muscle have been described in children (Smith & 
Milla, 1997). Intestinal pseudoobstruction may similarly be a feature of other 
recognised secondary myopathic disorders such as the collagen vascular diseases e. g. 
systemic lupus erythernatosus (Cacoub, et aL, 1993). 
1.6.4 INFECTIVEAGENTS 
The aetiology of STC might be explained by a systemic infection acting permanently to 
alter normal peristaltic activity via effects on the extrinsic enteric innervation, myenteric 
plexus, as is seen in Chagas' disease (see above), or directly on entenc smooth muscle. 
Sporadic cases of chronic idiopathic intestinal pseudoobstruction (CIIP) may follow a 
poorly defined illness, and recent evidence has linked a viral actiology (herpetoviridae) 
to this condition (Debinski et al., 1997). In addition, previous clinical case reports of 
CIIP had reported tissue localisation of viral inclusions in the myenteric plexus for EBV 
(Vassallo et al., 1991), Varicella (Chang et al., 1978) and CMV (Sonsino, et al., 1984). 
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Varicella zoster virus has also been identified in patients with oesophageal motility 
disorders (Robertson et al., 1993). A clear mechanism of causation of disease has not 
been shown for these agents, and may relate to a direct cytopathic effect or damage 
resulting from the host immune response, as is seen in Chagas' disease (Wood et al., 
1982). Of interest with respect to the latter is the observation that in both CIIP 
(Camilleri & Fealey, 1990; Bharucha et al. 1993; Camilleri et al., 1993) and STC 
(Altomare et al., 1992) there may be associated abnormalities of the autonomic nervous 
system in approximately one third of cases. Acquired selective cholinergic 
dysautonomia leading to CIIP has been shown to occur following acute infectious 
mononucleosis (Vassallo et al., 1991). A role for infective agents in STC has not been 
tested. 
1.6.5 ROLE OFENDOGENOUSOPIOIDS 
Opioid peptide immunoreactivity, principally for enkephalins, but also for endorphins 
and dynorphins is present in the normal human gut, principally in elements of the 
myenteric plexus (Polak et al., 1977), and opiate receptors are present in the intestinal 
wall both in the submucosa and in the myenteric plexus (Ahmad et al., 1990). The 
effect of opiates on motility is mediated both centrally and peripherally (Bueno et al., 
19,85) by 3 subtypes of opiate receptor, [t, 6 andK, with the relative inhibitory or 
excitatory effects of stimulation of each receptor subtype being species, site and 
opioid dependent (Porreca et al., 1984; Hoyle et al., 1990). In man, the combined 
effects of opiate receptor activation produce a stimulation of colonic contractions with 
reinforcement of tonic activity and a decrease in propulsive activity leading to an 
overall decrease in transit (Bueno & Fiormonti, 1988). 
Constipation is a regular and established sequel to treatment with opiates. 
Experimentally, morphine slows colonic transit (Kaufman et al., 1988), by increasing 
phasic contractile, but decreasing propagating activity (Frantzides et al., 1992), and 
these motility changes may be reversed by opiate antagonists (Sykes, t99l). Since 
naloxone also speeds colonic transit in healthy volunteers (Kaufman et al., 1988), it is 
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possible that endogenous opioids exert an effect on the colon of patients with STC. 
Studies of colonic opioid immunoreactivity in STC have shown no abnormalities of 
met-EnK (Dolk et al., 1990; Sjolund et al., 1997) and dynorphin (Dolk et al., 1990), 
but have demonstrated a reduced density of leu-EnK containing neurones (Porter et 
al., 1998). A reduced activity of enkephalins on inhibitory neurones in patients with 
constipation has also been suggested (Hoyle et al., 1989). The potential influence of 
such alterations remains unclear, and indeed a controlled study of patients with STC 
showed that neither naloxone nor a more potent opiold antagonist, nalmefene, were able 
to correct the transit abnormality (Fotherby et al., 1987). 
1.6.6 EXO GENO US 
MYENTERIC DAMA GE 
-NEURONAL 
TOXINS: LAXATIVE MEDIATED 
The idea that laxatives might play a role in the pathogenesis of severe constipation is not 
new, the "cathartic colon" being first described more than 50 years ago (Heilbrun, 
1943). However, no case of this radiologically characterised distinct entity has been 
published of a patient whose laxative intake started after 1960. An outdated laxative, 
such as podophyllin, a known systemic neurotoxin, was therefore the most likely 
candidate (Muller-Lissner, 1996). Similarly, melanosis coli, which is not an infrequent 
finding in patients with or without chronic constipation, and which is caused by 
accumulation of pigment laden macrophages following colonic epithelial. cell apoptosis, 
appears to be a harmless condition which is indicative of, but not specific to (Byers et 
a[ , 1997), chronic 
laxative, especially anthraquinone ingestion (Mengs & Rudolph, 
1993). 
Current laxatives 
Whether anthraquinone laxatives given in the long-term to patients with constipation 
can cause adverse functional or structural changes in the intestine is debatable. Smith 
(Smith, 1968) demonstrated abnormalities in colonic innervation, both in a patient, and 
in mice given senna experimentally. Neuronal abnormalities were confirmed on light 
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microscopy in humans (Smith, 1973), and also by a controlled blinded ultrastructural 
study (Reimann et al., 1980). However, subsequent experimental evidence in rodents 
given sennosides for up to one year did not demonstrate neural changes by light 
microscopy (Dufour & Gendre, 1988), and it is possible that Smith's original findings 
were caused by free anthroquinones rather than sennosides (Dufour & Gendre, 1988). 
Free anthroquinones have been shown to cause ultrastructural changes in the mouse 
(Dufour & Gendre, 1984), but not light microscopical changes in the dog (Case et al., 
1977). A case controlled study of the human submucous plexus following one year of 
anthroquinone ingestion showed no difference on electron microscopy (Riecken et al., 
1987). In addition, it should be noted that the neuronal morphological changes seen in 
some of these studies may be as indicative of a primary pathology leading to 
constipation as nerve damage from laxatives. Anthraquinones may, however, be 
responsible for some of the variations seen in neuropeptide immunoreactivity in studies 
of idiopathic constipation (Milner et al., 1992; Tzavella et al., 1995). Like the 
anthroquinones, polyphenolic laxatives lead to apoptosis of colonic epithelial cells with 
accumulation of macrophages containing colonic cell remnants, but these are not 
pigmented (Mengs et al., 1993). There is no current evidence to suggest that 
polyphenolic compounds cause adverse effects on long-term use (Gebboes et al., 1993). 
At least with respect to one year of laxative use, scientific evidence does not support the 
commonly held belief amongst the public and the medical profession alike, that long- 
term laxative use results in a "lazier" bowel. Whether patients taking unprescribed high 
doses of laxatives for a much longer duration do damage to their bowel is not known. 
1.6.7 PSYCHOGENIC FACTORS 
The role of psychological factors in the pathophysiology of severe chronic 
constipation is unclear. Personality may influence stool weight and frequency (Tucker 
et al., 1981), and a coexisting psychiatric disorder is common 
in patients with 
functional bowel disorders (Young et al., 1976; Johansen et al., 1992). Although early 
studies demonstrated that psychometric scores may be abnormal in patients with 
STC 
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(Devroede et al., 1989), the association between abnormal psychological symptom 
scores and STC is much less clear than in patients with normal transit constipation 
(Wald et al., 1989; Wald et al., 1992; Heyman et al., 1993; Grotz et al., 1994). 
There are 3 possible explanations for the commonly perceived association between 
psychological abnonnalities and STC. 
Psychological disorders cause STC 
Youle and Read (Youle & Read, 1984) demonstrated in healthy volunteers that painless 
rectal distension could slow gastric emptying and small bowel transit. Klauser et al. 
(Klauser et al., 1989) likewise demonstrated that healthy volunteers could substantially 
delay defecation when paid to do so, and that such delays were associated with some 
slowing of transit in the rectosigmoid and right colon. It is therefore possible that 
chronic rectal distension by, faeces, as a result of chronic inhibition of defaecation as a 
learned behaviour, perhaps in childhood (Whitehead et al., 1992; Leroi et al., 1995) 
could lead to STC. However , in chronically constipated patients, there is little relation 
between symptoms (Wald et al., 1989), or physiological evidence of obstructed 
defaecation (Wald et al., 1990; Wald et al., 1993; Pezim et al., 1993; Grotz et al., 1994; 
Karlbom et al., 1995), and transit findings. Likewise, psychological profiles do not 
correlate with anorectal sensory or motor function (Wald et al., 1989). In addition, the 
premise that anxiety-induced paradoxical puborectalis contraction might cause 
constipation by outlet obstruction is largely discredited by the finding that such 
sphincteric contraction is common in healthy controls, and may therefore have been a 
testing artefact (Voderholzer et al., 1997). 
Despite an excess incidence of constipation symptoms in patients with psychotic 
depression (Sonnenberg et al., 1994b; Parker et al., 1997), no study has proven a clear 
association between depression and slow colonic transit (Gorard et al., 1996). Likewise, 
a true association between STC and anorexia and bulimia nervosa is also questionable 
(Karnal et al., 1991; Chun et al., 1997); the possible role of laxative abuse-related 
myenteric damage, that can theoretically occur in such patients, has been discussed. 
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Constipation may lead to psychological disorders 
Whilst no objective evidence exists to prove such a causal link, it is possible that 
patients suffering from a chronic disorder characterised by severe symptoms including 
pain, for whom no adequate explanation or treatment exists, might develop secondary 
psychological problems (Wright et al., 1995). This may be especially true for those 
patients who acquire symptoms in adulthood, having previously been accustomed to a 
"normal" bowel habit. 
Coexistence ofpsychological disorders leads to self-selection for treatment. 
Self-selection for treatment has been shown to contribute to the association between 
psychological distress and irritable bowel syndrome (Whitehead et al., 1988; Drossman 
et al., 1988). However, anxiety and depression are found equally in constipated patients 
who have not consulted physicians as well as in those who have consulted (Whitehead, 
1994), implying that the association of constipation with psychological disorders is not 
explained by a greater tendency of psychologically distressed individuals to present to 
doctors. 
1.6.8 INTESTINAL ABSORPTIONAND STC 
Patients with STC invariably complain of hard stools, and hard stools contain less water 
than normal stools (Read & Timms, 1986). In addition, certain laxatives (e. g. 
magnesium salts) work at least in part by exerting an osmotic effect that causes water to 
be retained in the intestinal lumen (Izzo et al., 1996). 
1.6.8.1 Colonic absorption 
Two studies of large intestinal absorption in constipated subjects contained small 
numbers of widely heterogeneous patients without prior physiological selection (Nava et 
aL , 1973; 
Devroede & Soffie, 1973). Using a colonic perfusion technique, they 
concluded that water, sodium & chloride absorption were increased in the symptomatic 
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group, but that such excessive absorption was secondary to stagnation as a result of 
slowed colonic transit and / or variation in large bowel volumes rather than abnornial 
absorptive capacity of the large bowel. No defect in colonic mucosal absorption has 
been demonstrated to date in STC. 
1.6.8.2 Small intestinal absorption 
Low faecal bile acid losses have been reported in a few patients with severe constipation 
(Iser et al., 1977). Bile acids shorten intestinal transit experimentally (Kruis et al., 
1986), and have been used to treat constipation (Hepner et al., 1973). Furthermore, 
anion exchange resins that bind bile acids may be used to treat some patients with 
diarrhoea. Van Tilburg et al. (Van Tilburg et al., 1990) demonstrated, using an in vitro 
preparation of brush border membrane vesicles, that this low faecal bile acid loss was 
associated with a low sodium dependent ileal bile acid transport. Hosie et al. (Hosie et 
al., 1992), having validated a slightly different in vitro methodology utilising an intact 
ileal mucosa preparation, found no significant differences in bile acid absorption 
between patients with proven STC, cancer and ulcerative colitis. 
1.6.9 HORMONAL ABNORMALITIES AND STC 
There has been a special interest in the role of hormones in the aetiology of idiopathic 
constipation because of the well known constipating effects of some common 
endocrinopathies e. g. hypothyroidism, as well as the female predominance of the 
condition. 
1.6.9.1 Non-colonic gut hormones 
A number of substances are released by cells in the mucosa (and in some cases nerve 
endings) of the gastrointestinal tract, where they have a role in postprandial colonic 
motor activity by their participation in gut reflexes. These include the peptides: 
neurotensin, somatostatin, gastrin and cholecystokinin, and also motilin. 
75 
PLD Thesis 2000 
The first studies to measure such hormones in constipated patients showed an impaired 
release of circulating motilin, pancreatic polypeptide and gastrin in response to the 
standard stimulus of drinking water (Preston et al., 1985a), or demonstrated reduced 
basal and stimulated levels of motilin (Sjolund et al., 1986). Recent studies have had 
similarly conflicting results. Van der Sjip (van der Sjip et al., 1998) demonstrated no 
difference in circulating levels of a panel of upper gastrointestinal hormones including 
neurotensin, motilin, gastrin and pancreatic polypeptide, showing alterations only in 
somatostatin (basal increased but stimulated incremental level decreased) and glucagon 
(decreased). A subsequent study of 8 STC patients showed normal basal, but decreased 
postprandial patterns of motilin (absent), cholecystokinin, neurotensin and somatostatin 
(Peracchi et al., 1999). These discrepancies may result from the small numbers of 
patients studied, and ftu-ther studies are required. 
1.6.9.2 Sex hormones 
Because severe idiopathic constipation predominantly effects females, and a high 
proportion of patients have co-existent disorders of menstruation and previous 
gynaecological surgery (Preston & Lennard-Jones, 1986; Waldron et al., 1988), it is 
possible that a gynaecological or hormonal abnormality is associated with STC. 
Additionally, during pregnancy (Winship, 1975, Baron et al., 1993), and the menses 
(Heitkemper & Jarrett, 1992) there is an increased incidence of intestinal symptoms 
including constipation. 
Sex hon-nones are known to have a role in the control of colonic contractility, although 
their significance remains unclear. In vitro studies of canine and human colonic tissue 
have demonstrated a relaxant effect of progesterone on smooth muscle (Kumar, 1962, 
Gill et al., 1985). Similarly, the in-vitro responsiveness of the colon to ACh is reduced 
in the presence of progesterone (Scott & DeFlora, 1989). A similar effect is seen for 
progesterone in the upper gastrointestinal tract (Bruce & Behsudi, 1979). Both 
oestrodiol and progesterone have been shown to influence gastrointestinal transit in the 
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rodent (Ryan & Bhojwani 85). 
However, whilst steroid honnone abnonnalities have been detected in severely 
constipated women (Kamm et al., 1991), it remains unclear as to whether sex hormones 
have an effect on intestinal transit in vivo in the human female either in non-nals or in 
constipated patients (Rees & Rhodes, 1976, Wald et al., 1981, Hinds et al., 1989, 
Turnbull et al., 1989), and whether such alterations in circulating hormone 
concentrations may also reflect an alteration in their enterohepatic metabolism caused 
by stasis or surgery (Kamm et al., 1991). 
1.6.10 TRAUMATIC NEVRONAL INJURY (IATROGENIC) 
The role that pelvic trauma or surgery and childbirth might have in some patients with 
STC has been discussed, and is widely acknowledged. 
1.7 SUMNLARY 
Definition 
Slow transit constipation is defined by transit studies, and is a group disorder in which 
there is considerable patient heterogeneity. Currently used definitions may artificially 
select patients with multiple distinct biological entities, whilst excluding others. 
Pathophysiology 
Studies of colonic contractile activity in STC are extremely limited, and have shown 
some variability in findings. Whilst the failure of these studies to observe basal 
physiological conditions should be noted, patients with STC appear to have a reduction 
in the number, amplitude and duration of colonic HAPCs. Other findings include 
variable abnormalities of rectosigniold motility, and evidence of a generalised intestinal 
disorder in a proportion of cases. Few consistent observations have been made of 
colonic tissue from patients with STC, and this variability has been discussed. In 
general, the majority of studies point to a degenerative neuronal process, although 
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myopathic changes may co-exist. 
Proposed aetiologies 
Previously tested hypotheses (laxatives, absorption, hormones, psychological 
abnormalities, endogenous opioids etc. ) have not provided conclusive results. Accepting 
variability between studies, pathological and physiological evidence exists for a 
neuronal (particularly intrinsic neuronal or extrinsic pelvic parasympathetic neuronal) 
and / or smooth muscle disease process in the pathogenesis of STC. Primary and 
secondary aetiologies leading to such abnormalities may be responsible for the similar 
clinical end-point of STC. 
1.8 AIMS 
The primary aim of this study was to examine new aetiological hypotheses for STC 
following full clinical and pathophysiological characterisation of all patients with 
proven STC referred to our institution over the last 10 years. 
1.8.1 SPECIFICAIMS 
1. to clinically and physiologically classify a group of patients with STC for the 
purposes of further aetiological studies. Areas of interest include: 
a. findings from clinical history taking in relation to symptoms and 
their onset. 
b. findings on gastrointestinal physiological testing. 
C. the subclassification of patients on the basis of clinical and 
physiological findings. 
2. to investigate a potential role of neuronal dysfunction in STC. Specifically: 
a. to look for peripheral sensory or motor abnormalities using 
routine neurophysiology, and quantitatIve peripheral sensory and 
autonomic tests. 
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b. to examine colonic tissue for morphological abnormalities of 
neurones or neural supporting elements suggestive of intrinsic or 
extrinsic neuronal dysfunction. 
C. to examine the possible pathogenesis of neuronal dysfunction 
including: 
i. congenital mechanisms: germline mutations 
ii. acquired mechanisms: autoantibodies to neuronal ion channels 
3. to investigate a potential role of smooth muscle dysfunction in STC. 
Specifically: 
to examine colonic and small intestinal smooth muscle for the 
presence of inclusion bodies. 
b. to test whether such inclusions are a specific and unique feature 
of STC, or reflect a secondary cellular response to denervation or 
other tissue injuries. 
C. to establish the composition of such inclusions. 
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MATERIALS AND METHODS 
2.1 INTRODUCTION 
This chapter covers the recruitment and selection of patients for participation in 
clinical and tissue based studies of STC. The methodology of gastrointestinal 
physiological investigations required for selection of patients for further studies, i. e. 
the physiological entry criterion defining STC, is discussed in detail. Likewise general 
methodology relating to the preparation of the thesis is included. As a result of the 
diversity of the studies included in the thesis, specific methodology pertaining to each 
study and the background of such methods are discussed separately within each 
appropriate chapter. Control and comparison subjects are described in the chapters to 
which they refer, and listed in appendix 2.01. 
The latter part of the chapter presents a summary of all the clinical data collected for 
STC patients, which is tabulated. 
2.2 ETHICS APPROVAL 
The use of patient and control human subjects, for clinical studies (Chapter 5), and 
tissue studies (Chapters 6-8) was approved by the East London and the City Health 
Authority (ELCHA) Research Ethics Committee. The following ethics committee 
references cover the body of work contained within this thesis. 
ELCHA no: P97062 
ELCHA no: P97338 
ELCHA no: P98258 
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2.3 STC PATIENTS 
2.3.1 RECRUITMENT 
Patients for study were recruited by written invitation from the author, or directly 
approached in person at times of clinical presentation to the Royal London Hospital. 
Initial selection of patients for recruitment was based on information provided from 
surgical colleagues, the Gastrointestinal Physiology Unit (GIPU) (Dr Mark Scott), and 
from lists of patients used in previous research studies of this condition (Dr Marie- 
Anne Pilot; Dr Mark Scott). In all cases, where participation was invited for further 
research investigations, appropriate consent was obtained. The GIPU investigates an 
almost exclusively adult population. 
23.2 SELECTION 
2.3.2.1 Inclusion criteria 
Patients with STC were identified from those referred consecutively to the Royal 
London Hospital for lower gastrointestinal physiological investigation of constipation 
between 1988 and 1999. Patients were included on the basis of- 
1. Fulfilment of clinical criteria for idiopathic constipation. Constipation was defined 
according to agreed criteria (see chapter 1) (VA-iitehead et al., 1991), as the presence 
of fewer than 2 bowel movements per week for at least 12 months, or the presence 
of 2 or more of the following complaints for at least 12 months: 
- Straining on at least 25% of bowel movements when not taking laxatives. 
- Feeling of incomplete evacuation after at least 25% of bowel movements when not 
taking laxatives. 
- Stools less frequent than 3 per week without laxatives. 
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2. Demonstration of a reduction in the rate of progress of colonic intraluminal contents 
by radio-opaque marker studies, "'In DTPA isotope scintigraphy, or both (see 
CHAPTER I and below). 
3. Proof of the above, regardless of the time or mode of onset of symptoms. Patients 
were included if they had idiopathic STC, or symptoms were coincident temporally 
with any defined event i. e. pelvic surgery, neurological disease. Such divisions did 
however effect subsequent study inclusion and analysis of data (see chapter 3). 
Z3.2.2 Exclusion criteria 
Patients were specifically excluded for the following. 
1. Failure of proof of STC. i. e. severe intractable constipation without transit study, or 
with a negative study. Some such patients were however included in chapter 4, and 
were used as positive controls in chapter 8. This group predominantly included 
patients with isolated rectal evacuation disorders (RED). 
2. Inadequate data available. These included patients who were known historically to 
have had a positive transit study, but in whom the patient was lost to follow-up, and 
the notes unavailable for review. 
3. Isolated functional rectosigmoid hold-up, as demonstrated by isotope scintigraphy, 
with proctographic evidence of significant mechanical pelvic outlet obstruction. 
These patients were excluded on the basis that they do not fulfil the criteria for STC 
(Krevsky et al., 1989; McLean et al., 1995). 
4. Evidence of megabowel (megacolon or megarectum). This is defined by increased 
bowel calibre on contrast studies (Preston et al., 1985b), and is a separate clinical 
(Gattuso & Kamm, 1997), and probably pathological (Gattuso et al., 1994) 
condition from STC. These patients were however included as disease controls in 
chapter 7. 
5. Histological evidence of Hirschsprung's disease (HSCR). Patients with equivocal 
rectoanal inhibitory reflexes (see below) underwent rectal biopsy to exclude HSCR. 
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[No such patients were referred]. 
6. Evidence of an obstructive organic cause for constipation i. e. neoplasia / stricture. 
[No such patients were referred]. 
2.3.3 DATA COLLECTION 
2.3.3.1 Methods of collection 
Clinical information was obtained by interview and review of records (patient hospital 
notes and computerised records (patient administration system, PAS). Data were 
collected: 
1. Prospectively 
2. Retrospectively 
2.3.3.2 Data storage 
Patients presenting during the course of the thesis study period 
i. e. October 1996 to October 1999. 
Patients seen before October 1996 
a. Patients recalled for interview or participation in research 
protocols. 
b. Patients unavailable for recall; notes review only. 
All data, regardless of method of acquisition, were stored on a dedicated, password 
protected database, which was established at the start of the study, and modified 
subsequently as required. Data were stored on Microsoft 9 Access 97 for Windows 
95 (Microsoft Corporation, Santa Rosa, CA, USA). Subsequent data manipulation 
was performed by executing 'queries'. Hard copies of data were produced using 
'report' fanctions. 
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2.3.3.3 Clinical data 
A full clinical history, including the nature of the patients presenting symptoms, mode 
of onset, personal past medical / obstetric / psychiatric / treatment history, family 
history, and systematic enquiry was obtained, and included the variables listed in table 
2.01 
Table 2.01: Clinical data collected for STC patients 
Basic details 
Duration 
Mode of onset / 
precipitating 
events 
Presenting 
symptoms 
Name lAge ID. O. B lAddress / Occupation 
Age of onset 
Age atpresentation 
Duration (years) 
Obstetric episode lpelvic surgery 
Neurological disease/ injury 
Physical/ sexual abuse 
Other 
None 
Defaecatory symptoms 
Other gastrointestinal 
svmptoms .1A 
Frequency of bowel action 
Straining 
Time spent per attempt 
Incomplete evacuation 
Unsuccessful evacuation 
Painful evacuation 
Stool consistency 
Incontinence 
Sensation of rectal prolapse 
Digitation: rectal / vaginal 
Rectal bleeding 
Abdominal pain 
Abdominal bloating 
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Dyspepsia 
Nausea / vomiting 
Management Drugs Laxatives 
Suppositories / enemata 
Prokinetics 
Behavioural therapy Biofeedback 
Surgery Anorectal or abdominal 
Personal History Surgical history 
Obstetric & gynaecological 
history 
Past medical history Metabolic / endocrine 
Neurological / spinal disease 
Rheumatological 
Autoimmune 
Other 
lyschiatric history 
Drug history 
Family history Constipation I other 
Systems enquiry Urological symptoms 
Neurological symptoms Central nervous system 
Peripheral nervous system 
Autonomic nervous system 
Rheumatological symptoms 
Patients had previously undergone routine clinical examination performed in an 
outpatient setting by a surgeon or physician of consultant grade. This included general 
and abdominal examination, and pelvic examination by digital rectal examination, 
proctoscopy and sigmoidoscopy. Such examination is directed primarily at excluding 
organic disease, and these data were not specifically collected for the purposes of this 
study. 
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2.3.3.4 Routine investigations 
Patients had previously undergone blood tests to exclude metabolic or endocrine 
disease (thyroid function tests, serum calcium, and random blood glucose). An 
anatomical study of the large intestine was performed using either double contrast 
barium enema and / or colonoscopy. 
2.4 GASTROINTESTINAL PHYSIOLOGICAL TESTS 
A number of tests have been developed, principally in the last 30 years, to examine 
the physiological function of the colon and anorectum. An introduction to transit 
studies has been made in chapter 1, and the contractile activity of the colon and 
rectosigmoid in health and disease, as tested by manometric studies has also been 
discussed. Such manometric tests predominantly remain a research tool. This section 
specifically describes the tests used routinely to assess patients presenting with 
constipation to the GIPU. Whilst some other tests may have been performed for some 
patients, including anorectal electromucosal sensitivity testing, pudendal nerve motor 
latencies and anal ultrasound, these had not been uniformly perfon-ned, and are not 
presented in this thesis. The data from the following tests are included in this thesis: 
1. Transit studies 
2. Anal manometry 
3. Rectal sensory testing 
4. Evacuation proctography 
5. Upper gastrointestinal studies 
Radio-opaque marker and / or radioisotope 
Anal sphincter resting and squeeze pressures 
Rectoanal inhibitory reflex testing 
First constant sensation 
Defaecatory desire volume 
Maximum tolerated volume 
Prolonged ambulatory small bowel 
manometry 
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2.4.1 TRANSIT STUDIES 
2.4.1.1 Radio-opaque markers 
Laxative medication and opiate analgesics were stopped 24 h prior to the start of the 
study and avoided until its completion. Patients remained on their normal diet during 
the study period. Studies were carried out as previously described (Roberts et al., 
1993), with a single plain abdominal radiograph performed at 100 h after 
administration of a gelatin capsule (broken down rapidly in the stomach) containing 
50 radio-opaque markers, cut from a length of 2.5 mm (external diameter) diameter 
radio-opaque vinyl tubing (SIMS Portex Ltd., Hythe, UK). A positive study was 
defined as >20% of 50 administered markers remaining at 100h (Hinton et al., 1969; 
Evans et al., 1992; Roberts et al., 1993). 
2.4.1.2 "'In-[DTPAI isotope colonic scintigraphy 
Laxative medication and opiate analgesics were stopped 24 h prior to the start of the 
study and avoided until its completion. Patients remained on their normal diet during 
the study period. Colonic scintigraphy was carried out as previously described 
(Roberts et al., 1993). 3.7 MBq of [1111n]DTPA (Amersham International Plc, 
Amersham, UK), equivalent to an effective whole body dose of 1.1 mSv in normal 
individuals, was ingested orally in a small quantity of water on the afternoon of day I 
(TimeO h). Anterior (supine) and posterior (prone) abdominal scans were taken with a 
gamma camera (Scintiview; Siemens Plc., Bracknell, UK) twice a day for the 
following four days at T18,24,42,48,66,72,90 & 96 h-Any bowel movement that occurred 
following ingestion of the radioisotope was collected and the activity counted. 
Data Processing and Analysis 
Seven regions of interest (ROIs) were drawn around computer generated images of 
the anterior and posterior abdominal scans for each patient, namely: (1) caecum and 
ascending colon, (2) hepatic flexure, (3) transverse colon, (4) splenic flexure, (5) 
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descending colon, (6) sigmoid colon and rectum, and (7) excreted faeces (Roberts et 
al., 1993). The percentage activity (of total ingested activity) in each ROI was 
calculated at each time point by customised computer software (Micas V Nucmed 
software; Park Medical Systems (UK) Ltd., Farnborough, UK) which corrected scans 
for decay, and averaged corresponding anterior and posterior scans to correct for 
tissue attenuation (geometric mean). Time-activity curves for each ROI were then 
generated, and the geometric centre of isotope mass (GCI) at each time point plotted 
(Figure 2.01) (Krevsky et al., 1986; Roberts et al., 1993). GO is synonymous with 
MAP (mean activity position: (McLean et al., 1995), COM (centre of mass: van der 
Sijp et al., 1993), or geometric centre (Krevsky et al., 1986; Stivland et al., 1991). 
STC was defined by scintigraphy as a failure of total excretion of isotope by 
approximately 70 hours (based on control data from the Radioisotope Department, 
Royal London Hospital) (Roberts et al., 1993). In practice, patients showed significant 
slowing of isotope progression at 48 hours with minimal faecal elimination occurring in 
the duration of the study (96 hours) (Roberts et al., 1993). Delineation of differential 
patterns of colonic transit was based on previous published guidelines: a delay 
throughout the entire colon (generalised delay), based on a GCI of < 3.6 at 48 h 
(Roberts et al., 1993; Maurer & Krevsky; 1995) or a distal colonic delay only, based 
on a GO of ý! 3.6 at 48 h (Roberts et al., 1993). 
2.4.2 OTHER PHYSIOLOGICAL TESTS 
2.4.2.1 Anal manometry 
Satisfactory measurements of anal canal pressures and anal sphincter responses can be 
obtained with open-tipped or side-opening water-perfused catheters, direct online 
solid-state transducers, or air- or water-filled balloons of various sizes and 
configurations. Normal anal canal pressures vary according to sex, age and technique 
used (see AGA Technical review, Diament et al., 1999). In general, pressures are 
higher in men and younger people (Jameson et al., 1994), and are reduced by 
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Region of interest (ROI) 
F 7' 
SUR 
DC 
SF 
TC 
HF 
C/AC I 
6000 
Normal 
Time (hours) 
= normal control range 
Figure 2.01: Isotope scintigraphic transit study. Progress of the geometric centre of 
isotope mass (GC1) through the colon with time. Seven regions of interest (ROls) are 
defined: 
C/AC= caecurn / ascending colon; 
HF = hepatic flexure; 
TC = transverse colon; 
SF splenic flexure; 
DC descending colon; 
SUR = sigmoid colon / rectum; 
faeces. 
The graph shows a normal control, control range, and a typical trace of a patient with 
generalised STC. 
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childbirth (Sultan et al., 1993). 
For patients included in this thesis, standard anorectal manometry was performed 
using 2 systems. Earlier studies used a water-filled 4mm microballoon system 
connected to a Bell and Howard pressure transducer (Type 4-422-0001, Bell & 
Howard Ltd., UK) (Hallan et al., 1989), whereas more recent studies used a single- 
channel side-hole catheter (McHugh & Diament, 1987) linked to a Amdorfer-type 
pneumohydraulic water perfusion system (Amdorfer Medical Specialities, Greendale, 
USA). Similar methodologies i. e. closed (balloon) vs. open (side-hole perfusion) 
systems have been compared and some differences demonstrated (Hancock, 1976). 
For both methodologies, measurements of functional anal canal length, maximal 
resting tone and maximal voluntary squeeze pressures were determined using a station 
pull-back technique (Read et al., 1979). Presence or absence of the recto-anal 
inhibitory reflex (RAIR) was also confirmed by positioning the manometry catheter in 
the high-pressure zone of the anal canal and distending the rectum with an air-filled 
balloon tied to a Foley-catheter (Farthing & Lennard-Jones, 1978). For the closed 
system departmental control values for women < 50 years of age were used to define 
abnormal results (Hallan et al., 1989): resting pressure (40 -I 10 cm H20), squeeze 
increment (40 - 160 cm H20). For the perfusion system, no departmental control 
values were available, and control values were taken according to data using the same 
methodology from St Mark's Hospital: resting pressure (50 -I 10 cm H20), squeeze 
increment (50 - 160 cm H20). Such values are comparable to those obtained from the 
literature for this technique (Read et al., 1979; Read et al., 1986). Reference values, 
stratified for age and parity were not available for this study, and any conclusions 
derived from these findings have been accordingly treated with caution (Chapter 3). 
2.4.2.2 Rectal sensory testing 
Rectal sensation was assessed by inflating the same rubber party balloon with air at I 
ml/sec and determining the threshold volumes for first constant sensation, defaecatory 
desire and maximum toleration (Farthing & Lennard-Jones, 1978). Values obtained 
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for each sensory threshold were compared with normal ranges matched for age and 
sex (Jameson et al., 1994). 
2.4.2.3 Evacuation proctography 
Evacuation proctography was perfori-ned by instilling barium paste (artificial stool) 
into the rectum to the previously determined maximum tolerable volume and allowing 
the patient to evacuate under fluoroscopy (Mahieu et al., 1984; Womack et al., 1985). 
The semisolid contrast medium was prepared by mixing barium sulphate and scotch 
porridge oats at body temperature to make a thick paste. The contrast was injected 
into the rectum using a wide tipped syringe via a proctoscope. With the patient seated 
on a radiolucent commode, lateral fluoroscopy was performed using an image 
intensifier (Siemens Plc., Bracknell, UK). The amount of contrast voided, and the 
time taken to void were recorded. Any radiological abnormalities in the rectum were 
identified. 
The definition of what constitutes normality or a rectal evacuation disorder (RED) 
with respect to evacuation proctography is difficult because (a) control ranges for time 
and volume do not exist; (b) the amount voided is estimated by eye only; (c) 
proctographic "abnormalities", especially small rectoceles occur in subjects without 
defaecatory symptoms (Shorvon et al., 1989); (d) The traditional barium paste used 
for performing defaecography may not accurately represent normal rectal evacuatory 
function, when in the case of patients with STC the stool often has a consistency of 
hard pellets (89% of patients in this series: see appendix 2.04), and (e) embarrassment 
may inhibit defaecatory effort. Attempts have been made to use more "realistic" 
artificial stool types, but this has usually been at the expense of visualising 
proctographic filling abnormalities (Pelsang et al., 1999). For the purposes of this 
thesis, the presence of a functional rectal evacuation disorder was made by a 
consultant coloproctologist with experience in gastrointestinal physiological 
investigation, based loosely on the inability of the patient to evacuate the "majority 99 
(approx. 80%) of the contrast in a reasonable time period (approx. less than 2 min), 
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and the absence of an anatomical proctographic obstruction which retained contrast. 
Patients with everting prolapse were defined as having an RED regardless of their 
I-I'k ability to evacuate. 
2.4.2.4 Small bowel manometry 
Prolonged proximal small bowel manometry was used to establish the presence or 
ni, dusence of a generalised intestinal disorder (Redmond et al., 1995). Twenty-four hour 
ambulatory studies were performed in the Gastrointestinal Science Research Unit of 
the Royal London Hospital (GISRU) according to protocol (Castillo PhD Thesis, 
1994; von Schonfeld et al., 1997). Studies used a thin, flexible manometric catheter 
incorporating 3-6 strain-gauge micro-transducers [type: CTG/L3] (Gaeltec Ltd., 
Dunvegan, Isle of Skye), and a central air channel and 10ml balloon. Catheters were 
pre-cleaned and calibrated. Patients were intubated in the sitting position with the use 
of a water-soluble lubricant, and xylocaine spray to anaesthetise the nasal and oral 
mucosa. Advancement of the tip of the catheter was facilitated by asking the patient to 
swallow water. Catheter position was confirmed using fluoroscopy, with measures 
taken to limit radiation exposure. Once the middle catheter had reached the ligament 
of Trietz the balloon was deflated, the catheter securely taped to the side of the face 
and ear, and the connector plugged into a Flex 3000 multichannel intestinal data 
logger (IDL) (Oakfield Instruments, Oxford, UK). At the end of 24 hour recording, 
the catheter was removed, and data transferred to an IBM PC. 
Analysis was performed by Dr Mark Scott and Dr Etsuro Yasaki using specialised 
software developed in the GISRU (Benson et al., 1993). The computer algorithm used 
to analyse the large numbers of pressure events over the recording period has been 
shown to be superior in reliability and reproducibility, as well as considerably faster, 
than manual visual analysis (Benson et al., 1993). In particular, the algorithm 
overcomes the problems of variable baseline and sudden changes in pressure due to 
body movements that are unavoidable in prolonged recording from the small bowel of 
ambulant subjects. 
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Interpretation of data analysed by the computer algorithm was performed by Professor 
David L Wingate (GISRU). Interpretation reviewed 22 main parameters of phasic 
activity of the intestinal interdigestive migrating motor complex (IMMC) for daytime 
and nocturnal recording periods, comparing numeric activity values with departmental 
controls (Castillo PhD Thesis, 1994). Patterns of abnormality, said to be indicative of 
neuropathic or myopathic disease have been previously described (Soffer & 
Thongsawat, 1996), and continue to be further validated (Wingate, 1999; manuscript 
in preparation) 
2.5 DATA ANALYSIS 
25.1 SOFTWARE 
Following database entry, data were generally exported following appropriate 
execution of 'queries' into a spreadsheet application (Microsoft 9 Excel 97, SR-1, 
Microsoft Corporation, Santa Rosa, CA, USA). After manipulation within this fon-nat, 
further statistical analysis and graphic presentation of data were perfort-ned using a 
computerised statistical package (GraphPad Prism v. 2.0, GraphPad Software, Inc., 
San Diego, CA, USA), unless otherwise stated (see chapter 4: Systat v. 8.0, SPSS, 
Inc. Chicago, USA). 
25.2 STATISTICAL ANALYSIS 
Specific statistical analyses are described within the chapters to which they refer. 
Deviations from a Gaussian distribution were tested using the Kolmogorov-Smirnov 
test with ap value calculated from Dallal and Wilkinson's approximation to 
Lilliefor's method (Dallal & Wilkinson, 1986). In general, most data comparison was 
performed with non-parametric analyses based on the distribution of data points. 
Comparing numerical data between groups 
The Mann-Whitney U-test was used for comparison of 2 independent populations of 
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non-parametric numeric data, and the Wilcoxon rank-sum test for paired sets of data. 
For studies comparing 3 or more groups, an analysis of variance (ANOVA) was 
performed using the Kruskal-Wallis test +/- a post test for multiple comparison of 
individual groups (Dunn's multiple comparison post test). 
Contingency analyses 
Contingency analyses were performed using Fisher's exact (2 rows and columns in 
contingency table) or chi-square tests (more than 2 rows or 2 columns in contingency 
table). A two-tail p value was calculated in all cases. 
Correlation 
Linear correlation or regression was used to compare the covariation of 2 numeric 
variables. In simple terms, regression was chosen when X values were controlled e. g. 
age. When linear regression analysis was used, 95% confidence intervals (CI), 
goodness of fit (r 2) , and residuals were calculated. Ap value testing whether the slope 
is significantly different from zero was calculated from an F test. These parameters 
are shown on the graphs, as is now the recommended convention (Porter AM, 1999). 
When correlation was applied, parametric (Pearson correlation) or non-parametric 
(Spearman correlation) methods were used as appropriate. 
The measure of inter-rater or inter-method agreement for categorical data was 
presented as the kappa (K) statistic to correct proportional agreement for chance 
(Altmann, 1996). The interpretation of the K value was based on published guidelines 
(Landis & Koch, 1977). 
For all tests, p<0.05 was considered to show a significant difference. 
2.6 LITERATURE REVIEW AND REFERENCING 
References within this thesis were obtained by literature review, including the use of 
Medline searches from: Ovid for Windows v. 3.0, release 7.05 (Ovid technologies 
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Inc, New York, USA), and Pubmed, National Center for Biotechnology Infonnation 
[www. ncbi. nlm. nih. gov]. 
All references have been prepared in accordance with the "Uniform requirements for 
manuscripts submitted to medical Journals" developed by the international Committee 
of Medical Journal Editors (N EngI J Med 199 1; 324: 424-428), based on formats for 
bibliographical references first developed by the Vancouver Group. 
2.7 STC PATIENT DATA SUMMARY 
27.1 SELECTION OF THE STUDYPOPULATION 
Inclusion (see 2.3.2.1) 
Of 1365 patients referred for lower gastrointestinal investigation during the 10 year 
period, 1989 to 1999,485 presented with symptoms of severe intractable constipation. 
Of these, 146 patients were found to have slow colonic transit. 
. 
Exxclusion (see 2.3.2.2) 
Ten patients were excluded for lack of information. Four patients were found to have 
megarectum and are excluded from this data. Two further patients were excluded on the 
basis of the demonstration by scintigraphy of isolated functional rectosigmoid hold-up, 
coincident with a significant mechanical RED, leaving a total of 130 patients. No 
patient was found to have HSCR or an obstructive organic cause for constipation. 
The final figure of 130 was equal to 9.6% of the total, and 26.8% of constipated patients 
referred to the GI physiology Unit for investigation. Patients with normal colonic transit 
(73.2%) had constipation attributable to other causes (e. g. isolated rectal evacuation 
disorders, constipation-predominant irritable bowel syndrome). The proportion of 
patients with STC as a function of the total presenting with intractable constipation is 
higher than that reported from the Mayo Clinic in an equally large series (Nyam et al., 
1997), but comparable with European series (de Graaf et al., 1996). This difference 
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from series in the USA may reflect an increased presentation or prevalence of IBS in 
this population, or may simply reflect referral pattern to our institution which 
historically has a surgical bias. Indeed, some patients were referred for finiher specialist 
investigation on the basis that STC had already been proven at the referring centre. 
2.7.2 RECRUITMENT DATA (see 2.3.3.1) 
Fifty patients were recruited prospectively. A further 35 patients were recalled for 
interview, leaving 45 whose data were collected by notes review only. 
2.7.3 DEMOGRAPHICDATA (APPENDIX2.02) 
The wide age range reflects the heterogeneity of the population (Chapter 3), and is 
comparable with previous series (Kamm et al., 1988; Yoshioka & Keighley, 1989; 
Piccirillo et al., 1995; Lubowski et al., 1996; Platell et al., 1996; Nyam et al., 1997). 
The strong female predominance (32: 1) is also recognised (Preston & Lennard-Jones, 
1986; Kamm et al, 1988; Chaussade et al, 1989). The interpretation of the strong 
caucasian predominance is difficult. The majority of patients from Greater London 
were residents of the London Borough of Tower Hamlets which has a large ethnic 
proportion of the population. The relatively low incidence of ethnic minorities may 
reflect cultural differences with respect to the decision to report constipation, or may 
be a true reflection of a lower incidence in these populations. Large demographic 
studies in the USA have not shown differences in self-reporting of symptoms of 
constipation between such populations (Johanson & Sonnenberg, 1990). The 
geographical make-up of patients reflects the referral practice of consultants within 
and without the Royal Hospital's catchment area. 
2.7.4 AGE AND MODE OF ONSET (APPENDTX2.03) 
Data with respect to the age and mode of onset are discussed in detail in chapter 3. 
Commonly, the patient was unable to ascribe an exact age to the start of their 
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symptoms. In such cases, a notional age was given dependent on the patient's 
response to this question. Where the patient described the onset as "a baby" or 4'in 
infancy", the age of onset was taken to be I year; onset "in early childhood", 5 years; 
"in childhood" (unspecified), 8 years; and in teenage, 15 years. Duration of symptoms 
was then calculated by subtracting the age of onset from the age at presentation. 
Patients in whom symptoms were present from childhood, but who presented only 
after a significant worsening of their symptoms in adulthood (n = 11) usually as a 
result of pelvic surgery, are discussed in chapter 3. These patients are not shown in 
the appendix. Median age of initial onset in these patients was 8 years (range 4- 8), 
and median age of symptomatic worsening was 40 years (range 22 - 50). The wide 
rage of ages of onset overall reflects the heterogeneity in the STC population, and has 
been shown in previous series (Preston & Lennard-Jones, 1986; Waldron et aL, 1988). 
Symptom duration was similarly highly variable: median 20 years, range (I -7 1). 
The mode of onset i. e. idiopathic vs. following a recognised precipitating event e. g. 
pelvic surgery is discussed in detail in chapter 3. The main precipitating factors are 
listed in appendix 2.04. 
27.5 PRESENTING SYMPTOMS (APPENDIX 2 05) 
The frequency of bowel action was taken as the time numerically in days between 
successive bowel actions (with laxatives if these were being taken) at the time of 
presentation. The value was based on the mean of the extremes when ranges were 
given. In some patients a numeric value could not be obtained on questioning. The 
median bowel frequency was 8 days (range I- 49 days) in the 115 patients where a 
value was recorded, and is comparable with previous series (Preston & Lennard- 
Jones, 1986; Waldron et al., 1988). Abdominal bloating was the commonest symptom 
(after constipation), occurring in 97% of patients. Incomplete evacuation and 
abdominal pain were similarly very common (95%). Less common symptoms 
included incontinence of faeces (self-defined by the patient: 20%), a feeling of rectal 
prolapse (14.5%), and the need for digitation (either vaginal or rectal: 24%). 
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Interestingly, upper gastrointestinal symptoms, particularly nausea or vomiting were 
reported by over half the patients, The frequencies of these symptoms were again 
comparable to previous studies (Preston & Lennard-Jones, 1986; Waldron et al., 
1988). 
Z 7.6 MA NA GEMENT (A PPENDIX 2.06) 
Ninety percent of patients were taking, or had taken laxatives for the treatment of 
constipation. Multiple laxative preparations had commonly been tried, and included 
bulk forming laxatives (commonly ispaghula husk), stimulant laxatives (commonly 
bisacodyl, danthron, senna and sodium picosulphate), osmotic laxatives (commonly 
lactulose). A smaller proportion used suppositories (usually glycerine) (39%) or 
enernata (usually phosphates) (28%). Only 7% had been prescribed a prokinetic 
(cisapride in all cases). 
A wide variety of surgical interventions had been used. These included anorectal 
procedures for the treatment of mechanical obstructions to defaecation such as 
rectopexy for prolapse, and rectocele repair. A proportion of patients had undergone 
colonic resections, most commonly subtotal colectomy and ileorectal anastomosis 
(Preston et al., 1984) (n = 15,12%). Colonic conduit formation is a relatively new 
operation (Williams et al., 1994) to allow anterograde colonic irrigation through a 
continent stoma, and was performed in 6 patients. In general, the results of surgery 
were variable: of the total of 8 ileostomies formed, 4 were performed electively as a 
first procedure, but 4 were performed for poor outcome from colonic surgery. 
Two patients had been included in a trial of botulinum injections for a diagnosis of 
44anismus" (see Hallan et al., 1988). Interestingly, despite the demonstration of the 
efficacy of behavioural therapy in some centres (Chiotakakou-Faliakou et al., 1998), 
only 2 recently investigated patients had been further referred for biofeedback 
therapy. This small number probably reflects the lack of availability of this service in 
the East London Region. 
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27.7 PERSONAL HISTORY (APPENDIX 2 07) 
2.7.7.1 Surgical history 
Common general surgical operations included appendicectomy (11%) and 
cholecystectomy (4%). In general, a history of abdominal surgical procedures was 
much less frequent than gynaecological procedures with only 31% of patients having 
undergone one or more procedure. 
2.7.7.2 Obstetric history 
Over 2/ 3'd of patients were parous. The distribution of parity is shown with the rates 
of instrumentation (venteuse or forceps) and caesarean section. Rates of episiotomy 
and tears (of any degree), and of prolonged second stage of labour were recorded for 
some patients, but not specifically questioned in the majority. These data have not 
therefore been tabulated. Overall, approximately 10% of patients had one or more 
caesarean section, and 7% had one or more instrument assisted deliveries. 
2.7.7.3 Gynaecological history 
Commonly reported gynaecological conditions and interventions are shown in the 
appendix. Approximately one third of patients had a diagnosed coexistent 
gynaecological disease. Over half (64 / 113) of patients had undergone some 
gynaecological surgical intervention, with some having multiple procedures. This 
figure is comparable with other STC series in which the coincidence of procedures 
was similarly high (Preston et al., 1984; Kamm et al., 1988), and may reflect a role 
either of such surgery in the causation of STC (20 patients attributed origin or 
worsening of symptoms to gynaecological surgery, especially hysterectomy) (see 
chapter 1.4.1.1), or that gynaecological surgery was performed for symptoms 
(especially pelvic and abdominal pain) that were actually related to STC. 
Hysterectomy was the most commonly perfon-ned procedure (38 patients, 34% total). 
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The low incidence of recorded gynaecological disorders (especially in comparison 
with gynaecological surgery) reflects the fact that the majority of surgery was 
performed on the basis of symptoms rather than an underlying diagnosis i. e. 
menorrhagia, dysfunctional uterine bleeding and dysmenorrhea. Although such 
symptoms were commonly reported, data were not specifically collected, and have 
therefore not been included. 
2.7.7.4 Past medical history 
The numbers of patients with metabolic / endocrine, cardiorespiratory, neoplastic, 
neurological and spinal conditions are shown in the appendix. No patient had diabetes 
mellitus, and although 5 patients had thyroid disease, all these had been successfully 
treated. Both patients with malignant disease (malignant ocular melanoma, pulmonary 
carcinoid) had been successfully treated, and at the time of review were in remission 
from disease. Reported neurological conditions were uncommon, but spinal disease 
(13%) or spinal surgery (8%) were relatively common. This reflects in part, the 7 
patients whose bowel symptoms arose as a result of CNS injury. 
2.7.7.5 Psychiatric history 
A history of psychiatric illness was present in 23% of patients. It should be noted that 
this figure included patients with a disorder at any time in the past regardless of 
severity, or need for specific therapy. For instance, whilst depressive illness was 
relatively common (13%), only 7% of patients (see below) were currently taking anti- 
depressant medication. Other disorders e. g. anxiety states, behavioural disorders were 
less common. 
27.8 DRUG HISTORY (APPENDIX 2 08) 
Current (at the time of study), physician or self-prescribed medications have been 
tabulated. Analgesics were most commonly used (22%). Eleven patients were taking 
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opiate-containing medications, and this group included several post-colectomy 
patients using codeine for its anti-diarrhoeal properties as well as those taking opiates 
for analgesia. Antidepressants or antianxiolytics were only used by 9 patients, With 
the exception of 2 patients (see above: drug abuse) the use of opiates post-dated 
diagnosis of STC. Antidepressants may have influenced constipation, but no patient 
was taking any other drugs that are known to be neurotoxic, or induce constipation 
e. g. verapramil, anticholinergics. 
2.7.9 FAMILYHISTORY (APPENDIX 2.09) 
Of the total of 91 patients in which data were recorded (37 data not available, 2 
adopted), 39 patients (43%) gave a history of constipation in one or more family 
relative. Seventeen patients (19%) had relatives who had consulted medical 
practitioners for their problem, and included patients who had undergone 
investigation and surgery for constipation (n = 3). One patient had an identical 
(monzygotic) twin with severe symptoms comparable with her own. Four index cases 
had one or more relative with HSCR who are further discussed in chapter 6. A family 
history of autoimmune and rheumatological conditions was elicited in those patients 
tested for ion channel autoantibodies (see chapter 7). 
2.7-10 SYSTEMATIC ENQUIRY (APPENDIX 2.10) 
A high proportion (39%) of patients had coexistent urological symptoms. Commonly 
reported symptoms included urinary frequency (24%) and incontinence (stress and 
urge) (19%). Such urinary problems are known to commonly occur in patients with 
STC (Abdel-Rahman et al., 1981; Watier et al., 1983; Bannister et al., 1988; Kerrigan 
et al., 1989). Enquiry for neurological symptoms, including those suggestive of 
peripheral and autonomic dysfunction was undertaken for patients having 
neurophysio logical studies (Chapter 5). Similarly, symptoms suggestive of 
autoimmune or rheumatological disease are included in chapter 7. 
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SLOW TRANSIT CONSTIPATION: 
RESULTS OF PHYSIOLOGICAL 
STUDIES; CLINICAL AND 
3 
PHYSIOLOGICAL HETEROGENEITY 
3.1 INTRODUCTION 
Patients with STC may be considered for surgical intervention, including subtotal 
colectomy and ileo-rectal anastomosis or segmental resection (Preston et al., 1984). The 
highly variable outcomes of such surgical procedures in this group of patients (Preston 
et al., 1984; Kamm et al., 1988; Piccirillo et al., 1995; Nyam et al., 1997; Bemini et al., 
1998; Hasegawa et al., 1999) have been described. These may be due to the lack of 
effectiveness of such interventions as a whole, or may simply reflect heterogeneity 
within this group of patients. However, difficulty exists in comparing outcomes after 
surgery because of lack of detail regarding patient selection (Knowles et al., 1999). In 
particular, most publications do not detail clinical history beyond duration of symptoms, 
and uniform or complete pre-operative physiological work-up is not always 
documented. 
It is well recognised that heterogeneity of clinical presentation exists amongst patients 
with STC. In the majority of patients, symptoms arise de-novo in childhood, and these 
have been labelled chronic and idiopathic (Preston & Lennard-Jones, 1986). The 
aetiology of such idiopathic cases remains unclear, and is probably itself heterogeneous, 
with attribution to extrinsic autonomic, intrinsic neuropathic or myopathic dysfunction, 
and even psychogenic causes. 
A proportion of patients with intractable slow transit constipation present in later life. 
Some of these patients will have no obvious trigger for their complaint (Waldron et al., 
1988), whereas others follow events such as hysterectomy (Roe et al., 1988, Vierhout et 
al., 1993) or childbirth (MacDonald et al., 1993; MacDonald et al., 1997). An additional 
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sub-group includes those patients whose constipation appears to follow a recognised 
acute or chronic neural injury. This sub-group includes presumed myenteric damage e. g. 
diabetes (Iber et al., 1993; Maleki et al., 1998), progressive systemic sclerosis (Howe et 
al., 1993; Eaker et al., 1999), Chagas' disease (Wood et al., 1982; de Oliveira et al., 
1998; Goin et al., 1999), spinal injury (trauma, tumour) (Devroede et al., 1979; Beuret- 
Blanquart et al., 1990; Keshavarsian et al., 1995; Leduc et al., 1997; DeLooze et al., 
1998), and CNS disease (Parkinson's, CVA, demyelination e. g. MS) (Weber et al., 
1987). 
It is similarly recognised that, in addition to the finding of a colonic transit disturbance, 
other gastrointestinal and extra-gastrointestinal physiological abnormalities may co- 
exist, including: (a) disorders of rectal evacuation, either anatomical (Waldron et al., 
1990; Wald et al., 1990; Nyam et al., 1997; BerniM et al., 1998; Hasegawa et al., 1999), 
sensory (Akervall et al., 1988; Waldron et al., 1990; Kamm & Lennard-Jones, 1990), or 
functional (Read et al., 1986; Wald et al., 1990); (b) upper gastrointestinal dysmotility 
(Watier et al., 1986; Panagamuwa et al., 1994; Bassotti et al., 1996; Ghosh et al., 1996; 
Glia & Lindberg, 1998); and (c), bladder dysfunction (Abdel-Rahman et al., 1981; 
Watier et al., 1986; Kerrigan et al., 1989; Ghosh et al., 1996). 
In this chapter: 
1. The physiological data collected from all STC patients are presented. 
2. Patients have been classified into sub-groups based on clinical findings, especially 
with respect to those features outlined above i. e. clinical presentation. The results of 
gastrointestinal physiological investigations have then been analysed to see if 
differences exist between these sub-groups. The chapter focuses principally on the 2 
main sub-groups (patients with chronic idiopathic STC and those whose symptoms 
arose following pelvic surgery or childbirth). 
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3.2 STC: PHYSIOLOGICAL RESULTS 
3.21 TRANSITSTUDIES 
3.2-1.1 Radio-opaque marker studies (Table 3.01) 
A positive marker study was defined as ý! 20% of 50 markers retained at 96 hours 
(Hinton et al., 1969; Evans et al., 1992; Roberts et al., 1993). The majority (93%) of 
patients had documentation of a positive study. 
Table 3.01: Results of radio-opaque marker studies 
Number 
Not known (but positive scintigraphy) 3 
Not performed (but positive scintigraphy) 3 
Negative c/o diarrhoea at the tiMe of study (but positive scintigraphy) 3 
Positive 121(93%) 
Distribution known 
Median marker retention [range] 
Retention of all markers 
108/121 
43 / 50 (86%) [20 - 100%] 
45 / 108 (42%) 
The distribution of markers was right-sided in 4 patients, generalised in 5 1, left-sided in 
29, left-sided and rectum in 24, and not-known (film not available for review of 
distribution, but study reported positive study) in 13. 
3.2.2.1 ... In-DTPA isotope scintigraphy 
A total of 80 patients underwent radioisotope scintigraphy. The remaining patients did 
not undergo scintigraphy because some had attended before the introduction of this 
investigation, and others were unable to attend because of time constraints or 
104 
CH Knowles 
geographical reasons. A delay throughout the entire colon was diagnosed in 53 patients 
(66%), and a left-sided (i. e. distal colonic delay) in 27 (34%). For the 71 patients 
undergoing scintigraphy with a prior positive radio-opaque marker study, 61 x-ray films 
were available for quantitation (see 2.4.1) of the centre of markers at 96 hours. Table 
3.02 demonstrates that in the prediction of a generalised or left-sided delay, the radio- 
opaque marker studies were poorly predictive of the final pattern as evidenced by 
scintigraphy (inter-method agreement: K == 0.31, CI 0.28 - 0.34,31% misclassified). 
Assuming scintigraphy to be the gold standard, this is in keeping with previous reports 
that have suggested that a single radio-opaque marker study is only adequate in 
screening for STC, not for determining pattern of transit, especially if surgery is 
considered (van der Sijp et aL, 1993; Lennard-Jones, 1994). 
Table 3.02: Cross tabulation of pattern of transit by radio-opaque markers and 
radioisotope scintigraphy 
Prediction by radio- Pattern as evidenced by radioisotope study 
opaque marker study Generalised Left-sided Total 
Generalised* 31 7 38 
Left-sided* 12 11 23 
Total 43 18 61 
* defined by C. O. Markers (see text) 
3.22 ANALMANOMETRY 
The results of anal manometry are shown in table 3.03. Test results were available in 
124 patients, and compared with control values for women, or men :! ý or > 50 years of 
age, obtained from the literature (see chapter 2). Reduced resting anal canal pressures 
were uncommon, occurring in only 7% of patients. That three patients had demonstrable 
anal hypertonia is consistent with a previous report in a cohort of patients with chronic 
constipation (Meunier, 1986). 
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Table 3.03: Results of anal manometry 
Nonnal 
Resting pressure (cmH, O)* 
Squeeze pressure(cmH, O)t 
Reduced Increased Not known 
112 
81 
9(7%) 3 
41(33%) 
6 
6 
* based on a lower limit of normal of 40 or 50 cm H, O dependent on method used, and 
upper limit of non-nal of 110 cm H, O. 
t based on a lower limit of normal of 40 or 50 cm H, O dependent on method used, and 
an upper limit of normal of 160 cm H20(see CHAPTER 2.4.2.1: Modified from Hallan 
et al., 1989; Read et al., 1979; Read et al., 1986) 
A total of 41 (33%) of patients had reduced anal squeeze pressures. The proportion of 
patients with reduced squeeze pressures increased with parity (Table 3.04). Further 
comment on the pathophysiological significance, (for instance in keeping with a 
generalised neuropathological or myogenic disorder), of these findings in respect of 
STC can not be made because: 
1. There is no uniform agreement of what pressure values constitute normality. In 
female subjects, parity must be considered as a further independent variable since 
this is known to affect both squeeze and resting pressures (Snooks et al., 1990; 
Sultan et al., 1993; Jameson et al., 1994) regardless of any documentation of 
instrumentation or other complication during delivery (Snooks et al., 1990), or 
proven obstetric-related sphincter defects which further reduce pressures (Sultan et 
al., 1993). The control values used (Read et al., 1979; Read et al., 1986; Hallan et 
al., 1989) do not distinguish values by parity, and those studies which do (Sultan et 
al., 1993; Jameson et al., 1994), do not use identical methodology, nor give 
sufficient data to be used as control ranges, There was a decrease in squeeze 
pressures with parity in the female STC patients (Table 3.04) consistent with these 
observations. 
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2. The absence of data from testing of pudendal nerve motor latencies and 
endosonographic visualisation of the sphincter complex in the majority of patients 
(techniques only introduced recently) prevented identification of the cause of 
sphincteric dysfunction. It is likely, based on the number of patients with 
episiotomies, tears and instrumented deliveries (Appendix 2.06) that a proportion 
will have obstetric-related mechanical disruption of the sphincter complex. 
Table 3.04: Anal canal maximum squeeze pressures vs. parity 
Anal canal squeeze pressures 
Parity Normal Reduced 
0 27 7(26%) 
1 10 5(33%) 
2 23 13(36%) 
36 7(54%) 
>4 5 7(58%) 
3.23 RECTAL SENSORY TESTING 
The results for rectal sensory thresholds to balloon distension were available in 121 
patients, and are shown in table 3.05. Overall, 62 patients (5 1 %) had a raised threshold 
to one or more of the 3 thresholds tested compared with control figures (Jameson et al., 
1994). Two or more thresholds were raised in 41 patients (34%), and all three in 16 
patients (13 %). A raised threshold for defaecatory desire was the most common finding. 
This has been previously reported (Read et al., 1986; Shouler & Keighley, 1986), and 
may underlie the common complaint of loss of urge in STC patients. There was no 
correlation between the presence of rectal hyposensation, and the number of radio- 
opaque markers retained on transit studies. 
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Table 3.05: Results of rectal sensory testing 
Threshold Median (range) Normal Number Number Not 
Range* normal abnormal known 
Minimum perceived 
Volume (MPV) 
Defaecatory desire 
Volume (DDV) 
Maximum tolerated 
40 (10 -> 400) 
135 (20 -> 400) 
0-75 87 30(26%) 13 
Volume (MTV) 
21-141 60 
200 (50 -> 400) 61-265f 86 
48(44%) 22 
36(30%) 8 
KEY: * based on values for women :! ý 50 years of age (from Jameson et A, 1994). t 
304 ml if > 50 years of age (from Jameson et al., 1994). All values in ml. 
3.24 EVA CUA TIONPROCTOGRAPHY 
Evacuation proctography was performed in a total of 120 patients. Common 
proctographic abnormalities occurred in all but 29 patients tested (76%), and are listed 
in table 3.06. These figures are comparable with previous studies of STC, and are 
unlikely to be of overall significance for reasons discussed in chapter 2 (Shorvon et aL, 
1989). 
A rectal evacuation disorder (RED) by any cause was present in 55 (46%) of patients 
undergoing proctography (n = 120). Median contrast evacuated was 90% (0 - 100%). 
The "main" causes of failure to evacuate are listed in table 3.07 (see notes, Chapter 2). 
Patients labelled as having mechanical obstruction included a proportion without 
proctographic abnormality, but who failed to relax and open the anal canal on straining 
with or without, in addition, failure to open the anorectal angle. Such patients have been 
variably referred to as having "idiopathic or fanctional" outlet obstruction (Duthie & 
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Bartolo, 1992). When puborectalis muscle fibre recruitment has been demonstrated by 
EMG, this condition is often described as "anismus" (Preston & Lennard-Jones, 1985b). 
It now seems likely, on the basis of subsequent studies, that this latter physiological 
entity has been overdiagnosed (Miller et al., 1991; Voderholzer et al., 1997). 
Table 3.06: Proctographic abnormalities 
Proctographic abnormality typ e Number 
Intassusception Anterior 18 
Posterior 7 
Large circumferential 4 
Unspecified 8 
Sub-total 37(31016) 
Rectal prolapse (any) 2 
Rectocele Small 35(29%) 
Moderate 21 
Large 16 
Unspecified 4 
Sub-total 76 (63 Yq) 
Any abnonnality Total 91 (76Yo) 
Nil 29 
Not known 10 
A prolonged discussion of this topic is not relevant to this thesis, but based on our own 
observations and those of others (personal communication: Professor DZ Lubowski), 
some of these patients may be unable to evacuate actually as a result of loss or rapid 
adaptation of urge i. e. rectal hyposensation. When further contrast was installed in the 
rectum of 6 such patients, evacuation was rapid and complete. This physiological 
situation is in accord with the description of "pseudoanismus", which may be secondary 
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to disordered reflex colorectal motility (Bampton et al., 1998; DZ Lubowski, personal 
communication). 
Table 3.07: Causes of failure of rectal evacuation 
Mechanical Functioning rectocele / 
obstruction intussusception / prolapse 33 
Failure anal canal opening 20* 
Sub-total 46 
Failure to strain Embarrassment 2 
Pain 2 
Unable 5 
Sub-total 9 
Total with RED 55(46%) 
No RED 65(54%) 
Not known 10 
KEY: RED = rectal evacuation disorder, * includes 9 patients labelled as having 
64 anismus" i. e. paradoxical puborectalis contraction, in isolation, or in combination with 
other causes of mechanical obstruction, and II patients with gross rectal hyposensation 
and verbally-reported loss / rapid adaptation of urge to evacuate. Some were able to 
subsequently evacuate after installation of further contrast (see text). 7/ 20 patients also 
had proctographic evidence of other abnormalities. 
3.25 SMALL BOWEL MANOMETRY 
A total of 29 patients underwent investigation; intubation failed in two subjects. 
Patients were initially selected for study because of upper gastrointestinal symptoms 
(6 / 27), although subsequently, this investigation had been performed prospectively 
on all patients newly diagnosed with STC (21 / 27). Overall, small bowel manometry 
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revealed the following main abnormalities: increased overall contraction frequency, 
altered overall contraction frequency (increased or decreased), increased nocturnal 
phase 11 contraction frequency, and perturbances of nocturnal phase III activity 
(duration, cycle length and velocity). Based on expert interpretation (see chapter 2), 8 
(28%) patients were defined as having definitely abnormal small bowel motility (3 or 
more abnormalities of measured parameters): these included 6 of the 21 (29%) 
patients investigated prospectively and 2 of the 6 (33%) patients referred for study 
because of upper GI symptoms. A further 6 (22%) patients were described as having 
minor abnormalities or borderline normal motility (usually based on the presence of 2 
abnormalities). Of the patients with clear abnormalities, phase III abnormalities e. g. 
diminished velocity, prolongation and abnormal diurnal pattern, and nocturnal phase 
11 abnormalities were strongly suggestive of a neuropathological process similar to 
that seen in Chagas' disease and neuropathic intestinal pseudoobstruction (Soffer & 
Thongsawat, 1996). No patient had a recording suggestive of myopathic 
abnormalities. The total figure (definite + minor abnormalities; 28 + 22%) of 50% 
STC patients with manometric abnormalities is in keeping with data from five hour 
(Mollen et al., 1999), and prolonged antroduodenal studies (Glia & Lindberg, 1998), 
and shorter studies of more distal small bowel motility (Bassotti et al., 1996). 
3.3 CLINICAL AND PHYSIOLOGICAL HETEROGENEITY OF 
PATIENTS WITH STC 
3.3.1 PATIENTS AND METHODS 
One hundred and twenty patients were placed into sub-goups based on clinical 
history. [10 patients were excluded because they had not undergone complete 
physiological assessment, defined for the purposes of this study as a minimum of 
anorectal manometry, rectal sensory thresholds to balloon distension, and evacuation 
proctography]. Patients were classified with particular reference to the age and mode 
of onset of constipative symptoms. The sub-groups included those previously 
described (see introduction to this chapter). 
III 
PhD Thesis 2000 
The results of physiological investigations (scintigraphic pattern of colonic transit, co- 
existence of extracolonic disturbances, including sphincteric dysfunction, rectal 
hyposensation, rectal evacuatory disorder (RED), or abnormal small intestinal motility) 
were then re-analysed by sub-group. 
3.3.2 RESULTS 
3.3.2.1 Sub-groups of patients based on clinical history 
Patients were placed into one of 6 sub-groups on the basis of clinical presentation, and 
included those previously described (Preston & Lennard-Jones, 1986; Waldron et al., 
1988; Roe et al., 1988; Keshavarzian et al., 1995; MacDonald et al., 1997). The sub- 
classification of patients is shown in figure 3.01, and the main demographic data for 
individual sub-groups, in table 3.08. Abbreviations have been assigned to each sub- 
group for brevity of further use. 
The largest and best recognised sub-groups were (1) patients whose symptoms arose 
de-novo in childhood or teenage years, classified as chronic (early-onset) idiopathic STC 
(CIST: n= 64,5 3 %) (ages of onset: <5 years, n=9; 5-10 years, n=37; 11 - 15 years, n 
= 11; 16-20 years, n= 7); and (2), patients who presented following events including 
hysterectomy (n = 5), childbirth (n = 12, complicated in 7 cases) or other pelvic 
procedures (2 tubo-ovarian, I appendicectomy, I uterine myomectomy, I laser 
treatment of endometriosis), which were classified as post pelvic intervention STC 
(PIST: n= 22,18%). 
Four other sub-groups were apparent. These included: patients whose symptoms arose 
de-novo in adulthood (after the age of 20 years) i. e. adult (late-onset) Idiopathic STC 
(AOIST: n= 13,11 %) (Waldron et al., 1988); patients whose symptoms arose in 
childhood but were substantially worsened by pelvic surgery or childbirth (obstetric in 
2, hysterectomy in 8, urological surgery in 1) (C/PIST: n= 10,8%); patients with 
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central neural (especially spinal) injuries (spina bifida (n 1) or trauma (n = 1)ý 
discogenic disease (n = 2), infection (n = 1) or tumour (n 1)) (NIST: n=6,5%) 
(Keshairvarsian et al., 1995; Weber et al., 1987); and patients with other miscellaneous 
attributable factors e. g. drug abuse (Kauftnann et al., 1988) or anorexia nervosa (Chun 
et al., 1997) (MIST: n=5,4%) 
Table 3.08: Main demographic data of STC sub-groups 
Sub-group Number (Yo) age 1years 
med. (range) med. (range) med. (range) 
CIST 64(53.3%) 39(13-79) 32: 1 29 (2-71)* 1(0-5) 
AOIST 13(10.8%) 39(24-60) 13: 0 6(1-10) 2(0-6) 
PIST 22(18.3%) 35(20-69) 22: 0 6(1-51) 2(0-5) 
C/PIST 10(8.3%) 46(29-66) 9: 0 7(3-23) 3 (2-5)' 
NIST 6(5.0%) 59(22-64) 5: 1 6(1-20) 1(0-4) 
MIST 5(4.2%) 39(27-69) 4: 1 6(1-51) 0(0-2) 
Total 120(100%) 39(13-79) 122: 3 1-71(19) 2(0-6) 
Key: * Kruskal Wallis ANOVA: p<0.0001 
Kruskal-Wallis ANOVA: p=0.001 
There was no significant difference in age distribution between the 2 main sub-groups, 
but the NIST, and C/PIST sub-groups tended to have a slightly higher age range. The 
duration of symptoms was longer in the CIST sub-group, reflecting the childhood onset 
in the majority. The 3 male patients in the study were distributed I in the CIST, and one 
each in the MIST, and NIST sub-groups. 
sex F. - M duration Parity 
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3.3.2.2 Physiological assessment 
Physiological data were collected and analysed for all sub-groups, but the emphasis of 
presentation and discussion of results has been focussed on the 2 largest clinical sub- 
groups: chronic idiopathic STC (CIST) and post pelvic intervention STC (PIST). 
Pattern of colonic transit 
The pattern of transit abnormality was characterised in all 76 patients who had an 
isotope study. The results of scintigraphy for each main clinical sub-group are shown 
in table 3.09. Overall, a generalised delay was much more common than a left sided 
segmental delay (50 vs. 26 patients) (66% generalised), and this held true for the 2 
main clinical sub-groups, including PIST (77% generallsed). Although there was 
some variation in the smaller sub-groups, there was no difference in contingencies (p 
= 0.18, chi-square test). 
Table 3.09: Results of transit studies by sub-group 
Number Isotope scintigraphy 
number generalised left-sided 
CIST 64 41 26(63%) 15(27%) 
AOIST 13 12 5(42%) 7(58%) 
PIST 22 13 10(77%) 3(23%) 
C/PIST 10 4 4(100%) 0(0%) 
NIST 63 2(67%) 1(33%) 
MIST 53 3(100%) 0(0%) 
Total 120 76 50(66%) 26(33%) 
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C/PIST (ý 
AOIST (10.8%) 
Fig 3.01. Sub-classification of 120 patients with slow transit constipation by clinical 
history. The pie chart demonstrates the percentage of patients falling into each clinical 
sub-group. Key: CIST: chronic idiopathic slow transit. PIST: Post pelvic intervention 
slow transit, AOIST: adult onset idiopathic slow transit, C/PIST: constipation from early 
childhood (chronic), becoming significantly worse following pelvic intervention, NIST: 
neural injury slow transit, MIST: miscellaneous slow transit. 
100 
75 
number of patients (%) 
50 
25 
No RED 
0 
RED All patients Chronic 
idiopathic STC 
[CISTI 
Acquired 
(pelvic) STC 
[PISTI 
Fig 3.02. Bar chart showing the percentage co-existence of a rectal evacuation disorder 
(RED) with slow transit constipation. Overall approximately 50% of patients had 
evidence of RED, but the incidence was significantly higher in the PIST than in the 
CIST sub-group (Fisher's exact test: p=0.04). 
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A norectal physiology 
Anorectal manometry (Table 3.10). 
Anorectal sphincter function was normal in 61% of all patients. Overall, 38% of patients 
had a reduced voluntary anal squeeze pressure. There were similar incidences of reduced 
voluntary anal squeeze pressure in the main sub-groups: CIST: 38%, PIST: 23%. 
However, all 6 patients with NIST had reduced squeeze pressures. Eight patients with 
chronic idiopathic STC had reduced resting tone (7 of which also had reduced squeeze 
pressures), a finding that was not observed in the PIST sub-group. Two patients, both 
with PIST, had abnormally elevated resting tone. 
Table 3.10: Results of anal manometry and rectal sensory testing by sub-group 
a. N Anal manometry rectal hyposensation 
normal red squeeze red resting 
pressure tone 
CIST 64 39(61%) 24(38%) 8(13%) 36(56%) 
AOIST 13 9(69%) 4(31%) 0 4(31%) 
PIST 22 17 (77%)* 5(23%) 0 12(55%) 
C/PIST 10 6(60%) 4(40%) 0 3(30%) 
NIST 6 0(0%) 6(100%) 1(17%) 5(83%) 
MIST 5 2(40%) 3(60%) 0 3(60%) 
Total 120 73(61%) 46(38%) 9 (8%) 63(53%) 
Key: red squeeze == reduced maximum squeeze pressure 
red resting = reduced maximum resting pressure 
*=2 had increased resting pressures with hypersensitivity 
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Rectal sensory testing (Table 3.10). 
Overall, 63 patients (53%), had raised thresholds to rectal balloon distension 
(hyposensation), and the incidence did not vary significantly between the 2 main sub- 
groups. However, hyposensation was present in 5/6 NIST patients (83%). 
Evacuation proctography (Table 3.11). 
On evacuation proctography, a rectal evacuatory disorder (RED) was found in 53 / 120 
(44%) patients (Figure 3.02). Overall, mechanical obstruction (e. g. rectocele, intrarectal 
intussusception, non-relaxing striated pelvic floor muscles) was the most common cause 
of RED, occurring in 37 / 53 (70%) patients. Eighteen of these 37 patients with a 
mechanical evacuatory obstruction also had rectal hyposensation. A further II patients 
(21%) were unable to evacuate, apparently as a result of gross rectal hyposensation 
alone (verbally reported loss of urge in addition to abnormal sensory thresholds). The 
remaining 5 patients had no demonstrable reason for evacuatory difficulty, presumably 
due to lack of evacuatory effort, caused in most cases by embarrassment or pain. 
Table 3.11: Results of evacuation proctography by sub-group 
Group N abnormal mechanical hypo- both no cause 
result only sensation found 
CIST 64 22(34%) 7(32%) 8(36%) 4(18%) 3(14%) 
AOIST 13 5(38%) 3(60%) 1(20%) 1(20%) 0 
PIST 22 15 (68%)* 4(27%) 1(7%) 9(60%) 1(7%) 
C/PIST 10 6(60%) 5(83%) 1(17%) 0 0 
NIST 6 2(33%) 0 0 2(100%) 0 
MIST 5 3(60%) 0 0 2(67%) 1(33%) 
Total 120 53(44%) 19(36%) 11(21%) 18(34%) 5(9%) 
(* p=0.04, Fisher's exact test). 
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Notably, there were marked differences in the incidence of RED between certain sub- 
gToups. Only 34% (22 / 64) of patients in the CIST sub-group had problematic 
evacuation, compared to a significantly greater proportion of patients in the PIST sub- 
group (15 / 22 = 68%; p=0.04, Fisher's exact test). 
Upper gastrointestinal physiology 
Of the 25 patients investigated, 12 (48%) had abnormalities: these included 10 of the 19 
(53%) patients investigated prospectively and 2 of the 6 (33%) patients referred for 
study because of upper gastrointestinal symptoms (Table 3.12). Clear abnormalities 
were demonstrated in 7 (28%), and minor abnon-nalities in a further 5 (20%). Of 9 
patients tested with CIST, 5 were reported as normal studies, 2 had abnonnalities which 
were characteristic of neuropathic disorder, and 2 had borderline abnormalities. Of 7 
patients tested with PIST, 3 had neuropathic-type abnormalities, 2 had borderline 
abnormalities, and only 2 were normal. Nine further patients included 6 with AOIST, of 
which 2 (33%) had abnormal studies. The other 3 patients fell one each into the NIST, 
MIST and C/PIST sub-groups, of which only the C/PIST patient had a borderline study. 
Table 3.12: Results of small bowel manometry by sub-group 
Number Small bowel manometry 
number abnormal borderline normal 
CIST 64 9 22 5 
AOIST 13 6 20 4 
PIST 22 7 32 2 
C/PIST 10 1 00 1 
NIST 6 1 00 1 
MIST 5 1 01 0 
Total 120 25 7(28%) 5(20%) 13(52%) 
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Table 3.13 surnmarises all the physiological results between the 2 main sub-groups 
(CIST and PIST). 
Table 3.13: Summary of physiological results between the 2 main sub-groups 
Chronic Acquired STC Investigation Idiopathic STC (Pelvic) 
... In DTPA Colonic Generalised pattern 27(68%) 10(77%) 
Scintigraphy 
Left-sided delay 13(32%) 3(27%) 
Anal Manometry Normal 39(61%) 17 (77%)t 
Reduced Resting 8 (13%)* 0(0%) 
Reduced Squeeze 24(38%) 5(23%) 
Rectal Hyposensation Normal 28(44%) 10(45%) 
Abnormal 36(56%) 12(55%) 
Evacuation Normal 42(66%) 7(32%) 
Proctography 
Abnormal 22(34%) 15(68%)l 
Ambulatory Small Normal 6(67%) 2(29%) 
Bowel Manometry 
Abnormal 3 (33%) 5(71%) 
7 patients had combined reduced anal resting and squeeze pressures 
2 patients had elevated anal resting tone 
p=0.04 (Fisher's exact test) 
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3.3.3 DISCUSSION 
3.3.3.1 Summary of results 
Heterogeneity within patients with documented STC is well recognised (Preston et al., 
1984; Preston & Lennard-Jones, 1986; Waldron et al., 1988; Roe et al., 1988; 
MacDonald et al., 1997; Keshavarzian et al., 1995). In addition to the 2 largest sub- 
groups, chronic idiopathic (CIST) (Preston & Lennard-Jones, 1986; Waldron et al., 
1988), and post pelvic intervention (PIST) (Roe et al., 1988; MacDonald et al., 1997), 
we have, on a similar basis of clinical history, incorporated 4 other sub-groups. We 
have compared the results of physiological tests between these sub-groups, in a large 
cohort of 120 patients with proven STC. 
We have provided evidence that the pattern of colonic transit abnormality is similar 
between STC sub-groups, with the majority (approximately 70%) of patients suffering 
from a generalised delay throughout the large bowel (Krevsky et al., 1989; Roberts et 
al., 1993), regardless of history, and a smaller proportion with delay localised to the left 
colon (Krevsky et al., 1989; Stivland et al., 1991; Roberts et al., 1993; McLean et al., 
1995). It has generally been considered that in patients with STC following pelvic 
surgery or childbirth (PIST), colonic motor disturbance is limited to the distal / left-side, 
perhaps secondary to rectal-pelvic floor dysynergia (MacDonald et al., 1993; 
MacDonald et al., 1997), whereas patients with chronic idiopathic symptoms are 
thought to suffer primarily from generalised colonic inertia (MacDonald et al., 1993). 
However, previous studies, having clearly demonstrated differential colonic transit 
patterns in patients with chronic constipation, have not equated findings with mode of 
onset (Kamm et al., 1988; Krevsky et al., 1989; Roberts et al., 1993; van der SiJp et al., 
1993). Likewise, reports of physiological differences between patient groups with 
varying clinical histories e. g. with regard to upper gastrointestinal and rectal function, 
have not considered the pattern of colonic transit itself (Roe et al., 1988; Smith et al., 
1990; MacDonald et al., 1997). 
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Anorectal manometric findings were similar between the 2 main sub-groups. A 
proportion of patients had either reduced resting tone, reduced squeeze pressure, or 
both, in keeping with changes expected within a female population of variable age and 
parity (Sultan et al., 1993; Jameson et al., 1994). The abnon-nalities of resting tone 
which were almost exclusive to a small group of patients in the CIST sub-group, 
might be said to be indicative of a primary myopathic process (Vaizey et al., 1997), 
but further comment can not be made regarding this observation because of lack of 
endosonographic data. 
Approximately 50% of all patients had rectal hyposensation, consistent with previous 
reports (Akervall et al., 1988; Waldron et al., 1988; Kamm & Lennard-Jones 1990). 
Although this incidence did not vary between the main sub-groups, nearly all of the 
small number of patients with NIST had hyposensation and this has been previously 
documented in patients with spinal cord injuries (MacDonagh et al., 1992; Sun et al., 
1995; De Looze et al., 1998). There were differences between the sub-groups with 
respect to the results of evacuation proctography. Although half of the patients with 
STC overall had a co-existent RED,, a significantly higher proportion of patients with 
acquired (pelvic) STC had an RED compared to those with chronic idiopathic STC. 
The rectal sensory findings in this study concur with those of Smith et al. (Smith et 
al., 1990) who studied patients with constipation occurring after hysterectomy (transit 
unspecified), but are in contrast to those of Roe et al. (Roe et al., 1988) who described 
rectal hyposensation only in chronic idiopathic patients. The latter study reported that 
rectal evacuatory problems, as assessed by ability to expel a balloon, were seen at a 
higher frequency, although not significantly so, in chronic idiopathic patients than 
those with post-hysterectomy STC. 
The finding that 3/9 of CIST patients had abnormal small bowel motility equates 
reasonably well with previous larger studies of chronic idiopathic cases, in which the 
presence of upper gastrointestinal dysmotility in approximately half of patients is well 
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accepted (Bassotti et aL, 1996; Glia & Lindberg, 1998; Mollen et aL, 1999). No study 
has previously examined whether such abnormalities can follow pelvic surgery, and only 
one has examined patients whose symptoms followed childbirth (MacDonald et aL, 
1997). This latter study measured gastric emptying, and suggested that abnormalities 
only occurred in the chronic idiopathic group. In fact, although it is not discussed in the 
text, the figure for solid-phase gastric emptying clearly demonstrates that at least one 
patient with STC following childbirth had an emptying time outside the normal range 
presented. 
This is the first study to use current sensitive methodology i. e. prolonged ambulatory 
small bowel manometry in patients clearly defined to each of these groups. Our results 
might be treated with a degree of caution because of the initial selection bias, but it is 
important to note that only 6 of the 25 patients were initially investigated purely on the 
basis of having upper gastrointestinal symptoms. Indeed, a greater proportion of those 
patients studied prospectively, regardless of upper GI symptomatology, had evidence of 
a upper gastrointestinal dysmotility, including 5/7 patients with STC acquired 
following pelvic intervention. These results demonstrate, therefore, that in some cases at 
least, a generalised gastrointestinal disturbance can follow pelvic surgery or childbirth. 
This confirms the view that whilst some patients clearly have an isolated disorder of the 
colon, others have a more diffuse disorder of the gastrointestinal tract. 
In general, the results of physiological testing were similar between patients with adult 
onset idiopathic slow transit (AOIST) and those with CIST. In contrast, the C/PIST sub- 
group, albeit small, had similar findings on anorectal physiology to the PIST sub-group. 
Naturally these observations must be interpreted with caution in view of the lack of 
physiological data pre-dating the pelvic event in the C/PIST sub-group, and the 
relatively small number of patients. The findings in patients with central (spinal) neural 
injuries differed from other sub-groups i. e. almost uniformly affected sphincteric and 
rectal sensory function. 
Regardless of the implications derived from the smaller sub-groups in this study, this 
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study has demonstrated the following important findings with respect to the 
comparison of patients with chronic idiopathic STC (CIST) and those with acquired 
(pelvic) STC (PIST): 
1. The pattern of colonic transit is similar in both groups i. e. predominantly 
generalised. 
2. The incidence of rectal evacuatory disorder is significantly higher in patients 
acquiring STC after pelvic surgery or childbirth 
3. Small bowel motility disturbances occur in both groups, and are not limited to 
patients with chronic idiopathic STC. 
These 3 observations are in contrast to previously published reports which were all 
based on smaller numbers of patients studied. 
3.3-3.2 Pathogenetic considerations 
Although a plethora of aetiological theories have been proposed for chronic idiopathic 
slow transit constipation, including hormonal, laxative abuse, endogenous opioids, 
absorption, psychogenIc etc., the cause or causes remain elusive. The role of muscle and 
nerves in control of gut motility is well established, and it is likely that a disorder of 
nerve, muscle or both is implicated. A substantial proportion of studies of chronic 
idiopathic STC have found degeneration of neurons in the myenteric plexus, said to be 
suggestive of a distinct, possibly congenital, intrinsic neuropathy (1.5.3.4). In contrast, 
STC acquired following pelvic intervention (PIST) may provide a model of acquired 
extramural pelvic parasympathetic damage (1.5.4.1.1). The high incidence of rectal 
evacuatory problems in patients with post pelvic intervention STC in this study may 
complement the pelvic nerve dysfunction hypothesis. The pathogenesis in this sub-group 
of a generalised disturbance of colonic transit, and in some patients of small intestinal 
dysmotility as well, might be explained either by degeneration of ascending colonic 
nerves, with or without sympathetic re-innervation, as occurs in the bladder, or by reflex 
inhibition of proximal motility by distal stasis and distension. These theories have been 
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addressed in detail in the introduction (1.5.4-1.1). Whilst the pathogenesis might be 
different, the final physiological and clinical consequences could thus become 
indistinguishable. The finding of patients with pre-existent symptoms, which were 
worsened by a pelvic event (CPIST) supports the hypothesis that multiple independent 
or additive events might play a part in the actiopathogenesis of STC. An underlying 
abnormality made clinically apparent by the effects of pelvic surgery or childbirth can 
similarly not be excluded in the PIST sub-group. 
To our knowledge, no morphological study has presented findings by such clinical sub- 
groups, and the lack of uniform histopathological findings in STC, methodological 
differences apart, might therefore also reflect biological heterogeneity. 
3.3.3.3 Management considerations 
Reported patient satisfaction rates after colectomy for STC range between 39% and 
100% in recent studies (Knowles et al., 1999). The co-existence of certain physiological 
abnormalities is known to influence surgical outcome. Some studies have demonstrated 
a deleterious effect of untreated disorders of rectal evacuation (Bernini et al., 1998; 
Hasegawa et al., 1999) or rectal hyposensation (Akervall et al., 1988; Pluta et al., 1996). 
Others have treated co-existent abnormalities of the pelvic floor by pre-operative 
retraining (Nyam et al., 1997), or rectopexy at the time of colectomy (Piccirillo et al., 
1995) with apparently excellent results. It is generally accepted that patients with a 
generalised gastrointestinal disorder rather than an isolated disorder of colorectal 
dysmotility have poor outcomes in comparison with other cases (Redmond et al., 1995). 
The influence of pattern of colomc motility disturbance itself (i. e. generalised vs. left 
segmental) on outcome after surgical intervention remains unclear (de Graaf et al., 
1996). 
Regardless of the importance of physiological differences, it is also unclear what 
independent effect a variation in pathogenesis of STC might have on outcome, i. e. the 
response to surgery might be expected to be different for diseases with diverse 
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pathogenesis. The influence that these differences might have on outcome from surgery 
for STC is not known because studies have not stratified results by such sub-groupings 
(Knowles et al., 1999). The results of this chapter continue to emphasise the need for 
thorough investigation of patients with STC before specific management, including 
surgery, is advised. 
3.3.3.4 Sub-classirication 
The exercise of clinical sub-classification of patients with STC is implicitly dependent 
on factors such as the patients' recall of events, and the necessity to define a cut off 
between sub-groups which may be arbitrary (e. g. the age of 20 for AOIST, and the 
severity of symptoms accepted as indicating constipation preceding the event in patients 
with C/PIST), but we have demonstrated that all patients included in this study could be 
placed without difficulty into a single sub-group by this system. 
Whether such a classification system has a clinical role cannot be addressed by this 
study. However, this classification system is used for subsequent chapters of this thesis 
in which aetiological hypotheses are addressed: 5,6,7 and 8. 
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LINEAR DISCRIMINANT ANALYSIS 
OF S YUP TOMS IN PA TIEN TS Wl TH 
CHRONIC CONSTIPATION: 
VALIDATION OF A NEW SCORING 
SYSTEM (KESS) 
4.1 INTRODUCTION 
Investigation of patients presenting with severe chronic constipation reveals a sub- 
group who have underlying physiological abnormalities. On the basis of these 
investigations, patients may be further subdivided into those whose underlying 
physiological abnormality is either a rectal evacuatory disorder (RED), slow transit 
constipation (STC), or a mixture of the two (Keighley & Schouler, 1984; Nyam et al., 
1997; Koch et al., 1997; Halverson & Orkin, 1998; Bernini et al., 1998; Hasegawa et 
al., 1999). Distinguishing these sub-groups may be important in planning treatment 
and predicting prognosis. For example, subtotal colectomy and ileorectal anastomosis 
can be successful in the treatment of STC (Pemberton et al., 1991; Wexner et al., 
1991; Piceirillo et al., 1995; Lubowski et al. 1996; Nyam et al., 1997), but is less 
satisfactory if the underlying cause of constipation is related to a disturbance in rectal 
evacuation (Kamm et al., 1984; Yoshioka & Keighley, 1989; Pfeifer et al., 1996). 
Conversely, patients with outlet obstruction but normal colonic transit may respond 
favorably to pelvic floor retraining, biofeedback (Wexner et al., 1992; Karlbom et al., 
1997) or surgery to restore normal anatomy (Jorge et al., 1994; Pfeifer et al., 1996). 
Previous studies have investigated the symptoms associated with constipation, and 
scoring systems have been used in its diagnosis (Agachan et al., 1996). Some groups 
have attempted to identify patho-physiological sub-groups by analysis of symptoms 
prior to investigation, with application of various statistical methods, with variable 
results (Grotz et al., 1994; Karlbom et al., 1995; Agachan et al., 1996; Koch et al., 
1997; Mertz et al., 1999). We aimed to devise and validate a new scoring system, 
utilizing appropriate statistical analyses, which might be able both to diagnose cases 
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of constipation and to discriminate between the important patho-physiological sub- 
groups. 
4.2 METHODS 
Questionnaire Design 
A structured interviewer-led questionnaire consisting of eleven questions was devised 
by incorporating internationally agreed criteria (Whitehead et al., 1991) for 
constipation and previous reported relevant symptoms of constipation (Agachan et al., 
1996). This questionnaire (Figure 4.01) was designed to be simple enough to be 
completed in under five minutes. Each question had four or five possible answers 
which were scored on an unweighted linear integer scale to produce a range of 
between 0 and 3 or 0 and 4 points. Lower scores represented symptom-free states and 
higher scores, increased symptom severity. The total KESS (Knowles-Eccersley- 
Scott-Symptom) score was the sum of all scores gained on individual questions with a 
maximum possible of 39 points. The answers to each question were worded such that 
any patient who fitted agreed criteria (Agachan et al., 1996) for constipation would be 
likely to score at least I point per question. 
Patient recruitment and investigation 
Seventy-one patients (66 women) with intractable constipation who had been referred 
from specialist colorectal surgical clinics, and who underwent full investigation of 
their constipation during the period 1997-1999, were recruited. In addition, 20 normal 
controls (18 women) of similar age distribution, with no history of constipation, were 
recruited from staff and visitors to the unit. Prior to referral, all patients had been fully 
assessed in the outpatients clinic, endocrine or metabolic abnormalities excluded, and 
colonic imaging by either barium enema or colonoscopy performed to exclude 
structural abnormalities. Patients with radiological evidence of megabowel were 
excluded from the study. 
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Figure 4.01: The KESS questionnaire 
1. Duration of constipation 
0- 18 months 
18 months to 5 years 
5-10 years 
10-20 years 
>20 years (or all life) 
2. Laxative use 
None 
Laxatives pm or 
for short duration 
Laxatives regular, 
long duration 
Laxatives long duration, 
ineffective 
0 
1 
2 
3 
4 
7. Bloating 
Never 
Perceived by patient only 
Visible to others 
Severe causing satiety or nausea 
Severe with vomiting 
8. Enemas / Digitation 
None 
Enernata / suppositories 
0 occasionally 
Enernata / suppositories regular 
Manual evacuation occasionally 
Manual evacuation always 
2 
9. Time taken 
3 (minutes in lavatory/ attempt) 
3. Frequency of bowel movement 
(using current therapy) 
1-2 times / 1-2 days 0 
2 or less times / week I 
Less than once per week 2 
Less than once per 2 weeks 3 
4. Unsuccessful evacuatory attempts 
Never / rarely 0 
Occasionally I 
Usually 2 
Always = manual evacuation 3 
5. Feeling incomplete evacuation 
Never 
Rarely 
Occasionally 
Usually 
Always 
6. Abdominal pain 
Never 
Rarely 
Occasionally 
Usually 
Always 
<5 minutes 
5-10 minutes 
10-30 minutes 
> 30 minutes 
0 
1 
2 
3 
4 
0 
1 
2 
3 
4 
0 
1 
2 
3 
10. Difficulty evacuating 
(causing a painful evacuation effort) 
Never 0 
Rarely I 
Occasionally 2 
Usually 3 
Always 4 
11. Stool consistency 
(without laxatives) 
0 Soft / loose/ normal 0 
1 Occasionally hard 1 
2 Always hard 2 
3 Always hard, usually pellet-like 3 
4 
0 
1 
2 
3 
4 
KEY 
Rarely 
Occasionally 
Usually 
< 25% of time 
= 25-50% of the time 
=> 50% of the time 
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The questionnaire was completed prospectively (before any investigations) in 51 
consecutive patients. In 20 further patients, some investigations had already been 
performed prior to the completion of the KESS questionnaire. A researcher who was 
unaware of the patients' referral source, previous history or investigation results 
conducted a fully structured interview to assess each persons' current bowel 
symptoms. The interviewer was instructed to avoid discussion with the interviewee, 
and to ask which single answer to each question was most appropriate at the time of 
the interview. 
At the same time that the KESS questionnaire was completed, the constipation 
scoring system questionnaire (Agachan et al., 1996), previously used at the Cleveland 
Clinic was also completed (Cleveland Clinic score: CCS). 
All 71 patients were fully investigated according to our standard protocol which 
included anorectal manometry, anorectal sensory function testing, evacuation 
proctography, and assessment of colonic transit by radio-opaque marker studies (see 
chapter 2). The results of these investigations were reviewed by a surgeon of 
consultant status with a special interest in lower gastrointestinal dysfunction who, 
unaware of the questionnaire results or of the patients' identities, assigned each 
patient to one of the three p atho-physio logical sub-groups: STC, RED and mixed 
(STC & RED). 
Delayed colonic transit was diagnosed if more than 20% of 50 radio-opaque markers 
were still present on a single abdominal radiograph taken 100 hours after ingestion 
(Hinton et aL, 1969; Roberts et aL, 1993). A rectal evacuatory disorder (mechanical 
or functional) was diagnosed by evacuation proctography, performed after filling the 
rectum with semi-solid barium paste to the previously measured maximum tolerated 
volume (Chapter 2). 
Data Analysis 
In order to measure the agreement between KESS and CCS scores for each patient, 
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the scores were expressed as percentages of the totals for each scoring system (total 
KESS = 39, total CCS = 30). Agreement between the two scoring systems was 
described by subtracting CCS percentage scores from KESS percentage scores and 
calculating the 95% limits of agreement as 1.96x the standard deviation of the 
differences (Bland & Altman, 1986). Any tendency for patients" scores to be higher 
using one or other system was tested using a paired t-test. 
As the scores for each individual question were ordinal, non-parametric methods of 
analysis were used. Hence median KESS scores were compared between controls and 
constipated patients, and between patho -physiological groups, using Mann Whitney 
and Kruskal Wallis tests respectively (GraphPad Prism v. 2.0, GraphPad Software 
Inc. San Diego, USA). Linear discriminant analysis (Systat v. 8.0, SPSS Inc. Chicago, 
USA) was used to investigate the extent to which symptoms could be used to classify 
patients into the three sub-groups. Discriminant analysis using maximum likelihood 
methods (the bases of most implementations of discriminant analysis in statistical 
software) assumes that variables used to predict group membership are continuous 
and normally distributed. The robustness of the method using other kinds of variables 
is uncertain (Moore, 1973; Krzanowski, 1975; Titterington et al., 1981; Krzanowski, 
1995; Reeves et al., 1997) and the definitive test of any classification algorithm is its 
performance on a new dataset. In the present study, the sample size was not sufficient 
to validate classification perfon-nance by dividing the data into 'train' and 'test' 
samples and cross-validation was used instead to correct the performance estimates 
based directly on the data (Reeves et al., 1997). 
4.3 RESULTS 
Correlation of KESS with CCS 
Scores were distributed normally on both scoring systems and were highly correlated 
(Pearson r=0.90). The 95% limits of agreement were +14%. Scores for some patients 
on one CCS question were not available (unsuccessful evacuation attempts per 24 
hours, see discussion). However, the limits of agreement were unaffected whether the 
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CCS percentage for these patients was calculated out of a total of 26, (i. e. excluding 
the question for which a response was not available), or out of 30. The extent of 
agreement appeared to be independent of the mean of the KESS and CCS scores 
(Figure 4.02). Patients scored marginally (mean difference 3%) higher on KESS score 
than CCS (95% confidence interval = 1.0% to 5.0%, p=0.003). 
28% 
j 
14% 
01 CA (J 0% 
-28% 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Mean of KESS% and CCS% 
Figure 4.02: Bland-Altman plot showing the range of agreement between KESS and 
CCS scores as a function of increasing symptoms of constipation. 
KESS score delineates constipated patients from normal controls 
The median total KESS scores were significantly different between patients and 
normal controls: median 20 (range 11-35) vs. median 2 (0-6), p<0.0001. Moreover, 
as demonstrated by figure 4.03, there was no overlap at all between the scores of 
constipated and control patients. Using a cut-off criterion of >10, the total KESS score 
had a sensitivity of 100% (95% CI=95-100%) and a specificity of 100% (95% CI=63- 
100%). 
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Kruskal Wallis between 
subgroups p=0.13 
Polysymptomatic 40 - 
Mann Whitney U between 
patients and controls, p<0,0001 
v 
30 - 
vv 
AAvv 
vv 
v 
Total Avv AzV V 
KESS 20 - Av vv A ; v; v 
! 
-' 
A 
Score 
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A vv 
v 
10 AAA + 
0 
Asymptomatic 
Nonnals RED Mixed STC 
Patho-physiological group 
Fig 4.03. Scatter plot showing distribution and medians of total KESS score for 
controls and patients All test patients had a KESS total >= 10, whereas no control had 
a score > 6. There was a significant difference between patients and controls, Mann 
Whitney U-test, p<0.000 1, but not between patient sub-groups (Kruskal-Wallis, p 
0.13). 
Independent physiological review 
After review of all investigation results, the numbers of patients allocated to each of 
the 3 patho-physio logical sub-groups were : STC, n= 18; RED, n= 25; and mixed, n 
= 28. Median marker retention in those patients with a transit abnormality (n = 46) 
was 96% at 100 hrs. RED was attributable to one or more of the following: intrarectal 
intussusception, n= 20; external rectal prolapse, n=2; functional rectocele, n= 22; 
rectal hyposensation (abnormally reduced sensation to balloon distension combined 
with failure to evacuate due to loss of urge), n= 11; poor evacuatory effort, n=9; 
failure of pelvic floor relaxation on attempted defecation, n=3. No patient included 
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in the study was subsequently found to have entirely normal colorectal function on 
investigation. 
There was no significant difference between the median total KESS scores for 
patients in each patho-physiological sub-group (p = 0.13), (Figure 4.03). 
Discriminant analysis 
Stepwise discriminant analysis of all symptoms identified five that were predictive of 
the patho-physiological sub-group to which each patient had been allocated as a result 
of investigation. These were, duration of constipation [dur], laxative assistance [lax], 
frequency of bowel movement [freq], abdominal pain [abdopn], and time in lavatory 
per evacuatory attempt [time] (see Table 4.01). Prior probabilities (required for such 
an analysis) were based on validated diagnoses for all patients referred to our clinic 
over the last 4 years, i. e. RED=0.39, Mixed=0.35, STC=0.26. The classification 
functions for each sub-group were: 
RXJEjD = -5.813+(0.969*dur)-(0.005 *Iax)-(1.484*freq)+(1.899*abdopn)+(2.003 *time) 
Mixed = -6.233+(1.475*dur)+(0.882*lax)-(0.007*freq)+(1.035*abdopn)+(1.169*tlme) 
STC = -6.566+(1.766*dur)+(0.666*lax)+(0.447*fTeq)+(1.039*abdopn)+(0.339*tlme) 
A new patient would be classified by calculating the total for all three classification 
functions (by summing the constant and the products of the symptom scores and the 
coefficients, as shown in the equations above), and would be assigned into the group 
which yielded the highest score. Thus, for a patient with scores of 3,2,2,3,3 for the 
five symptoms, the function scores would be 4.338,6.547 and 5.539 respectively, and 
the patient would be classified as belonging to the mixed sub-group. The performance 
of these functions in classifying the patients who were studied is shown in table 2a; 
the performance of these functions in classifying new patients was estimated by cross- 
validation and is shown in table 2b. 
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Table 4.01: Classification functions derived from the discriminant analysis. 
Symptom STC Mixed RED 
Constant -6.566 -6.233 -5.813 
Dur 1.766 1.475 0.969 
Lax 0.666 0.882 -0.005 
Freq 0.447 -0.007 -1.484 
Abdopn 1.039 1.035 1.899 
Time 0.339 1.169 2.003 
New patients are classified by comparing the total discriminant scores for the three 
sub-groups, calculated by summing the constant and the products of the symptom 
scores and the coefficients shown in the table. The patient is classified into the group 
which yields the highest discriminant score. Key: Dur = duration of constipation, Lax 
= laxative use, Freq = frequency of bowel movement, Abdopn = abdominal pain, 
Time = time taken to evacuate / attempt. 
Table 4.02: Classification matrix. 
Sub-group into which patient 
classified by classification 
functions 
STC 
Mixed 
RED 
Number (%) correct by group 
Total number (%) percent correct 
Allocated (true) sub-group by physiology 
STC 
11 
7 
0 
11/18(61%) 
Mixed 
5 
15 
8 
15/28(54%) 
46/71(65%) 
RED 
1 
4 
20 
20/25(80%) 
(a) The table shows the frequencies of patients in allocated patho-physiological sub- 
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groups that were assigned into each of the sub-groups by the classification functions. 
Sub-group into which patient 
classiried by classiflcation 
functions 
STC 
Mixed 
RED 
Percent correct (95% CI) 
Total percent correct (95% CI) 
Allocated (true) sub-group by physiology 
STC 
7 
11 
0 
39%(17-64) 
Mixed 
5 
15 
8 
46%(26-66) 
55%(43-67) 
RED 
1 
4 
20 
76%(55-91) 
(b) Cross-validated estimates of the percentages (95% confidence intervals) of new 
patients in validated patho-physiology sub-groups that would be classified into each 
of the sub-groups by the classification functions. 
4.4 DISCUSSION 
Constipation is a poorly defined clinical symptom, not a definitive diagnosis. 
Investigations aim to identify underlying functional (physiological) abnon-nalities 
contributing to the disorder. Either delayed colonic transit or rectal dysfunction alone 
can cause many of the symptoms ascribed to constipation, yet the two abnormalities 
frequently co-exist (Keighley & Schouler, 1984; Nyam et al., 1997; Koch et al., 1997; 
Halverson & Orkin, 1998; Bernini et al., 1998; Hasegawa et al., 1999). The results of 
investigation are important in guiding management (Wexner et al., 1991; Pemberton 
et al., 199 1; Piccirillo et al., 1995; Pfeifer et al., 1996; Lubowski et al., 1996; Nyam 
et al., 1997). 
The KESS questionnaire is a modified version of that used in the CCS (Agachan et 
al. , 1996). 
Changes in questions were based upon our clinical impression of those 
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symptoms most likely to be discriminatory. Furthen-nore some questions were 
modified to improve ease of interview. For example, the question of unsuccessful 
evacuation attempts (per day in the CCS) was altered to allow this question to be 
answered by patients who have less than one evacuation (successful or unsuccessful) 
per day. Four of the KESS questions were based on the commonly quoted guidelines 
for diagnosing constipation (Whitehead et al., 1991), with a score of one or more 
points signaling fulfillment of each criterion. Patients with severe chronic constipation 
have usually tried multiple remedies for their condition before seeking a specialist 
opinion. The KESS score takes account of this by asking patients to indicate whether 
long term laxatives have been used, and whether they continue to be effective. The 
questionnaire also asks patients about their bowel frequency and other symptoms 
while taking their current medication. The only question that may not be 
contemporary for all patients is the request for a description of stool consistency 
'without laxatives'. The questionnaire also recognizes the possibility that severe 
constipation can have pan-enteric effects by assigning higher scores if bloating causes 
loss of appetite or nausea. 
The KESS total score delineates patients with constipation clearly from normals. 
Although it should be noted that controls had not been subjected to physiological 
testing, they were selected on the basis of being asymptomatic. The new questionnaire 
was validated by comparison with the CCS (Agachan et al., 1996). This had itself 
been validated as a tool for distinguishing constipated patients with a proven patho- 
physiological abnormality from those in whom physiological investigations were 
normal, predicting 96% of cases correctly. There is no known biological or 
physiological marker for the severity of constipation, so it is unclear what the 
significance of a total score is. The score may be used, however, to monitor the 
efficacy of treatment modalities, simply by omitting the score for duration of 
symptoms from the total. 
Previous studies have attempted to divide constipated patients into RED, STC and 
mixed sub-groups on the basis of symptoms and investigation results. Karlbom et al. 
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(Karlbom et al., 1995) assessed bowel ftequency and evacuation symptoms, and 
found that these were closely related to physiological findings. However the study did 
not clearly describe the method of symptom analysis, and failed to indicate whether 
allocation to sub-groups was made before or after investigation. Koch et al. (Koch et 
al., 1997) divided a series of patients into similar sub-groups on the basis of 
investigation, and then examined their perceived symptoms. They found that some 
symptoms were associated with STC, whilst others were associated with RED. A 
significantly different distribution of symptoms between pathophysiological groups 
was demonstrated using a chi-square analysis, but the specificity of single symptoms 
was low. Discriminant analysis showed no superiority of combinations of symptoms, 
but the methods and results of such analyses were not presented. Grotz et al. (Grotz et 
al., 1994), who also included patients with normal transit constipation, sought to 
classify 184 patients into patho-physiological sub-groups based on psychological 
stress and colorectal symptoms. Although when matched for age and sex, some 
symptoms were independently discriminatory, the authors were unable to demonstrate 
significant correlation between symptoms and type of constipation when multiple 
logistic rýegression analysis was used. Recently, Mertz et al. (Mertz et al., 1999) found 
clusters of symptoms from which they defined sub-groups of patients with 
constipation, using a method of factor analysis. The discriminatory capacity of this 
study for physiologically defined sub-groups is not clear. 
Unlike previous symptom questionnaires, the KESS questionnaire appears to be able 
to discriminate between patho-physiological sub-groups for the majority of patients 
with constipation (55%, CI 43% to 67%). Discriminant scores predict patients with 
pure STC or RED better than patients with mixed abnormalities. Both the selection of 
variables for the discriminant analysis and the level of classification performance 
ideally need to be validated in a new sample of patients. 
The relatively low level of discrimination could have been caused by adoption of sub- 
optimal questions. In addition, the diagnostic specificities of current "gold standard" 
physiological tests of transit and anorectal function are themselves not absolute. 
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Furthermore, it is possible that allocation of patients to one of three sub-groups may 
introduce error because of artificial "pigeonholing" of disorders that in reality may 
represent a more continuous spectrum of disease. We accept that the analysis 
presented for the prediction of patho-physiology in this study may be unwieldy for 
use in the routine clinical setting, but modem spreadsheet applications allow the 
equations of classification functions to be calculated easily. 
Whilst this is the first study utilizing appropriate statistical methodology to 
demonstrate the discriminatory ability of multiple symptoms in constipation, the 
overall discriminatory power is insufficient for its immediate application in clinical 
practice. However, we have explored the ability of KESS scores to discriminate single 
pathologies from other groups. For example, in attempting to predict which patients 
have isolated RED. ) 
it proved possible to choose a criterion that had a sensitivity of 
48.0% (95% CI = 28% to 69%) and a specificity of 100% (95% CI = 0% to 8%) (see 
ROC curve: Figure 4.04). In other words, this cut-off criterion should, on average 
identify almost half the RED only patients with high confidence that they do not have 
STC. However, the wide confidence intervals around the estimates of sensitivity and 
specificity, and the fact that the logistic model has not been validated in any way 
(neither by cross-validation nor using an independent patient sample), means that this 
finding should be viewed with some caution. As in the case of the discriminant 
analysis, it is also desirable to check the selection of variables for the logistic model in 
an independent patient sample. 
Since the identification of patho-physiological sub-groups amongst constipated 
patients affects management and prognosis (Wexner et al., 1991; Pemberton et al., 
1991; Piccirillo et al., 1995; Pfeifer et al., 1996; Lubowski et al., 1996; Nyam et al., 
1997), extensive physiological testing of patients with intractable constipation 
remains the optimal method of evaluation when management strategies are being 
planned. 
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Fig 4.04: ROC curve for a logistic regression model to predict RED only from 
discriminant scores for RED, MIXED and STC groups. The figure shows the trade-off 
between sensitivity and specificity in discriminating RED only patients from MIXED 
and STC patients. 
Whilst it is accepted that an experienced coloproctologist may be able to derive all 
pertinent information from history taking, the use of a questionnaire by others in the 
clinical assessment of patients with constipation may be helpful in prompting 
complete symptom assessment, monitoring treatment efficacy, and in the future, 
rationalizing further investigation. This is the first study utilizing appropriate 
statistical methodology to demonstrate a discriminatory ability of multiple symptoms 
in constipation. 
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SENSORYAND AUTONOMIC 
NEUROPA THY IN PATIENTS WITH 
%5 SL 0W TRA NSI T CONS TIPA TION 
5.1 INTRODUCTION 
The important role of extrinsic neuronal influences in the control of colonic motility has 
been discussed in the introduction. Autonomic dysfunction is an established cause of 
constipation in common conditions such as diabetes mellitus (Feldman et al., 1983; 
Sharma et al., 1995), and in rarer conditions associated with dysautonomia, such as the 
acute and subacute autonomic neuropathies (Khurana et al., 1988). These may affect 
both sympathetic and parasympathetic systems (pandysautonomia), or be selective e. g. 
"pure" cholinergic dysautonomia, as is seen for instance in the Shy-Drager syndrome 
(Khurana et al., 1980). Constipation may be the most common gastrointestinal 
manifestation of diabetes (Feldman et al., 1983; Sharma et al., 1995), and is associated 
with colonic motor abnormalities (Battle et al., 1980), and prolongation of transit 
through all bowel segments (Battle et al., 1980; Iber et al., 1993; Maleki et al., 1998). 
Gastrointestinal motor abnormalities in diabetes occur in both type I (insulin-dependent) 
and 11 (non-insulin-dependent) diabetes, and are associated with generalised autonomic 
neuropathy (cardiovascular and genitourinary dysfunction) (Low et al., 1975; Werth et 
al., 1992), and other diabetes-related complications such as sensorimotor peripheral 
neuropathy (Hollis et al. , 1977; Russell et al., 
1983). Anorectal sensorimotor 
abnormalities are also common in diabetics with or without faccal incontinence (Rogers 
et al. , 198 8; Sun et al., 
1996). 
A number of studies of patients with STC have indicated that dysmotility may exist in 
any of the extracolonic regions of the gastrointestinal tract: oesophagus (Watier et al., 
1983; Reynolds et al., 1987; Redmond et al., 1995; Ghosh et al., 1996), stomach 
(Reynolds et al., 1987; Van der Sijp et al., 1993; Ghosh et al., 1996; McDonald et al., 
1997), duodenum (Bassotti et al., 1996; Glia & Lindberg, 1998), and ileum 
(Panagamuwa et al., 1994). In addition, sensory or motor abnormalities of the urinary 
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tract have been demonstrated in some patients (Abdel-Rahman et al., 1981; Watier et 
al., 1983; Bannister et al., 1988; Kerrigan et al., 1989). The suggestion has therefore 
been made that STC might be a manifestation of a systemic, possibly autonomic disease 
process (Watier et al., 1983; Waldron et al., 1989). 
Sweat regulation has been used as a test of autonomic function in diabetics since 1942 
(Kahn & Rothman, 1942), and a number of methods are now available (Low et al., 
1983; Ewing et al., 1988; Low, 1993). Such methods have subsequently been used to 
test a variety of patients with "functional gastrointestinal disorders". The first study by 
Camilleri and Fealey (Camilleri & Fealey, 1990) using the thermoregulatory test and a 
quantitative sudomotor axon reflex test to iontophoresed acetylcholine (Low et al., 
1983), showed in 8 patients with severe (principally upper) gastrointestinal problems 
that idiopathic autonomic denervation may be an aetiological factor in non-organic 
intestinal dysmotility. All these patients had patchy anhidrosis, and 2 had positive 
cardiovascular tests. A further study by the same group from the Mayo Clinic (Bharucha 
et al., 1993) used this methodology to test 113 consecutive patients with a variety of 
gastrointestinal motility disorders, finding similar evidence of autonomic dysfunction in 
approximately 70% of diabetics and patients with neurological disease, and in 
approximately 30% of other motility disorders including EBS. Neither of these studies 
tested patients with STC. 
Waldron et al. (Waldron et al., 1989) used conventional cardiovascular autonomic tests 
described by Ewing and Clark (Ewing & Clarke, 1982) in a small number of patients 
with intractable constipation. The inconsistent results, may have reflected the poor 
sensitivity of the tests used (Fisher & Frier, 1989), or reflect the heterogeneity of the 
group studied. The same researchers (Altomare et al., 1992) went on to test 23 patients 
with idiopathic slow transit constipation using the acetylcholine sweat spot test 
described by Ryder (Ryder et al., 1988). They found patchy anhidrosis in 11, and 
concluded that the results indicated a reduction in post-ganglionic sympathetic 
sudomotor fibre function, which might reflect a similar disturbance of extrinsic 
sympathetic inhibitory fibre function in the gut. The acetylcholine sweat test cannot 
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however differentiate between intrinsic sweat gland dysfunction and that caused by 
denervation because acetylcholine can stimulate receptors both on the nerve and the 
gland itself (Jolliffe et al., 1995). Raethjen et al. (Raethjen et al., 1997) used a range of 
quantitative peripheral sensory and autonomic tests, including direct and axon-reflex 
sweat tests (described below in detail). Their finding of selective autonomic and sensory 
deficits in patients with STC was moderated by the small patient number. 
The aim of this study was to test a large cohort of patients with STC with a range of 
standard neurophysiological and selective quantitative tests of sensory and autonomic 
function (Anand et al., 1996), and to compare these findings with other factors, 
including familial association, prognosis and gastrointestinal physiological 
measurements. Normal controls and diabetics with gastrointestinal involvement were 
studied for comparison. 
5.2 METHODS 
5.21 PA TIENTS 
Forty-one patients were referred consecutively for study between October 1996 and 
February 1998. All had proven STC by the criteria previously described (Chapter 2). 
Thirty-nine women, and 2 men, median age 39 years, range 13-62 were studied. 
Notably, no patient had any evidence of any other disease process that might lead to 
peripheral neuropathy in the lower limb such as diabetes mellitus or spinal trauma. No 
patient had been previously studied (Altomare et al., 1992; Raejthen et al., 1997). 
20 age and sex-matched healthy volunteers acted as controls. 12 diabetic patients (8 
male, 4 female) with gastrointestinal involvement were studied as a positive control 
population. 
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5.22 METHODS (GENERAL) 
The subjects underwent a number of tests to assess both small (autonomic and sensory) 
and large fibre function (sensory and motor) (see table 5.01). 
Table 5.01: Autonomic and somatic fibre tests 
Test 
Sweat tests 
Cardiovascular tests 
Thermal thresholds 
Axon reflex vasodilatation 
Tactile threshold 
Vibration threshold 
Sural nerve conduction 
Peroneal nerve conduction 
Fibre type 
Autonomic function tests 
Post-ganglionic cholinergic sympathetic 
Mixed sympathetic / parasympathetic 
Somaticfunction tests 
Cool Small myelinated sensory (A6) 
Warm Small myelinated / unmyelinated sensory (A5 / C) 
Heat pain Unmyelinated sensory / nociceptive (C) 
Urunyelinated nociceptive (C) 
Large myelinated sensory (AP) 
Large myelinated sensory (AD) 
Large myelinated sensory (AP) 
Large motor (Aoc) 
All tests were carried out at a single visit in a quiet, air conditioned and thennostatically 
controlled room (21-23'C). Subjects lay supine for all tests, except when seated upright 
for thennal threshold and vibration tests. All sites tested for axon reflex vasodilatation or 
sweating were cleaned prior to injection with an alcohol wipe to remove dirt and grease, 
which may have affected recordings. Test solutions were drawn up into 28-guage 
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hypodermic syringes (Lo-dose, Beckton-Dickinson, 0.5ml capacity) and administered 
immediately. Details on the preparation of solutions used for injection are given in 
an endix 5.0 1. IT 
5.23 SMALL FIBRE TESTS 
Thermalperception thresholds (unmyelinated & small myelinated sensoryfibres) 
Thresholds for warm and cool sensation, and heat pain were measured using a Marstock 
stimulator (Thermotest, Somedic Ab, Stockholm, Sweden) (see Figure 5.01) as 
described by Guy et A (Guy et aL, 1985). By means of the Peltier principle, accurate 
stimulator paddle temperatures are produced when pre-calculated electric currents pass 
through the bimetallic junction of dissimilar materials within the stimulator. The instep 
of the foot rested on the stimulator paddle (2.5 cm x5 cm), which was placed on a firm 
surface. Ramp thermal stimuli were delivered with a standard rate of change of 
temperature of VC per second, rising from a neutral temperature (30.5'C) up to the 
temperature when the subject was aware of the desired sensation (method of limits). 
Each subject was given instruction to press a button immediately when they became 
aware of a given sensation, which then returned the stimulator to the neutral starting 
point. Each sensation was tested 5 times in succession, and the threshold was taken as 
the average degree centigrade change from the neutral point calculated from the 
recording. 
Sweat tests (cholinergic sympathetic sudomotorfibres) 
The principle of direct and indirect sweat tests is shown in Figure 5.02. Nicotine (0.8 ýtg 
in 0.2 nil) was injected intradernially (Jolliffe et al., 1995; Anand et al., 1996) into the 
skin of the lateral calf to produce an indirect sweating response via a sudomotor axon 
reflex. Absolute peak sweat rate in g/M2 /h was quantified locally in each case over an 
area of 1.13 CM2 by an evaporimeter (Servoined Evaporimeter EPI Ab Stockholm, 
Sweden) (Nilsson, 1977) (Figure 5.03). The peak usually occurred within about 5 
minutes of injection, and rapidly declined thereafter (see figure 5.04). 
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Figure 5.01: Thresholds for warm and cool sensation, and heat pain were 
measured using the Marstock stimulator (Thermotest, Somedic Ab, Stockholm, 
Sweden). The instep of the foot rested on the stimulator paddle (2.5 cm x5 cm). 
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Figure 5.02: Principle of sweat tests. Acetylcholine, as used in previous studies 
stimulates both the sweat gland directly, and the neural reflex. in contrast, the use 
individually of both nicotine which stimulates the neural reflex, and methacholine 
which stimulates the sweat gland directly allows the site of any sweating abnormality 
to be defined. 
When a poor indirect response was obtained, the test was repeated in the calf and volar 
forearm, and intradermal methacholine (4ýtg in Ural) was injected at a nearby site to 
give a direct sudomotor response, also measured with the evaporimeter. In each case, 
care was taken to place the head of the evaporimeter (using surgical tape) over the bleb 
of the intradermal injection, avoiding the entry point of the injecting needle, where fluid 
may leak back. 
Axon reflex vasodilatation (unmyelinated sensoryfibres) 
Axon reflex vasodilatation is the flare component of Lewis' triple response in skin. This 
was induced by intradermal capsaicin (0.05 jAg in 10 ýil), which selectively activates 
nociceptive fibres. 
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Fig 5.03: Sweat testing. Nicotine or methacholine are injected intrademally into 
the skin of the lateral calf to produce an indirect (axon-reflex) or direct sweating 
response respectively. Absolute peak sweat rate in g/mI/h was quantified locally in 
each case over an area of 1.13 cmI by an evaporimeter (Servomed Evaporimeter 
EPI Ab Stockholm, Sweden). 
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Figure 5.04: The figure shows 2 sweating responses from a normal control and a 
patient with STC. The upper trace demonstrates a normal response both to nicotine 
(axon-reflex sweating) and methacholine (direct gland stimulation). In contrast, the 
STC patient has a minimal axon-reflex response, both in the lateral calf and on 
repetition in the forearm, but a normal direct response when methacholine is used. 
Both subjects were females of the same age. 
The immediate increased capillary flux as a result of vasodilatation was measured with a 
laser-Doppler (Jolliffe et al., 1995; Anand et al., 1996) (Perimed PF 4, Stockholm) 
(Figure 5.05a), and recorded in flux units. Laser (coherent) light is transmitted to the 
skin via one fibre of a standard probe, and the scatter of this light by moving red cells 
undergoes a Doppler frequency shift. Reflected light is transmitted back via a second 
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fibre, and converted to a voltage signal in mV by a sensitive photoelectric cell 
(expressed as "flux units"). The signal produced is related linearly to the flux of red 
cells, i. e. number of cells times their velocity (Nilsson et al., 1980; Parkhouse & Le 
Quesne, 1988). The increase in capillary flux, calculated as the peak minus baseline was 
recorded (see Figure 5-05b). The probe was carefully placed on the skin of the lateral 
calf in a perspex holding device away from previously tested areas (above) (Figure 
5.05a). A small bleb was created intradermally, and any leakage of blood or solution 
from the testing site was carefully wiped away to prevent false high recordings. Care 
was also taken to attach the probe holding device (using surgical tape) so as to avoid 
compression of the tissue (reducing blood flow) or formation of an air interface 
(reducing signal). The test was repeated once when abnormally low or high results were 
obtained [accurate figures for reproducibility are not available for this test, because of 
the discomfort of repetition]. 
5.2.4 LARGE FIBRE TESTS 
Nerve conduction studies 
These were performed by a single consultant neurophysiologist using a Dantec 
Counterpoint (Denmark) by conventional methods. The sural nerve (sensory) and deep 
peroneal nerve (motor) were stimulated, and the sensory action potential (SAP), and 
motor action potential (MAP) delay and amplitude were recorded. Conduction velocity 
(in m/sec) was then obtained by calculation. 
Mechanical and vibration thresholds 
Both were tested using a method of limits, progressively larger stimuli being applied to 
the dorsal aspect of the great toe with the patients' eyes closed. Semmes-Weinstein 
monofilaments ("von Frey hairs") were used to produce a punctate stimulus on the 
dorsum of the great toe (Bell-Krotoski et al., 1993) (Figure 5.06a). Hairs are numbered I 
to 20. The relationship between the hair number and log,,, force in tenths of milligrams 
is linear, i. e. there is a curvilinear relationship between actual forces and hair numbers 
(Weinstein et al., 1993). 
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Figure 5.05: Axon-reflex vasodilatation. (a) This was induced by injection of 
intradermal capsaicin (0.05 gg in 10 gl), as this selectively activates nociceptive 
fibres. (b) The immediate increased capillary flux as a result of vasodilatation was 
measured with a laser-Doppler = [(a-b/2) - baseline flux]. 
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Vibration was tested at the metatarsophalangeal joint of the hallux using a 
Biothesiorneter (Bio-Medical Instrument Co,, Ohio, USA) (Figure 5.06b). Increasing 
vibrameter relative amplitudes were applied starting at zero, the subject indicating when 
they were first aware of the stimulus (vibration, not pressure or touch). Reproducibility 
of the procedure has been validated (Guy et al., 1985). 
5.25 NON-INVASIVE CARDIOVASCULAR AUTONOMIC TESTS 
Four standard tests were used: heart-rate responses to deep breathing, valsalva & 
standing up, and the blood pressure response to standing up. All have been previously 
validated, and control ranges established (Ewing et aL, 1988). All tests were performed 
using a portable digital ECG machine, employing only the 4 limb leads to obtain a 
continuous rhythm strip. 
Heart-rate response to deep breathing. 
The patient sat quietly and was then asked to breathe deeply and evenly at 6 breaths per 
minute (5 seconds in, 5 seconds out). The maximum-minimum heart rate during each 10 
second breathing cycle was measured and the mean of the differences during three 
successive breathing cycles gave the "maximum-minimum" heart rate (beats per 
minute). 
Heart rate response to the Valsalva manoeuvre 
This test was performed by asking the patient to sit quietly, and then blow into a 
mouthpiece attached to an aneroid pressure gauge at a pressure of 40-50mmEg, and to 
hold for 15 seconds. The ratio of the longest R-R interval shortly after the manoeuvre 
(within about 20 beats) to the shortest R-R interval during the manoeuvre was then 
measured. The result was expressed as the Valsalva ratio. 
Heart rate response to standing up. 
The patient lied supine quietly on a mechanical tilt table, and was then tilted rapidly to 
an upright position. 
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(a) 
(b) 
Figure 5.06: Mechanical and vibration thresholds. Both were tested using a 
method of limits, progressively larger stimuli being applied to the dorsal aspect of 
the great toe. (a) Semmes-Weinstein monofilaments (4fvon Frey hairs") were used 
to produce a punctate stimulus on the dorsum of the great toe. (b) Vibration was 
tested at the metatarsophalangeal joint of the hallux using a Biothesiometer. 
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The characteristic heart rate response was expressed as the 30: 15 ratio, which is the 
ratio of the longest R-R interval around the 30"' beat after standing to the shortest R-R 
interval around the 15"' beat. 
Blood-pressure response to standing up. 
This test was performed by measuring the blood pressure while the patient was supine, 
and then I minute after tilting to the upright position. The difference in systolic blood 
pressure (rise or fall) was taken as the measure of postural blood-pressure change. 
5.26 STATISTICAL ANALYSIS 
Statistical analysis was performed using the Kruskal-Wallis one-way ANOVA for non 
parametric data. Individual groups were compared using Dunn's multiple comparison 
test. Control values were obtained for all tests except for the non-invasive cardiovascular 
autonomic tests, and abnormal results were defined as lying outside two standard 
deviations from the control population mean, allowing for age. For the cardiovascular 
tests, the presence of single test abnormalities, and of autonomic neuropathy and its 
classification by severity (according to the degree and number of abnormalities) were 
defined from published series (Ewing et aL, 1988). 
5.3 RESULTS 
5.3.1 CLINICAL AND PHYSIOLOGICAL DATA 
STC patients 
Range of duration of constipation in STC patients was 1.5 to 52 years. 32 / 41 (78%) 
arose de-novo in childhood or teenage (CIST). A further 3 patients had symptoms 
arising in childhood, but worsened by hysterectomy (C/PIST). A total of 4 patients (I 
teenage onset, and 3 adult onset) gave a history of pelvic events associated with onset 
of symptoms (PIST). Two of these patients' symptoms arose following normal 
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vaginal deliveries (both primagravidae without complicated labour other than first 
degree tears), I arose after oophorectomy and I after hysterectomy, both without 
perioperative complications. A further two patients had de-novo adult onset of 
symptoms (AOIST). Nine patients had undergone colectomy (5 subtotal, 4 segmental 
resection) prior to the study. Taken as a group, the median bowel habit was once every 
14 days. Patients typically complained of other defaecatory symptoms, and abdominal 
pain and bloating. 
Eleven patients also gave a history of urinary symptoms especially frequency and 
urgency, 2 each of decreased sweating and dizziness on standing. Peripheral neuropathic 
symptoms, including a feeling parasthesiae, numbness or pain were uncommon, 
occurring in only 4 patients. Three STC patients had a history of psychiatric illness 
(depression), and 2 others used anti-anxiolytics. Thirty-four continued to regularly use 
laxatives. 
Median radioopaque marker retention (performed in all 41 patients) was 98% (range 
20-100% at 100 hours). Delayed transit, which was confirmed in 28 patients by a 
radioisotope transit study showed a generalised delay in 22 and segmental delay in 6. 
Twenty patients had rectal hyposensation to distension for one or more parameter 
compared to normal ranges (Jameson et al., 1994) (Chapter 3). Sixteen patients (from 
34 who underwent proctography) had disordered rectal evacuation secondary to a 
mechanical obstruction to defaecation or failure to strain by any cause (Chapter 3). 
A history of significant symptomatic constipation in one or more family members was 
elicited in 25 / 41 (61%) of STC patients. In addition, 4 index patients had a family 
history of Hirschsprung's disease, and I patient had an affected identical twin. 
Diabetic patients 
Eight insulin dependent (IDDM), and 4 non-insulin dependent diabetics were studied. 
Duration of disease since diagnosis ranged from 2 to 25 years, and duration of 
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gastrointestinal symptoms from I to 17 years. Frequency of defaecation ranged from 
every 4 days (constipated) to approximately 10 times per day (diarrhoea), with or 
without incontinence. Five patients had marked urinary problems, and 5/8 males had 
erectile dysfunction. 10 / 12 patients had a diagnosis of peripheral neuropathy, 5 of 
retinopathy, 3 of nephropathy, and 2 of a Homer's syndrome. Some gastrointestinal 
physiological studies had been performed for 5 diabetics included in the study. Marked 
anorectal abnormalities were present in all 3 tested (reduced sphincter function, 
prolonged pudendal nerve motor latencies, rectal hyposensation). Both patients 
undergoing small intestinal manometry had neuropathic changes consistent with 
diabetic enteropathy (interpreted and reported by D. L. Wingate, GISRU). 
Clinical neurological examination 
There were no significant abnormalities in the STC group on neurological clinical 
examination, apart from one patient with a healed right-sided malleolar ulcer who had 
clinically reduced pin-prick sensation below the ankle. 10 of 12 diabetics had clinical 
signs of peripheral neuropathy (sensory, motor or both). 
5.3.2 CONVENTIONAL NEUROPHYSIOLOGYAND AUTONOMIC TESTS 
The full results of these tests for all groups are listed in appendix 5.02 
Nerve conduction studies 
STC patients had no abnormalities of motor-sensory nerve conduction. In the diabetic 
patients, abnormalities of nerve conduction were found in 10/12 patients (sensory and 
motor abnormalities in 6 and sensory only in 4), with mixed features of axonal loss 
and demyelination. 
Non-invasive cardiovascular autonomic tests 
Two patients with STC had one abnormality each, and I had a borderline abnormality, 
indicating that cardiovascular evidence of significant autonomic neuropathy was not 
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present in any patient (early Involvement possible). In contrast, 5 diabetics (from 9 
tested) had "definite" or "severe" autonomic involvement by their disease (Ewing et 
al., 1988). 
5.3.3 QUANTITATIVE PERIPHERAL TESTS 
The full results for all groups are shown in appendix 5.03 
Control values and cut-offs of normality 
The numeric limits of normality for each quantitative test were taken from the control 
values (n = 20), and calculated from the control mean +/- 2 S. D. (Table 5.02). 
Table 5.02: Quantitative peripheral sensory and autonomic tests: control values 
and cut-offs for normality. 
Test Normal range Mean +1-2 S. D. (cut-ofj) 
Light touch (Log" force) 1- 7 8 
Vibration (Biothesiometer units) 5- 11 12 
Cool threshold (IQ 1- 3.5 3.3 
Warm threshold ff) 1.4 -5.1 5.4 
HeatPain threshold (OQ 7.7 -16.1 17.0 
Axon-reflex sweating (glm 2 h) 32 -84 :5 22 
Axon-reflex vasodilatation (flux) 44 -140 < 37 
Small sensoryfibre tests 
STC patients showed a significant elevation of warm sensory threshold (n = 41, median 
4.2 'C, range 2- 12.1) compared to controls (n = 20, median 3.2 'C, range 1.4 - 5.1, p< 
0.05) (Figure 5.07). 
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Figure 5.07: Scatter plot of warm thresholds for STC patients vs. controls and 
diabetics. Some STC patients, and most diabetics had raised thresholds leading to 
significant differences between the groups (Kraskal-Wallis one-way ANOVA). 
Cool thresholds were elevated, but not significantly (n = 41, median 2.1 'C, range 0.9 - 
5.6) compared to controls (n = 20, median 1.5 'C, range I-3.5, p<0.05). Both these 
abnormalities were more marked in the diabetics (p < 0.001 for both warm and cool 
sensory thresholds). Three STC patients had an increased threshold to heat pain, and 2 
of these patients had significantly reduced axon-reflex vasodilatation (both tests of 
unmyelinated nociceptor fibres). These 3 patients had marked abnormalities on other 
small sensory fibre tests. 10 diabetic patients had no threshold to heat pain within the 
safety limits of the study, and 7 of these had a significant reduction of axon-reflex 
vasodilatation. 
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Sweat tests 
Nicotine-induced axon-reflex sweating was significantly decreased in the STC patients 
(n = 39, median 39 g/m'h, range 7-74) compared to controls (n = 20, median 47 g/m'h, 
range 32-84, p<0.04) (Figure 5.08). STC patients, like the diabetics, appeared to fall 
into two subgroups, with an apparently distinct subgroup lying below 2 SD of the 
control mean (STC subgroup: n= 12, median 13 g/M2 h, compared to controls: p< 
0.0001, Mann Whitney U-test). Notably, on directly stiMUlating the sweat glands with 
methacholine, there was no significant difference between the controls (median 62 
g&h, range 42-92) and STC patients (median 62 g/M2 h, range 33-87) (Figures 5.03 and 
5.08). 
Large sensoryfibre tests 
Vibration threshold was not significantly different between patients (n = 41, median 
8.5, range 3-20) and controls (n = 17, median 7, range 5-11, p>0.05); however, 9 
STC patients had slightly elevated thresholds with respect to the defined cut-off of 
normality. Most diabetics had markedly elevated vibration thresholds (n = 12, median 
30, range 14-50, p<0.001). The range of tactile threshold (monofilaments) was 
similar between controls and constipated patients: only 2 STC patients, but 6 diabetics 
had a raised thresholds. 
5.3.4 SUMMARY OF RESULTS 
Twenty STC patients, i. e. approximately 50% of the total, shared a total of 38 abnormal 
test results (range I-5 per patient). Eight patients had sensory fibre abnormalities only, 
3 patients had an abnormality of sympathetic function only, and 9 patients had both. Of 
the patients with sensory abnormalities, over half had small sensory fibre deficits. There 
was no overall correlation of test abnormalities with age or mode of onset, or laxative 
use. Of the 8 STC patients with a previous colectomy, 7 had abnormalities on 
quantitative tests. There was no difference in symptom profiles e. g. infrequency of 
bowel habit etc. between patients with or without abnor malities. All the 4 patients with 
peripheral neuropathic symptoms on questioning had abnormalities, but there was no 
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Figure 5.08: (a) Nicotine-induced axon-reflex sweating is significantly decreased in 
the STC patients vs. controls. STC patients, like the diabetics, appeared to fall into 
two subgroups, with a distinct subgroup (n = 12) lying below 2 SD of the control 
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mean. (b) On directly stimulating the sweat glands with methacholine, there was no 
difference between controls and STC patients. KEY: one patient refused a further 
injection, therefore n=II (vs. n= 12 for axon-reflex) 
Of the 20 patients with decreased rectal sensation for dlstensioný II had small fibre 
abnormalities compared with 5 of the 16 patients who had normal rectal sensation. 
There was however no association between peripheral neuronal dysfunction and rectal 
hyposensation by contingency calculation (Fisher's exact test, p=0.5). Likewise, no 
association was observed between abnormal peripheral small fibre test results and anal 
sphincter function, radio-opaque marker retention, pattern of transit abnormality on 
isotope scintigraphy, defaecatory abnormalities on evacuation proctography or small 
intestinal manometry, 
5.4 DISCUSSION 
The results demonstrate that in a proportion of patients with STC there is evidence of 
autonomic and sensory dysfunction in the lower limbs. The decreased axon-reflex 
sweating indicates neural dysfunction, confirmed by the normal response of the gland 
itself when stimulated directly. The overlap with abnormal thermal thresholds and axon- 
reflex vasodilatation suggests a generalised small fibre neuropathy in some patients. 
Unlike diabetics, where abnormalities on neurological clinical examination or standard 
neurophysio logical tests were present, these quantitative functional tests may be the only 
indicators of an underlying small fibre neuropathy in patients with STC, although the 
degree of abnormality was in general less than that for diabetics with gastrointestinal 
involvement. 
Possible confounding variables 
Age has been shown to effect both autonomic tests (Foster et al., 1976), and small fibre 
sensory function (Meh & Denislic, 1994). However, significant changes are normally 
only observed after the age of 70 years, and the oldest patient in this study was only 62 
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years of age. In addition, the group with abnormalities did not differ in age significantly 
from those without, or from controls. Whilst prolonged neurotoxic laxative use could 
theoretically influence the findings of this study, the lack of correlation between 
prolonged use and the presence of abnormalities does not support this hypothesis. 
Indeed, only one patient included in the study could have potentially used for a 
sipificant period an outdated laxative which may have been systemically neurotoxic 
e. g. podophyllin, and we have no evidence that this was the case. No other drug was 
consistently used by a significant proportion of patients in the study to account for 
neurotoxicity. A high proportion (7 / 8) of the patients undergoing surgery for 
constipation prior to the study had significant abnormalities on testing. There is 
similarly no clear explanation for such neural dysfunction arising as a sequel to 
abdominal surgery. Because of the nature of consent, which was performed by the 
author, it was not possible at the time to perform the tests in a blinded fashion, and this 
may have introduced some observer bias. However, towards the end of the study, some 
patients were referred before the results of their transit studies were known. 
Pathophysiological implications 
The implications of the findings of the study to the understanding of the aetiology of 
STC are not entirely clear. The results would support, like previous studies (Altomare et 
al., 1992, Raethjen et al., 1997) a common, possibly selective disease process of 
autonomic neurones, or of small sensory fibres in patients with STC. This could explain 
the observations of systemic (generalised intestinal) physiological abnormalities and 
extragastrointestinal e. g. bladder abnormalities in patients with STC (see introduction), 
supporting the view that the presence of abnormalities such as rectal hyposensation may 
represent a primary neuropathic disorder, rather than one occurring secondary to 
prolonged constipation (Kamm & Lennard-Jones, 1990). Abnormalities of rectal 
sensation were most marked for defaecatory desire and maximum tolerable volume, 
which may reflect dysfunction of small unmyelinated afferents in the rectum. 
More problematic is the explanation of how dysfunction of certain peripheral fibre types 
could translate, were it to occur systemically, into a loss of propulsive activity in the 
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colon observed in STC. For instance, the consequence of sudomotor dysfunction, 
indicative of a postganglionic sympathetic impairment, would seem, at least on the basis 
of experimental studies of sympathetic nerve section or stimulation, to result in a 
disinhibition of colonic motility (see 1.5.4). Two explanations might explain this 
incongruence. Firstly, increased motility does not necessarily result in increased transit. 
Constipating drugs such as opioids increase motility while inhibiting propulsive activity 
(1.6.5), and abnormal hypen-notility patterns have been reported to occur in the 
constipation predominant irritable bowel syndrome (Kumar & Wingate, 1985). 
Secondly, the decrease in sudomotor, and indeed small fibre sensory function may relate 
to alterations in the expression of certain neurotransmitters with a role in gut motility, 
rather than a loss of one specific functional subset of autonomic neurons. Sudomotor 
and visceral efferents share acetylcholine and vasoactive intestinal polypeptide (VIP) as 
neuroeffector agents, and visceral and somatic small fibre afferents the peptides 
substance P (SP), and calcitonin gene-related peptide (CGRP) which mediate axon- 
reflex vasodilatation (Goyal & Hirano, 1996). These nerve fibres and agents have been 
implicated in diabetic sensory and autonomic polyneuropathy, and are attributed to 
changes in specific neurotrophic factors (Anand et al., 1996). The abnorinal findings in 
the limbs in some STC patients may therefore indicate a common mechanism 
contributory to enteric nerve dysfunction, leading to this form of constipation. In 
support, whilst the high variability of the studies must be noted (see 1.5.3), decreased 
levels of gut SP (Goldin et al., 1989; Tzavella et al., 1996; Porter et al., 1998) and 
VIP-immunoreactivity (Romanska et al., 1996), and in-vitro stimulated ACh release 
(Burleigh, 1988) have been associated with STC. Cholinergic deficits, occurring 
systemically are indeed associated with constipation (Inamdar et al., 1982; Vassallo et 
al., 199 1). 
This study, whilst demonstrating that peripheral sympathetic cholinergic and small fibre 
sensory function abnon-nalities are present in some patients with STC, still does not 
prove that such deficits are the cause of constipation. Whilst it is unclear how this might 
be directly proven, quantitative studies of unmyelinated fibres in sural nerve biopsies 
would at least allow morphological proof of peripheral fibre deficits in these patients. 
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Furthermore, studies of neurotrophic factors and their receptors in affected colon and 
sural nerve, may help answer whether a common mechanism exists to explain changes 
in both the skin and gastrointestinal tract. 
rl- 
I umilial and genetic implications 
This study revealed a history of constipation in close family relatives in approximately 
60% of STC patients. This is in accord with a previous study, which reported a family 
history in 55% of females with idiopathic constipation (Chaussade et al., 1986), and is 
greater than published population prevalence ranges (2-34%) (Whitehead et al., 1991). 
Whilst this finding may support genetic aetiology, social or dietary factors may also be 
responsible. This study also demonstrated four STC patients with one or more family 
relative with Hirschsprung's disease. A number of mutations have now been described 
in Hirschsprung's disease, including RET and its principle ligand, Glial cell-derived 
neurotrophic factor (GDNF). A potential role in the pathogenesis of STC for these 
factors is tested by screening of these patients for mutations in chapter 6. 
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SCREENING OF PATIENTS WITH 
IDIOPATHIC SLOW TRANSIT 
CONSTIPATION FOR MUTATIONS 
OF THE RET PROTO-ONCOGENE 
6 
AND GDNF 
6.1 INTRODUCTION 
Chapter I introduced the hypothesis that STC patients with early-onset symptoms 
(chronic idiopathic STC), might, like some other gastrointestinal phenotypes which arise 
in infancy or childhood, be the result of a primary neuronal abnormality caused by 
mutations of genes that are known to be important during ontogeny of the ENS (Lyonnet 
et al., 1993; Aurrichio et al., 1996). Interest in this hypothesis was strengthened by the 
findings of the neurophysiological study, described in the last chapter, in which a history 
of constipation was observed in one or more family members in approximately 60% of 
patients studied, and 4 index patients with idiopathic STC had one or more relative with 
Hirschsprung's disease (HSCR). A history of constipation in close family relatives of 
patients with STC had been elicited in about half the patients included in a previous 
publication (Chaussade et al., 1989), but the observation of a possible association 
between STC and HSCR was novel. The background to the genetics of HSCR relevant 
to this chapter is discussed below. 
6.1.1 Hirschsprung's ýdisease 
Hirschsprung's disease (HSCR) is characterised by the congenital absence of ganglion 
cells of the enteric nerve plexus in all or part of the hind gut, and in a few, the midgut. It 
occurs in approximately I in 5000 live births In both sporadic (80%) and familial (20%) 
forms (Passarge, 1967). In familial cases, the pattern of inheritance may be autosomal 
dominant, recessive or polygenic (Badner et al., 1990). Mutations of a number of genes 
have now been described for HSCR including those encoding the RET proto-oncogene 
(Lyonnet et al., 1993; Angrist et al., 1993; Edery et al., 1994a; Romeo et al., 1994), its 
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ligand glial cell line-derived neurotrophic factor (GDNF) (Angrist et al., 1996; Saloman 
et al., 1996), the G protein-coupled endothelin-B receptor (Puffenburger et al., 1996), its 
ligand, endothelin 3 (Hofstra et al., 1996), and more recently SOXIO (Pingault et al., 
1998) and neurturin (Doray et al., 1998). 
6.1.2 The RET proto-oncogene 
The human RET proto-oncogene (C-RE7) (REarranged during Transfection) was 
discovered as an oncogene activated by rearrangement with a foreign sequence in a 
fibroblast focus-fortning assay (Takashi & Cooper 1987; Takahashi et al., 1988). The 
gene has been mapped to human chromosome 10 at qI 1.2, and encodes a member of the 
receptor tyrosine kinase (RTK) family, RET protein. The key structural features of RET 
include extracellular cadherin-like and cysteine-rich domains, a transmembrane domain 
and an intracellular domain with tyrosine kinase function (Eng, 1999). As with other 
RTKs, RET spans the cellular membrane and is activated by the binding of certain 
ligands, including GDNF (see below) to novel glycosylphosphoinositol-linked 
extracellular proteins (Jing et al., 1996, Durbec et al., 1996a) which reside in association 
with RET on the cell membrane. These co-receptors have now been assigned the terms 
GFRoc-1-4 (Trupp et al., 1998; Thompson et al., 1998). The result is the formation of a 
multimeric complex between the activated GFR-a receptor and RET, with subsequent 
autophosphorylation, and phosphorylation of other intracellular substrates (Figure 6.01). 
The RET gene comprises at least 20 exons (Pasini et al., 1995a), and undergoes 
alternative 5' and 3' splices predicted to result in up to 10 different protein isoforms 
(Kwok et al., 1993; Lorenzo et al., 1995). 
FRET is expressed in tissues of neural crest origin, and in tamours of neural crest 
derivatives such as medullary thyroid carcinoma (MTQ and phaeochromocytoma. RET 
plays a crucial role in kidney morphogenesis and in the survival and differentiation of 
several sub-populations of neurones in the peripheral and central nervous systems 
(Schuchardt et al., 1994; Durbec et al., 1996a; Sanchez et al., 1996). It has now been 
recognised as the susceptibility locus for several inherited disorders of neural crest 
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development including: multiple endocrine neoplasia type 2 (MEN-2) (Mulligan et al., 
1993; Hofstra et al., 1994) and HSCR (Lyonnet et al., 1993; Angrist et al., 1993; Edery 
et al., 1994a; Hofstra et al., 1994; Romeo et al., 1994). A large number of germline 
mutations have been identified for both conditions, the majority of which are distinct to 
each disease, and have also been demonstrated somatically in phaeochromocytomas, and 
MTC (see recent reviews) (Eng & Mulligan, 1997; Eng, 1999). 
P13Kinase Other-, 
Pathway RAS-RAF 
Path^ ny 
Figure 6.01: The RET receptor tyrosine kinase is positioned in the cell membrane. It is 
activated when its ligand binds a co-receptor and the complex in turn interacts with 
RET. Reproduced with permission: Eng C. RET proto-oncogene in the development of 
human cancer. J Clin Oncol 1999; 17: 38 1. 
Mutations of RET have been recognised in both familial autosomal dominant, and 
sporadic HSCR cases (Lyonnet et al., 1993, Angrist et al., 1993). Whereas rare 
tnicroscopic and submicroscopic deletions of chromosome I Oq 11.2 result in the loss of 
a single RET allele (Luo et al., 1993), the majority of cases result from one of a range of 
point mutations scattered throughout the extracellular domain and intracellular tyrosine 
kinase domain (Edery et al., 1994a, Romeo et al., 1994; Angrist et al., 1995). 
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Frameshift and nonsense mutations are predicted to result in RET protein truncations, 
but missense point mutations also occur throughout the gene (see Figure 6.02). Recent 
evidence suggests that RET mutations may lead to severe impain-nent of RET tyrosine 
kinase activity (Pasini et al., 1995b) by a number of intracellular mechanisms, including 
failure of transport of the RET protein to the cell membrane, or lack of its maturation 
(Iwashita et al., 1996; Carlomagno et al., 1996; Ito et al., 1997). 
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Figure 6.02. Whereas rare microscopic and submicroscopic deletions of chromosome 
10ql 1.2 result in the loss of a single RETallele, the majority of cases result from one of 
a range of point mutations scattered throughout the regions encoding the extracellular 
domain and intracellular tyrosine kinase domain of RET. Reproduced with permission: 
Eng et al. Hum Mutat 1997; 9: 97-109. 
6.1.3 Glial cell line-derived Neurotrophic Factor (GDNF) 
A major step toward understanding the biological actions of RET was the identification 
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of one of its ligands, GDNF (Trupp et al., 1995). GDNF is a polypeptide, structurally 
related to members of the transforming growth factor-P (TGF-P) superfamily (Attisano 
et al., 1994). GDNF was purified from the conditioned medium of a glial cell line on the 
basis of its ability to stimulate dopamine uptake in primary cultures of embryonic rat 
ventral midbrain neurons (Lin et al., 1993). GDNF promotes the survival and phenotype 
of several populations of peripheral and central neurons, including sympathetic, sensory 
and motor neurones (Henderson et al., 1994; Trupp et al., 1995; Buj-Bello et al., 1995). 
RET is part of a multicomponent receptor complex for GDNF which includes the ligand 
binding GFR-a co-receptors discussed above. Whilst, GDNF, RET, and GFR-a show 
complementary and overlapping patterns of m-RNA expression in the rat CNS (Trupp et 
al., 1997), the search for the co-existence of other receptor components was prompted 
by the observation that certain areas of the CNS lacked one of the receptor components. 
This has lead to the very recent discovery of further receptor components (now ten-ned 
GFRa- 1 -4) and ligands: neurturin (NTN) (Kotzbauer et al., 1996), persephin (Milbrandt 
et al., 1998), and artemin (Baloh et al., 1998) whose activities are mediated through 
RET tyrosine kinase. GDNF and NTN signal via the multicomponent receptors (GFRa- 
I and GFRa-2) (GDNF Receptor Nomenclature Committee, 1997), with varying 
degrees of specificity suggested by competitive binding and equilibrium studies, and 
comparative neuronal survival studies (GFRa-1: GDNF affinity > NTN, GFRcc-2: NTN 
affinity > GDNF) (Klein et al., 1997; Buj-Bello et al., t997). GFR(x-3 is structurally 
related to the other GPI-linked proteins (Trupp et al., 1998), and its ligand has now been 
demonstrated to be arternin (Baloh et al., 1998). GFRoc-4, a further structurally related 
protein (Thompson et al., 1998) is now known to be the receptor for the ligand 
persephin (Enokido et al., 1998). The gene for GDNF has been mapped to human 
chromosome 5 at pl2-pl3.1 (Schindelhauer et al., 1995), has 2 exons, and gives rise to 
two alternatively-spliced fortris that code for prepropeptides (Springer et al., 1995). 
6.1.4 RET / GDNF and chronic idiopathic constipation 
Analysis of the RET gene in HSCR by Edery et al. (Edery et al., 1994b) identified 
gennline mutations in three of nine subjects with severe constipation starting in 
168 
CH. Knowles 
childhood. These were relatives of patients with proven HSCR in the study, and 8 of the 
9 were female. Whilst some of these had radiological evidence of megacolon, no 
physiological or histopathological data was available. Similarly, a further study 
screening for GDNF mutations in HSCR, demonstrated a single kindred with mutations 
of both GDNF and RET in which some female family members had "chronic 
constipation starting in childhood" (Saloman et al., 1996) but again, physiological or 
histological features were not discussed. Considerable diversity of phenotypes, even 
cosegregating to one allelic alteration has been demonstrated with RET (Mulligan et al., 
1994; Amiel et al., 1998) and GDNF mutations (Amiel et al., 1998), and patients with 
one such phenotype, MEN-2B, commonly first present with severe constipation. It is 
therefore possible that STC could represent a further diverse phenotype i. e. a variant of 
HSCR, possibly as a result of modifying gene activity. 
6.1.5 Aims 
The aim of this study was to test the hypothesis that RET / GDNF mutations are 
responsible for the functional abnon-nalities observed in STC. This was tested in 4 
families in which idiopathic STC was associated with HSCR, and a series of patients 
with the fully characterised chronic idiopathic slow transit phenotype and with a family 
history of constipation in one or more relative, but without a family history of HSCR. 
The selection of these 2 genes rather than others known to be involved in the 
pathogenesis of HSCR was based on the evidence above, and on the grounds that RET 
remains the commonest and best accepted gene implicated in HSCR. In addition, the 
methodology for performing studies of these genes was available in the UK at the time 
of the study (Cancer Research Council, Human Cancer Genetics Group, University of 
Cambridge). 
6.2 MUTATION SCREENING: BACKGROUND TO METHODOLOGY 
A number of methods have now been developed to faciliatate DNA mutation screening. 
Regardless of the exact methods utilised, there are a number of laboratory-based steps 
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common to this process. DNA must be extracted and purified (6.2.1), amplified to produce 
adequate arnounts for subsequent use (section 6.2.2 - polymerase chain reaction), and then 
mutations detected by the various available methods (6.2.3). 
6.21 PREPARA TION OF DNA 
A number of techniques can be used for the extraction and purification of DNA including 
phenol extraction, caesium chloride density purification and salt precipitation procedures. 
The latter are generally more popular because of the low toxicity of the reagents used 
(Miller et aL, 1988). There are a number of common steps to salt precipitation techniques: 
white cell isolation and lysis, deprotemation, RNAase treatment, DNA recovery (salt and 
alcohol to precipitate DNA, centrifuge to collect), and finally DNA rehydration. Some 
modem techniques use pre-prepared reagents in kits, and have high yields with acceptable 
purity. Following DNA preparation, the purity and yield can be assessed using optical 
density measurements (spectrophotometry). 
6.22 THE POL YMERASE CHAIN REACTION 
The polymerase chain reaction (PCR) is still a relatively new technique. In the short time 
since its invention it has revolutionised many aspects of molecular biology, in particular the 
analysis of small specific sequences for single base pair alterations. PCR provides a 
simplified alternative to scoring restriction fragment length polymorphisms, and is less 
laborious and time consuming than standard Southern blotting techniques. 
PCR is an in vitro technique designed to isolate and amplify small, specific segments of 
DNA between 105 and 108 fold from insignificant quantities of template (less than I gg) in 
a short space of time (Saiki et al., 1985). In principal, two synthetic oligonucleotide primers 
are designed, which are typically 20-25 nucleotides long, and flank the DNA segment to be 
amplified. These primers, orientated 5' to Y, are hybridised to opposite strands of the target 
sequence and extended using DNA polymerase until the region between the two primers is 
completely replicated. Initial hybridisation of the two oligonucleotides requires heat 
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denaturation of the double-stranded DNA template. The temperature is then lowered to an 
optimum at which primers anneal to their complementary sequences. Finally, polymerase 
elongation, again requiring an optimal temperature, completes the synthesis which 
effectively results in doubling the concentration of the target DNA segment. This cycle of 
events involving denaturation followed by annealing followed by elongation is repeated for 
25-35 rounds to obtain an enriched concentrate of specific DNA. Since it was initially 
reported, advances in PCR technology have greatly increased its efficiency while generally 
simplifying and speeding up the technique. Initially, the DNA polymerase used was derived 
from Esherichia coli, and was thermally unstable at the high temperatures used in the 
denaturation step, requiring it to be replaced during each round of amplification (Saiki et al., 
1985). In contrast the thermostable DNA polymerase isolated from the bacterium Thermus 
aquaticus (Taq) was found to have a higher optimum temperature (70-75'C) giving it 
greater specificity and yield, and also retained its activity after heat denaturation (Saiki et aL, 
1988). Commercially available thermal cyclers specifically designed for PCR and with the 
ability to accurately control the temperatures required for each stage of the PCR reaction, 
have simplified and improved the speed and efficiency of the technique as a whole. 
6.2.3 DETECTION OF SINGLE BASE CHANGES IN DNA 
The ability to detect single base changes in genomic DNA is of fundamental importance to 
the study of genetic diseases by identifying causal mutations. In addition, the identification 
of DNA polymorphisms provide invaluable genetic markers for linkage studies either in the 
localisation of particular genes or diagnostically through determining the segregation of 
genetic diseases within families (Gusella et al., 1982). Where target sequences are known, 
Southern analysis using radioactively labelled allele-specific oligonucleotide probes may be 
used to test for the presence or absence of a mutation by its ability or inability to hybridise to 
the target sequence, and has been used in clinical diagnostic testing (Shuber et aL, 1993). 
However, circumstances often require the detection of mutations when the precise nature of 
the alteration is not known. Direct DNA sequencing may be used to scan a gene for 
unknown mutations but is laborious, costly and very time consuming with present 
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technology. Restriction fragment length polymorphism (RFLP) analysis using Southern 
blotting with probe hybridisation can detect mutations which alter cutting sites of restriction 
enzymes, and in its own right has been employed successfully at the level of routine 
diagnosis (Chang and Kan, 1982; Orkin et al., 1982). However, palindromic sequences of 
the type recognised by restriction enzymes are uncommon and the chances of detecting 
single base mutations on this basis are consequently low. For these reasons further methods 
have been developed for the detection of subtle genetic alterations with a high degree of 
speed and efficiency. Single-strand conformation polymorphism analysis is an example of 
these methods and can detect the presence or absence of a mutation, whilst relying 
subsequently on direct sequencing to characterise the change. 
6.2.3.1 Single-strand conformation polymorphism analysis (SSCP) 
Single-strand conformation polymorphism analysis (SSCP) was first developed by Onta et 
al. (Onta et al., 1989). The basic principle on which SSCP relies is that under non- 
denaturing conditions single-stranded DNA molecules take on a folded secondary structure 
which is stabilised by weak intramolecular interactions. In general these interactions are 
base pairing hydrogen bonds and so, as a consequence, two strands differing by only a single 
base will have different confonnations which potentially manifest themselves in their 
electrophoretic mobility (Orita et aL, 1989). 
After heat denaturation with formamide to retain a single-stranded state, DNA fragments are 
electrophoresed through a non-denaturing polyacrylamide gel matrix. The two 
complementary strands will usually resolve as two SSCP conformers of distinct mobility, 
although under various conditions a single strand can adopt more than one conformation. A 
mutation resulting in heterozygosity will be characterised by the presence of extra bands in 
addition to those produced by the normal hornozygote, base-pair changes being identified as 
variants among DNAs of a sample set. Radioactively labelled DNA fragments generated by 
PCR are visualised after autoradiography (Sheffield et al., 1993), or alternatively non- 
radioisotopic methods for detection, such as silver staining, may be used (Ainsworth et al., 
1990). 
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After denaturation to generate single-stranded DNA a certain amount of reannealing 
inevitably occurs leading to heteroduplex. formation between mutant and wild-type 
fragments. When electrophoresed through a non-denaturing polyacrylamide gel these 
heteroduplex mismatches can been seen to run significantly slower than either mutant or 
wild-type homoduplexes. This feature has favourably increased the informativeness of the 
SSCP technique and is particularly useful for detecting small insertions and deletions e. g. 
Familial Adenomatous Polyposis (Cottrell et al., 1992). The estimated efficiency of SSCP 
appears to vary between studies but the general indications are that between 75 and 90% of 
single base mutations are detectable in DNA fragments ranging from 100-450bp, with an 
optimal size of approximately 200bp in length (Sheffield et al., 1993; Condie et al., 1993). 
Various parameters can be modified to increase the sensitivity of the technique, in particular 
the running conditions (e. g. temperature during electrophoresis; concentration of running 
buffer) and gel content (Orita et al., 1989). SSCP has been used to detect mutations in a 
number of human genes involved in disease including RET (Groden et al., 1993; Ceccherini 
et al., 1994; Gayther et al., 1995). 
6.2.3.2 Direct DNA sequenciug 
DNA sequencing can be performed using chemical or enzymatic methods. Both 
methods involve four base-specific reactions that remain incomplete, yielding a 
heterogeneous population of molecules that end in one of the four nucleotides in each of 
four different reactions. The enzymatic sequencing method as first described by Sanger 
(Sanger et aL, 1977) has now essentially replaced the chemical method (Maxam & 
Gilbert, 1977), and uses dideoxynucleotides (ddNTPs) which differ from normal 
deoxynucleotides (dNTPs) in that they cannot be extended by DNA polymerase. These 
populations of molecules are then resolved on a denaturing polyacrylamide gel. Modem 
enzymatic sequencing uses a thermal-stable DNA polymerase with thermal cycling to 
allow single tube reactions (one per sample), very small amounts of DNA template, and 
analysis of large constructs. The enzyme and fluorescent dye-labelled terminators are 
included in a single premix (kit) to prepare samples for automated sequencing. The 
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fluorescent dye-labelled terminator ddNTPs, when incorporated, allow laser-detection of 
bands on the gel, and computer led data acquisition and analysis. Modem enzymes 
compared with the original DNA polymerases have reduced discrimination for ddNTPS, 
and can use much lower initial levels of dye-labelled terminators, leading to reduced 
final levels of unincorporated dye-labelled terminators in each reaction. 
6.3 MATERIALS AND METHODS 
6.3.1 PA TIENTS 
We screened 4 STC patients and affected relatives with Hirschsprung's disease from 4 
families with both conditions (8 individuals in total), and 12 STC patients with a family 
history of constipation in one or more relative, including one patient with an affected 
identical twin, but with no family history of Hirschsprung's disease. The family trees of 
the patients with HSCR relatives are shown in figure 6.03. 
STCpatients (clinical andphysiologicalfeatures) 
The 16 cases studied were all female, median age 40 years, range 26-63. Chronic 
idiopathic STC was defined by criteria used in chapters 2 and 3. Notably, no patient had 
radiological evidence of idiopathic megabowel, and all had an intact rectoanal inhibitory 
reflex. Six patients had undergone segmental or subtotal colonic resection for the 
condition. No patient had evidence of aganglionosis or other neuronal abnormality on 
routine histological examination of tissue from resection or from rectal biopsy. 
IISCR cases 
Material from 4/6 relatives of STC cases with HSCR, from 3 of the 4 families was 
available for analysis (see Figure 6.03). The final family HSCR relative was unavailable 
for venepuncture (emigrant to Australia). Patients studied included 3 with short segment 
disease, and one with total colonic aganglionosis and sensorineural deafness, but no 
evidence of pigmentary abnormalities. All cases had previously undergone a pull 
through procedure, and had HSCR based on histological examination of affected gut. 
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Figure 6.03. Familial association of slow transit constipation (STC) with 
Hirschsprung' s disease (HSCR) in fou r families. 
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111.2 Anorectal HSCR 
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6.3.2 MA TERIALS 
6.3.2.1 Chemicals (general) 
All chemicals of general use were supplied by British Drug House (BDH, Poole, UK) 
unless otherwise stated, and were of AnalaR quality. In addition, BDH also supplied the 
specific reagents: trichloroacetic, acid, glycerine, gluteraldehyde, silver nitrate, sodium 
borohydride, sodium carbonate, sodium thiosulphate, NNN'N' tetramethylenediamide 
(TEMED) and urea. Sigma Chemical Company (Poole, UK) supplied 
phenylmethylsulphonylfluoride (PMSF), bovine serum albumin (BSA), ethidium bromide, 
standard grade agarose, phosphate buffered saline (PBS) tablets and dimethyl sulphoxide 
(DMSO). 
6.3.2.2 Solutions and buffers 
Unless otherwise stated solutions and buffers were prepared using distilled and 
deionised water (dH, O), and were stored at room temperature (i. e. between 15 and 
25'Q. Sterilisation was by autoclaving at l5lbs psi 121'C for 30 minutes. The 
components of general solutions and buffers are presented in appendix 6.01. 
6.3.3 METHODS: MUTATIONANALYSIS 
6.3.3.1 DNA isolation and purification 
Peripheral venous blood samples (10ml) were taken from a single antecubital fossa 
venepuncture, and stored in heparin ETDA containing vacutainer (Becton Dickinson & 
Co., NJ, USA) bottles at - 30T until use. Genomic DNA was isolated using a salt 
precipitation kit (Puregene, Gentra systems Inc., USA) (Appendix 6.02). Following 
rehydration, yield was assessed using spectrophotometry (compared to 100ng/ml calf 
thymus DNA standard) (Appendix 6.03), and samples were further diluted to give a 
final DNA concentration of approximately 50ng/ml. 
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6.3.3-2. DNA amplification 
Oligonucleotides. 
Primer sequences were initially taken from Ceccherini et al. (Ceccherini et aL, 1995), an 
erratum. to previously published material (Ceccherini et aL, 1994). Oligonucleotide primers 
were purchased from Operon Technologies Inc, Alameda, USA / MWG-biotech, Milton 
Keynes UK, and were supplied Iyophilized with the molar yield stated. Primers were diluted 
in dH20to 20[tM concentrations. Melting temperatures of the oligonucleotides had been 
calculated using the following formula, which takes into account the G and C content of the 
pnmer: 
Tm = 4(G+C) 2(A+T) 
However, most primers were initially assayed between 52' and 66'C to assess their optimal 
annealing temperature. 
Polymerase chain reaction (PCR) 
Polymerase chain reactions (PCR) were prepared under sterile conditions using sterile 
Gilson pipette tips to minimise DNA contamination. The 20 exons of the RET gene, and 
2 exons of GDNF were amplified in 3 Oýtl reactions containing DNA (25 -100 ng), 1 OMM 
Tris-HCI pH 8.3,50mM KCI, 1.5-2. OMM MgC'2,200ýM dNTPs and 0.06 ýd Red hot 
Taq polymerase (Advanced Biotechnologies Ltd., UK) with 0.006 ýM (3ý11 of 20MM) 
of each appropriate primer. PCR reactions were performed in a Hybaid Omnigene 
thermal-cycler (Hybaid Ltd., Ashford, UK). Thirty-five amplification cycles were 
performed with a preceding touchdown protocol (Appendix 6.04) in 96 well plates with 
foil heat-sealed covers. PCR primers and annealing temperatures are shown in appendix 
6.05. 
Agarose gel electrophoresis 
Amplified DNA was size fractionated by agarose gel electrophoresis to confirm the 
optimal annealing temperatures of oligonucleotides. Gels were prepared to a 
concentration of 1.5% by heat dissolving (microwave oven) 7.5g of agarose in 500ml of 
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x TBE. Molten agarose was premixed with ethidium bromide to a concentration of 
lmg/ml, and poured into midi-gel moulds (Scotlab, Coatbridge, LTK) with 20-well gel- 
slot-formers and left to set at room temperature. Prior to electrophoresis, 10vtl PCR 
products were combined with a one-tenth volume of loading buffer and loaded into 
well-slots submerged under running buffer (I x TBE). Electrophoresis was perfortned at 
90V for approximately I hour. Estimation of the size of fractionated DNA was achieved 
by similarly electrophoresing a lkb ladder (Advanced Biotechnologies Ltd., UK). 
Ethidium bromide stained gels were viewed under ultra violet trans-illumination. 
6.3.3.3 SSCP/HA methods 
DNA preparation 
Reaction products (5ýLl) were diluted 1: 1 with a denaturing buffer (formamide 95% with 
0.025% xylene cyanol and 0.025% bromophenol blue), heated to 99'C for 10min and 
quenched on ice, prior to loading onto 0.8% MDE gels (see below). 
Gelpreparation and electrophoresis 
The SSCP gel matrix used was MDE (Mutation Detection Enhancement matrix), an 
acrylamide substitute, and was run at 2 gel conditions: with and without 10% glycerol. 
The composition of each of these gels is shown in appendix 6.06. Gets were poured 
between glass plates measuring 20cm x 20 cm xI mm with 25-well gel-slot-formers. 
Electrophoresis was performed using a Bio-Rad Protean 11 gel system (Bio-Rad 
Laboratories, CA, USA) and 4 gels could be run per apparatus. This allowed a total of 
96 samples to be analysed with 4 ladders per apparatus. Gels were ran at 200 / 400V for 
12-18 hours at IOOC and stained with silver nitrate (Appendix 6.07) (Gayther et al., 
1995). 
6.3.3.4 Direct DNA sequencing 
Samples 
Samples that showed a variant by SSCP and / or heteroduplex analysis at one or more 
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condition were sequenced to characterise the nucleotide change. In addition, 10 patients 
with HSCR, MEN type 2A or Familial Medullary Thyroid Cancer in which mutations 
of exons 10 or II of RET had previously been identified were used as controls. In 10 of 
the 20 cases (including all HSCR / STC families) and all controls, the entire RET 
(except for exon 1) and GDNF coding sequences including intron-exon boundaries were 
sequenced in entirety. It was not possible to amplify exon I consistently, so as a result 
this exon was not screened for mutations, however all sites of mutations (Figure 6.02) 
(Eng, 1997), and polymorphisms (Table 6.01) (Ceccherini et aL, 1995, Eng, 1997) that 
have been previously reported in HSCR were sequenced. [Sequencing of exon 1: six 
attempts were made, and included the use of additional published, and computer- 
designed primers. These difficulties, principally as a result of the high G-C content of 
this exon, are well recognised (Charis Eng, Harvard, personal correspondence)] 
Table 6.01 Sequence polymorphisms in the RET proto-oncogene 
Exon Codon Polymorphism Amino acid Published Observed 
No 
--------- 
No 
------------ ---------------------- 
alteration 
--------------------- 
frequency 
---------- - - 
frequency 
- 
2 45 GCG to GCA Ala 
- --- ----- 
0.29 
-- ----------- 
0.25 
3 125 GTC to GTA Val 0.02 0.0 
7 432 GCG to GCA Ala 0.71 0.56 
11 691 GGT to AGT Gly to Ser 0.21 0.17 
13 769 CTT to CTG Leu 0.26 0.27 
15 899 GTT to TTT Val 0.79 0.48 
17 975 AACtoAAT Asn NK 0.0 
18 982 CGCtoTGC Arg to Cys NK 0.0 
Methods 
In all cases, both strands were sequenced using the fluorescent dideoxy tenninator 
method, using the TAQ SS sequencing kit (Perkin-Elmer, Alameda, USA). Sequence 
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reactions were performed in 20ýLl reactions containing 8ýfl of supplied terminator ready 
mix, 4ýtl DNA (PCR product), 1.6ýtl of diluted (2ýM) oligonucleotide and 6.4[d HA 
and using a Hybaid thermal cycler (25 cycles of 96'C for 30 secs, 50'C for 15 secs and 
60"C for 4 mins). 
Sequencing reaction products were then rehydrated, precipitated and washed as per 
protocol (Appendix 6.08). 5ýtl of loading dye was added (Blue dextran / fonnamide 
(1: 5), and the samples denatured at 90'C for 2 mins, and placed on wet ice before 
loading 2ýtl of each sample into the gel. Polyacrylamide sequencing gels were poured 
between glass plates measuring 50cm x 30 cm x 0.5 mm with 36-well gel-slot-fonners. 
The steps in gel preparation are listed in appendix 6.09. 
Fluorometric sequences were analysed using the Applied Biosystems 373 automated 
DNA sequencer", according to the manufacturer's protocol (Perkin-Elmer, Alameda, 
USA). Additional primer sequences were used for sequencing for exons 2 and 4 of RET, 
and exon I of GDNF (Appendix 6.05). 
6.4 RESULTS 
6.4.1 SSCP1HA 
In patients, single strand mobility variants were seen on analysis of exons 2,13,15, and 
17 of RET under one or both gel conditions. Nine out of ten positive controls 
demonstrated a clear mobility shift of the single or double stranded DNA conformation 
for the mutant exon under both conditions (Figure 6.04 a). No variants in GDNF were 
detected. 
6.4.2 DIRECTDNA SEQUENCING 
Published sequence polymorphisms were demonstrated for exon 2 (GCG-GCA, Ala 45), 
exon 7 (GCG-GCA, Ala 432), exon II (GGT-AGT, Gly 69 1- Ser), exon 13, CTT-CTG, 
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Leu 769), and exon 15 (TCC-TCG, Ser 899), exon 17 (AAC-AAT, Asn 975). The rarer 
exon 3 and 18 polymorphisms were not found. The allelic frequencies and PIC 
(polymorphism information content) values of these polymorphisms did not differ 
sipificantly from previously reported frequencies (Ceccherini et aL, 1995) (Table 6.01). 
No published or new mutation was seen in any of the exons of RET or GDNF. The 
predisposing MEN-2A, FMTC or HSCR mutations (missense changes in one of 4 
highly conserved Cys residues in RET exon 10 at codons 609,611,618 or 620) were 
detected by sequence alterations in all 10 positive control subjects (Figure 6.04 b). 
6.5 DISCUSSION 
The study failed to demonstrate germline mutations or rare polymorphisms of RET or 
GDNF in any of the HSCR or ISTC cases studied. The validity of the methodology was 
demonstrated by the study of positive control samples (sensitivity of SSCP/HA and 
direct DNA sequencing: 90 / 100% respectively), and by detection of common 
polymorphic nucleotide changes with a comparable frequency to published data 
(Ceceherini et al., 1995). It can be concluded that in the subjects studied, mutations of 
GDNF or RET are not the cause of either the chronic idiopathic STC or HSCR 
phenotype. The finding of a normal frequency of common polymorphisms, and absence 
of rare sequence polymorphisms suggests that coding region variants of RET or GDNF 
were also unlikely to have caused these conditions by a modifier effect on other genetic 
loci. Although exon I was not successfully sequenced, no mutation has been previously 
reported in this exon in any of the conditions associated with RET. Germline mutations 
of kET or GDNF therefore appear to have no role in the aetiology of the patients with 
chronic idiopathic STC that were included in this study. However, because the relatives 
with HSCR in the families studied also had no mutations, we cannot comment on 
whether such mutations might have a role in the aetiology of STC in other faxnilies 
containing mutation-positive HSCR patients. In addition, in view of the relatively low 
number of subjects studied overall, we can only conclude that such mutations are 
unlikely to be a common cause of STC. 
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Figure 6.04 
ss 
(a) SSCP / Heteroduplex analysis of RET exon 
10 PCR products on 0.8% MDE gel: 2/4 
samples with known mutations in exon 10 
demonstrate clear mobility variance. 
(Key: M= mutant, N= normal, SS = single 
strand, DS = double strand) 
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(b) Direct DNA sequencing. The positive control sample shows a missense change 
in the highly conserved Cys residues in RET exon 10 at codon 618: (TGC to GGQ, 
Cys to Gly. KEY: M= mutant, N= norrnal 
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This study only screened 2 genes implicated in the pathogenesis of HSCR: the RET 
proto-oncogene and GDNF- It therefore remains possible that mutations might be 
present in other (unstudied) HSCR candidate genes. In particular, one of the cases 
screened in this study had HSCR associated with congenital sensorineural deafness. 
This case, whilst lacking other features of Shah-Waardenburg disease (pigmentary 
abnormalities), may implicate involvement of the gene encoding Endothelin-3 (Hofstra 
et al., 1996; Edery et al., 1996) or the transcription factor, SOXIO (Pingault et al., 
1998). Furthermore, since the time of this study, a mutation of the gene encoding the 
RET receptor ligand neurturin has been identified in conjunction with a RET mutation in 
one large kindred of HSCR (Doray et al., 1998). This is of special interest to the study 
of patients with STC, because subsequent, very recent work (Heukeroth et al., 1999) has 
shown that transgenic mice with a targeted deletion of the gene encoding this 
neurotrophin have an almost identical clinical and tissue phenotype to that of STC 
(Chapter 1). Such mice, which actually represent the first animal "aetiological model" of 
constipation also had parasympathetic deficits, whose possible importance in STC has 
similarly been discussed in chapter 1. 
The role of the other ligands, persephin (Milbrandt et al., 1998), and artemin (Baloh et 
al., 1998), as well as the family of RET coreceptors (GFR-al-4) (Thompson et al., 
1998) in enteric neurogenesis is not known, although GFR-(X I mutations were not found 
by the recent screening of a large panel of HSCR cases (Angrist et al., 1998). 
Alternatively, STC and other "adult" functional bowel diseases may arise as a result of 
alterations in the local tissue expression of GDNF / RET, or other neurotrophic factors 
and their receptor components. Many such factors, their receptors, and associated 
neuropoietic cytokines are known to have an important role in the pre-natal 
development of the ENS (Durbec et al.; 1996b, Gershon et al., 1997; Chalonizitis et al., 
1998), and have been shown to be expressed in post-natal gut (Hoehner et al., 1996; Bdr 
et al., 1997; Wartiovaara et al., 1998) where their role is not known. Future studies are 
required to address these hypotheses, and as such, enhance the understanding of 
ontogeny of lifelong motility disorders at genetic, molecular and cellular levels. 
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DETECTION OF AUTOANTIBODIES 
TO EXPRESSED NEURONAL 
CHANNELS IN SLOW TRANSIT 
CONSTIPATION 
7.1 INTRODUCTION 
7.11 GENERAL: CHANNELOPATHIES 
Disorders of ion channels (channelopathies) are increasingly being identified and 
represent a rapidly expanding area of neurology, with a diverse range of neurological 
diseases having been found to be thus caused (Rose, 1998 [review]). 
Ion channel dysfunction would be an attractive hypothesis for the causation of STC 
because: 
1. The motility of the gut is dependent on nerve-muscle interaction (1.4), and the 
function of nerves and muscle is clearly dependent on ion channel function. 
Studies of colonic contractile activity in STC suggest neuronal or myopathic 
dysfunction (1.5.1). Channel dysfunction could be consistent with either the 
relative paucity of specific morphological findings in STC, especially on routine 
histological examination (1.5.3), or with the low grade ganglionitis accompanied by 
intraepithelial lymphocytosis, which has been observed in one recent study 
(Lindberg et al., 1999). 
2. Channelopathies can result from inherited genetic mutations of genes encoding 
channel components (Browne et al., 1994; Ophoff et al., 1996) or from 
autoantibody-mediated channel effects (Lang & Vincent, 1996). For instance, 
congenital myokymia may result from mutation of genes encoding voltage-gated 
potassium channel (VGKC) components (Browne et al., 1995), and from 
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antibodies to VGKCs in the acquired form (Shilito et al., 1995; Hart et al., 1997). 
The different mode and time of onset of STC within defined clinical sub-groups 
(Chapter 3) is consistent with the concept of distinct actiological strategies, 
convergent on a singular clinical phenotype. In particular, a major sub-group of 
patients with STC present in later life, some of whom have no obvious trigger for 
their complaint (Waldron et al., 1988). 
7.1.2 A UTOIMMUNE CHANNELOPA THIES 
Antibody-mediated autoimmunity underlies a diverse range of disorders, particularly 
in the nervous system where the extracellular domains of ion channels and receptors 
are especially vulnerable targets. Autoimmunity to ion channels can occur as a 
paraneoplastic effect or in the absence of neoplasia. Antibodies have been 
demonstrated to ion channels in several nervous system disorders (Table 7.01) 
The following indirect evidence exists for an autoimmune aetiology in conditions of 
gut dysmotility: 
1. Visceral involvement occurs in a proportion of patients with known autoimmune 
diseases e. g. connective tissue disorders (Sjogren, 1994), and can occur in the 
absence of other manifestations e. g. sclerodenna (Rodnan & Fennell, 1961; 
Nojima et al., 1996). In such patients with predominantly gut involvement, serum 
antibodies have been demonstrated to neurone-specific RNA/DNA-binding 
proteins (Nojima et al., 1996), and antibodies to myenteric neurofilaments (Howe 
et al., 1997) have been shown to cause alterations of intestinal myoelectric activity 
on murine passive transfer experiments (Eaker et al., 1999). Slow colonic transit 
is an accepted finding in some patients with scleroderma (Basilisco et al., 1993). 
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Table: 7.01: Main autoimmune channelopathies 
Clinical condition Autoantibody References 
----------------------------------------------------------------------------------------------------------------------- 
The Lambert-Eaton anti-voltage-gated calcium Lang et al., 198 1; Prior et al., 
inyasthenic syndrome channel antibodies (anti-VGCC) 1985; Roberts et al., 1985; 
(LEMS) 
(Lambert et al., 1956) 
Neuromyotonia 
(Isaacs' syndrome) 
(Isaacs, 1961) 
Myasthenia gravis (MG) 
Subacute idiopathic or 
secondary autonomic 
neuropathy 
(Suarez et al., 1994) 
anti-voltage-gated potassium 
channel antibodies 
(anti-VGKC) 
muscle acetylcholine receptor, 
ion channel receptor antibodies 
(Anti-AChR: aI subunit) 
Lennon et al., 1995; Meriney 
et al., 1996 
Sinha et al., 199 1; 
Newsom- Davis and Mills, 
1993; Shilito et al., 1995; 
Hart et aL, 1997 
Vincent & Newsom- 
Davis, 1985; Vincent, 1994 
ganglionic acetylcholine receptor Vernino et al., 1998 
ion channel receptor antibodies 
(Anti-AChR: 0 subunit) 
2. Antibodies directed to non-channel neuronal antigens have been described in 
paraneoplastic disorders of the ENS (Lennon et al., 1991 a, Condom et al., 1993). 
Intestinal pseudo-obstruction has long been recognised as a paraneoplastic 
accompaniment of small cell carcinoma of the lung (SCLQ (Lhen-nitte et al., 
1980, Schuffler at al, 1983), but the association of antibodies with 
pseudoobstruction (Lennon et al., 1991a), and a broader spectrum of dysmotility 
disorders (Lennon et al., 1991b) was recognised for the first time in 1991. The 
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finding of antineuronal nuclear antibodies (ANNA-1 also known as "anti-Hu") 
and pseudo -obstruction was confirmed in 1993 (Condom et al., 1993). Severe gut 
dysmotility is in fact the presenting complaint of 12% of patients with SCLC 
paraneoplasia, and can focally affect any level of the gut (Lucchinetti et al., 1998). 
Anti-neuronal antibodies have also been detected in association with other 
neoplasms (S chobinger- Clement et al., 1999; Gerl et al., 1992) and in small 
numbers of patients with severe Rut dysmotility without neoplasia (Smith et al., 
1997). 
3. Autonomic symptoms are found in some patients with LEMS (Rubenstein et al., 
1979), and anti-VGCC autoantibodies have been reported in patients with 
autonomic dysfunction and LEMS (O'Suilleabhain et al., 1998). Experimentally, 
LEMS sera can impair Ca2+ channel-dependent components of mouse 
postganglionic sympathetic neurotransmission (Waterman et al., 1997). Recently, 
antibodies to the neuronal nicotinic acetylcholine (ACh) receptor (AM), which 
is structurally related to the motor endplate AChR affected in MG (Lindstrom, 
1996), have been described in patients with idiopathic subacute autonomic 
neuropathy i. e. without neoplasia (Vemino et al., 1998), and gastrointestinal 
dysmotility was a prominent and initial symptom in approximately one third of 
patients (Vernino, et al., 1998). Gastrointestinal symptoms, including severe 
constipation occur in approximately 75% of patients with idiopathic autonomic 
neuropathy (Suarez et al., 1994), and conversely, autonomic abnormalities have 
been reported in STC and other conditions of severe gut dysmotility in previous 
studies (Camilleri & Fealey, 1990; Altomare et al., 1992; Camilleri et al., 1993; 
Bharucha et al., 1993; Raethjen et al., 1997), and this thesis (Chapter 5). 
7.1.3 BA CKGR 0 UND TO ME THODS 
A full discussion of the topological and recently elucidated crystallographic structure 
(Doyle et al., 1998) of ion channels and channel-neurotoxin interactions is beyond the 
scope of this thesis. It is sufficient to write that there is vast, and ever increasing 
spectrum of different channels which have different ion conductances, are gated by 
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different mechanisms, are found in different tissues, and which subserve different 
fanctions. Such pharmacological and functional diversity has a molecular basis; 
channel structure being dependent on the assembly of several protein sub-units which 
themselves are individually expressed by families of genes (Pongs, 1993; Wang et al., 
1993; Rettig et al., 1994; Lindstrom, 1996). 
Over the past 30 years, a number of specific neurotoxins from a variety of vertebrate 
and invertebrate species have been discovered and structurally characterised. In 
accord with their own amino acid sequence (Gasparini et al., 1998), such toxins have 
differential affinities to channel types and subtypes. These toxins have been an 
invaluable tool in the pharmacological classification of ion channels (Llinas et al., 
1989; Moczydlowski et al., 1988; Castle et al., 1989). In autoimmune neurological 
disease, the detection of circulating antibodies has largely depended on the 
availability of such target-specific neurotoxins e. g. 0-bungarotoxin in MG (Vincent & 
Newsom-Davis, 1985), which are used in immunoprecipitation assays. The principle 
of immunoprecipitation assays is shown in figure 7.01. 
7.1.4 AIMS 
In this study we used previously validated immunoprecipitation assays to: 
1. Detect antibodies to neuronal Shaker-related voltage-gated potassium channels 
(VGKCs) using radio-labelled cc-dendrotoxin, a neurotoxin from the elapid 
(eastern green mamba) snake (Dolly et al., 1984; Castle et al., 1989; Hart et al., 
1997). 
2. Detect antibodies to voltage-gated calcium channels (VGCCs) using radio- 
labelled co-conotoxins (MVIIC & GVIA), neurotoxins from the cone snail (LIinas 
et al., 1989), which bind to P/Q-type and N-type VGCCs respectively (Lennon et 
al., 1995; Motomura et al., 1995; Motomura et al., 1997). 
3. Detect antibodies to muscle-specific AChR ion channel al. subunits using the 
well-characterised toxin derived from the Taiwan banded krait snake, a- 
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bungarotoxin. This assay has been in use for more than 20 years and is similar to 
that originally described by Lindstrom et al. (Lindstrom et al., 1976; Vincent & 
Newsom-Davis, 1985). 
immunoprecipitation assay (1) 
toxin 
added serum added (VGCC 
WN110- VGCC toxin 
=00- 
( 
VGCC 
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ifuge 
antibodies precipitated but 
no bound toxin 
(b) immunoprecipitation assay (2) 
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VGCC MM'100"' 
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Fig 7.01: The diagrams show schematically the principle behind radio- 
immunoprecipitation assays. Radiolabelled toxin bound to extracted channel 
preparation is precipitated by anti-human IgG in the presence of antibody (b), but 
remains in solution when autoantibodies are absent (a). 
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Additional samples of sera were sent to C. Gotti, CNR Cellular and Molecular 
Pharmacology Center, Dept. of Pharmacology, University of Milan, Italy for 
immunoprecipitation assays to detect autoantibodies to specific neuronal subunits of 
AChR ion channels using either a-bungarotoxin (for 0 subunits) (Orr-Urtrreger et 
al., 1997; Balestra et al., 2000), or the toxin derived from the Equadorian poison frog, 
epibatidine (for 0 subunits) (Vernino et al., 1998; Balestra et al., 2000). 
7.2 MATERIALS AND METHODS 
7.2.1 CLINICAL MATERIAL 
Forty-two STC patients were tested, all female, aged 25-62, median 40 years. STC 
was defined and physiologically characterised as described in chapter 2. Three sub- 
groups were selected for study according to clinical sub-classification (Chapter 3). A 
deliberate emphasis was placed on including those patients with adult-onset idiopathic 
STC (AOIST). 
Findings were compared with positive and negative control groups, and 2 other 
conditions of severe gut dysmotility: intestinal pseudo-obstruction (IP) (Christensen, 
1990; Di Lorenzo, 1999), and idiopathic megacolon (IMC) (Gattuso & Kamm, 1997). 
The selection of positive control sera was dependent on the particular assay. Patients 
and control data are shown in Table 7.02. 
In addition, to "baseline" information recorded for STC patients (Chapter 2), all 
patients participating in this study were questioned in detail with respect to a personal 
or family history, or symptoms suggestive of autoimmune, neurological or neoplastic 
disease. These data and the main demographic data for test-groups are shown in 
appendix 7.01. No STC patient had MG or thymoma, lung carcinoma, SCLC or 
haemoptysis, or clinical evidence of myokymia or pseudomyotonia. 
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Table 7.02: Patients included in immunoprecipitation studies 
Study group Description N 
Chronic idiopathic STC (CIST) de-novo before the age of 20 years 22 
(< 5 years, n 4; < 10 years, n= 15; 
> 10 years, n 4) 
Post pelvic intervention STC (PIST) temporally related to childbirth (n = 5) 10 
or pelvic surgery (n = 5) 
Adult-onset idiopathic STC (AOIST) onset de-novo after the age of 20 years 10 
Total STC 42 
Healthy subjects negative controls 6 
Neuromyotonia positive controls: KGKC assay 8 
LEMS positive controls: KGCC assay 4 
MG positive controls: AChR-cc I subunit assay 6 
Intestinal pseudo-obstruction (comparison group) 10 
Idiopathic megacolon (comparison group) 4 
------------------------------------------------------------------------------------------------------------------------ 
Total (all included) VGCC assays 66 
VGKC assay 70 
AChR-al subunit assay 68 
7.22 ANTI-CHANNELANTIBODYIMMUNOPRECIPITATIONASSAYS 
Twenty millilitres of venous whole blood was taken by antecubital fossa 
venepuncture and centrifuged for 10 min at 3,500rpm. Serum was removed and stored 
at -70'C in Eppendorf aliquots (=- 4ml / patient) until use. Assay reagents and buffers 
are listed in appendices 7.02 and 7.03 respectively. 
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All assays were performed independently by 2 or more study participants who were 
blinded to the underlying clinical diagnosis by numerical coding of the sera. Positive 
sera were re-tested a farther 1-2 times (i. e. 3-4 times in total). 
7.2.2.1 Preparation of channel extracts 
Preparation of voltage-gated channel extracts (VGCs) 
Rabbit brain was used for the preparation of VGKC and VGCC channels (see 
appendix 7.04 for methods). [Results have previously been shown to be comparable 
using human and rabbit cerebellar extracts as an antigenic source for potassium 
(unpublished data), and calcium channels (Motomura et al., 1997)] For use in the 
assay, the membrane preparation was diluted 1: 5 in 2% digitonin solubilisation buffer, 
incubated and centrifuged. The supernatants were removed, and used as the source of 
VGCs in the assay (see appendix 7.05). 
AChR al subunit channel extracts 
Previous studies required muscle membranes for the preparation of AChRs, using 
muscle obtained fresh from human amputated limbs. AChRs can now produced by 
recombinant techniques, and were purchased from RSR Ltd., Cardiff, UK. Receptor 
extracts generated from 2 commercial in-vitro cell lines were mixed in equal volumes 
and diluted in bovine serum (additive) before toxin labelling and subsequent use in 
the assay. 
7.2.2.2. Immunoprecipitation assays 
Detailed methods are shown in the appendices: 
1. Sera were tested for antibodies to rabbit brain P/Q and N-type VGCCs using 
immunoprecipitation of VGCCs extracted from rabbit cerebellum and labelled 
with 1251_labelled- co -conotoxin MVIIC 
(1 251_(o 
-CmTx) or 
125 I-labelled-co-conotoxin 
GVIA (1251_0)-CgTx) (Appendix 7.06). 
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Sera were tested for antibodies to rabbit brain VGKCs using immunoprecipitation 
of VGKCs extracted from rabbit cerebellum and labelled with 1251_labelled-a- 
dendrotoxin (1251_ot-DnTx) (Appendix 7.07). 
3. Sera were tested for antibodies to muscle ACh receptors using 
immunoprecipitation of human recombinant AChRs labelled with 125 I-alpha- 
bungarotoxin (1251_0-BuTx) (Appendix 7.08). 
In brief, defrosted aliquots of extract were labelled with a saturating (5fMol) 
concentration of radiolabelled toxin and incubated with diluted sera overnight at 4'C. 
Excess sheep anti-human IgG serum was then added to precipitate serum antibodies 
and incubated for I hour at 4'C. The precipitates were pelleted, washed and counted. 
Results were expressed as picomoles of labelled toxin binding sites precipitated per 
litre of serum after subtraction of non-specific binding (calculated from control mean) 
(Appendix 7.09 for calculations). 
7.2.3 NEUROPHYSIOLOGICAL ASSESSMENT 
Patients with anti-VGKC antibodies, detected by immunoprecipitation underwent 
detailed neurophysiological assessment to exclude neuromyotonia. All studies were 
performed by a consultant neurophysiologist (Dr David Ingram, Department of 
Neurophysiology, St Bartholomew's Hospital, London). 
7.24 STATISTICS 
Agreements between repeated assays were expressed as the mean and 95% CI of the 
differences, with the Wilcoxon signed rank test used to test the effectiveness of 
pairing. (proportional agreements by log transformation of data were also calculated). 
The final result was calculated as the mean of the results from the 2 independently 
performed assays (3-4 assays for positive results). Antibody titres were considered 
positive if more than the mean plus 3 S. D. for the control sera. For groups, data were 
expressed as medians with ranges. Contingencies for the distribution of positive sera 
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to multiple groups were calculated using the chi-square test. 
7.3 RESULTS 
7.3.1 ANTI-CHANNELANTIBODYIMMUNOPRECIPITATIONASSAYS 
Voltage-gated calcium channels (VGCCs) 
Assays performed twice independently showed reasonable agreement between results: 
P/Q-type: mean difference between assays = -26 pM (95% CI -9 to - 60) 
(proportional agreement 41-52%), p=0.0003, N-type: mean difference between 
assays =+ 15 pM (95% CI +9 to + 50) (proportional agreement 123-157%), p= 
0.001. All positive and negative control sera were positive or negative respectively in 
both assays. All positive controls (LEMS) had strongly positive sera in the P/Q-type 
VGCC assay, and 50% were also positive in the N-type VGCC assay. In the VGCC 
P/Q-type assay, 4/ 10 patients with IP showed some precipitation of the complex 
(whole group median = 31, range -60 to 142pM). Although these fell outside the 
mean +3S. D. of the control sera (> 60 pM of o)-CmTx binding sites), they were not 
of an order of magnitude which was comparable to the LEMS positive control sera 
(median 866, range 267 - 967pM) (Figure 7.03a). No STC or IMC patient had a 
positive serum in this assay, and the contingency of such a distribution of 4 positives 
to this one group was highly significant (p< 0.0001, chi-square test). In the N-type 
assay, one patient with STC showed a consistently strong precipitation of the labelled 
complex in a range comparable to LEMS positive controls (whole STC group: median 
7, range -58 to 325pM). [LEMS median: 120, range -30 to 475pM; negative control 
mean: 0, range -9 to 31; mean plus 3 S. D. = 60pM] (Figure 7.03b). This patient is 
discussed below ('patient V). A further 3 STC patients had borderline results. 
Voltage-gated potassium channels (VGKCs) 
The 2 assays performed independently showed very high agreement of results: mean 
difference between assays + 16 pM (95% CI +6 to + 38), (proportional agreement 
106 - 13 8%), p<0.000 1- 
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Fig 7.02: Correlations between independently repeated assays. (a) VGCC: P/Q- 
type, (b) VGCC: N-type, and (c) VGKC (see text). Effectiveness of pairing is 
shown by p-values (Wilcoxon test). 
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Fig 7.03: Scatter plots of results from anti-VGCC immunoprecipitation assays: anti- 
VGCC P/Q-type (a), and anti-VGCC N-type (b). Four IP sera are weakly positive for 
anti-P/Q-type antibodies (arrowed); the contingency of the distribution of these 4 
positives to this single test group was highly significant, and unlikely to have occurred 
as a result of chance alone (p < 0,0001). A single STC sera is strongly positive sera 
for anti-N-type antibodies (arrowed). KEY: HC = healthy controls, LEMS = 
Lambert-Eaton myasthenic syndrome, STC = slow transit constipation, IP = intestinal 
pseudo-obstruction, IMC = idiopathic megacolon. 
Two of the 42 sera from patients with STC showed precipitation of the labelled 
complex (Figure 7.04a) that was greater than the mean plus 3 S. D. for control sera (> 
110 pmol of cc-DnTx binding sites / litre of serum) (whole STC group: median -7, 
range -45 to 645). These 2 patients both fell in the AOIST sub-group of STC and are 
described in detail below ('patients 2 and Y). The contingency of distribution of these 
2 patients to this one smaller sub-group alone was significant i. e. unlikely to be the 
result of chance alone (p < 0.04, chi-square test) (Figure 7.04b). 
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Fig 7.04: Scatter plots of results from anti-VGKC immunoprecipitation assay: (a) all 
groups studied, and (b) STC by sub-group vs. healthy controls only. Two patients 
with STC have clearly positive sera with titres comparable to sera from the positive 
control neuromyotonia patients (NMT). Both these patients had symptoms which 
arose de-novo in adulthood i. e. adult-onset idiopathic STC (AOIST). KEY: CIST - 
chronic idiopathic STC, PIST = STC arising following pelvic surgery or childbirth. 
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Six of the 8 patients with NMT, included as positive controls, had positive sera 
(whole group: median 283, range 74 to 415pM), but none of the 6 healthy controls 
(whole group: median -17, range -30 to 49pM), 10 patients with IP (whole group: 
median -12, range -46 to 37pM), or 4 patients with idiopathic megacolon (range -12 
to 48pM). The results for both positive and negative controls were comparable with 
those from a previously published series (Hart et al., 1997). 
Muscle acetylcholine receptor: alpha-I subunit 
No values for labelled channel binding were noted that differed from the non-nal 
range, regardless of group (Mean 0±0.3, range -4 to 4 pM) [positive sera =- 500- 
1 OOOPM]. 
Neuronal acetylcholine receptor: alpha-3 and alpha- 7 subunits 
Provisional results awaited from Italy indicate no STC positives. One positive sera 
from an IP patient requires further confirmation. 
7.3.2 PA TIENT CASE REPORTS 
Patient 1. A31 -year-old woman with no significant medical or surgical history 
presented in 1998 with a7 year history of severe defaccatory symptoms: infrequent 
passage of hard stool (bowels open every 2-3 weeks), and straining with unsuccessful 
or incomplete evacuation. She complained of some bloating and occasional 
abdominal pain, and was dependent on oral laxative ingestion. Her problems started 
after the birth of her 3 rd child by normal (uncomplicated) vaginal delivery. Isotope 
scintigraphy demonstrated a left-sided pattern of delay. 
She had reduced external anal sphincteric function, raised thresholds to rectal balloon 
distension, and was able to evacuate only 50% of the contrast at defaecography 
because of a functioning large rectocele / small anterior intussusception. Upper 
gastrointestinal motility studies demonstrated minor abnormalities of oesophageal. and 
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small bowel motility, but normal scintigraphic gastric emptying. A left 
hemicolectomy was performed in 1999 with adequate surgical outcome (bowels open 
1-3 times per day with symptomatic improvement). Routine histology demonstrated 
melanosis coli, but no other abnormality. Immunostaining with a variety of antibodies 
to cytoskeletal, neural, and other cellular proteins failed to demonstrate myopathic or 
neuropathic abnormalities. 
Patient 2. A 34-year-old woman with no significant medical or surgical history 
presented in 1996 with a6 year history of severe defaecatory symptoms: infrequent 
passage of hard pellet stool (bowels open every 2-3 weeks), and straining with 
unsuccessful, painful and incomplete evacuation. In addition she complained of 
bloating, abdominal pain and occasional nausea. Prior to this time she opened her 
bowels without straining every day. She had tried a variety of laxatives, and enemata 
and suppositories without sustained success. She had 2 children by normal vaginal 
delivery, and no gynaecological history. She denied any precipitating or temporally 
associated events with the onset of symptoms. Transit studies, including isotope 
scintigraphy confirmed generalised STC. She had normal sphincteric function, normal 
defaecography with no proctographic abnormality, but had raised thresholds to rectal 
balloon distension. Upper gastrointestinal motility studies were not performed. A total 
colectomy with ileorectal anastomosis was perforined in 1997 with poor surgical 
outcome (bowels open 2-3 times per day, but continued severe abdominal pain, 
bloating and nausea and vomiting). Routine histology, and immunostaining with a 
variety of antibodies to cytoskeletal, neural, and other cellular proteins failed to 
demonstrate myopathic or neuropathic abnormalities. Subsequent chest radiograph 
and upper and lower GI endoscopy were normal. 
Patient 3A 62-year-old woman with no significant medical or surgical history 
presented in 1998 with aI year history of defaecatory symptoms: infrequent passage 
of hard stool (bowels open every 2-3 days with laxatives), and straining with 
unsuccessful, painful and incomplete evacuation. In addition she complained of some 
bloating and abdominal pain. Prior to this time she opened her bowels without 
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straining or laxatives daily. She was dependent on a variety of laxatives, and enemata 
/ suppositories. She had 2 children by vaginal delivery, one requiring forceps 
assistance, but no gynaecological history. She denied any precipitating or temporally 
associated events with the onset of symptoms. Transit studies, including isotope 
scintigraphy confirmed generalised STC. She had normal sphincteric function but had 
markedly raised thresholds to rectal balloon distension and was able to evacuate only 
50% of the contrast at defaccography because of verbally-reported loss of urge. Upper 
gastrointestinal motility studies, demonstrated abnormal oesophageal and small bowel 
manometry, but normal gastric emptying. She has been managed medically (without 
surgery) to date, and has been referred for biofeedback. 
All 3 patients had a normal barium enema, and blood tests had excluded endocrine or 
metabolic disease. No patient had urinary or neurological symptoms, or a personal or 
family history of neurological, autoimmune or neoplastic disease. All patients were 
non-smokers. Clinical examination and neurophysiological tests, including nerve 
conduction studies and electromyography (EMG) were normal in both patients with 
anti-VGKC antibodies, excluding neuromyotonia. 
7.4 DISCUSSION 
Summary of results 
The study shows 3 of 42 patients with STC who have high serum levels of either anti- 
46 native" VGKC or N-type VGCC antibodies. The 2 patients with anti-VGKC 
antibodies were both from the smaller adult-onset idiopathic clinical sub-group, i. e. 
patients whose symptoms arose de-novo in adulthood, without a temporally related 
pelvic event, or other precipitating factor (Waldron et al., 1988). The single patient 
with anti-VGCC was from the larger post-pelvic intervention sub-group, having 
symptoms which arose following normal childbirth. In addition, 4 patients with 
intestinal pseudo-obstruction (IP) had low levels of anti-P/Q-type VGCC 
autoantibodies. All these findings were reproducible in blinded independent assays. 
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Significance and interpretations 
There are several possible interpretations of these results. Firstly, the observed high 
titres of antibodies might be a false finding reflecting a methodological error. This 
seems unlikely given the blinded repeatability of the results, and the consistent 
positive and negative control values which were comparable with published series, 
and historical data from the laboratory. 
Secondly, antibodies whilst present may be of no pathogenic potential. In general, a 
much higher frequency of positive sera, such as that observed for anti-P/Q-VGCC in 
LEMS i. e. 90% (Lennon et al., 1995) is considered to indicate a high probability of 
disease causation. The low frequency of patients with anti-channel autoantibodies in 
this study would therefore not generally support a pathogenic role in these syndromes. 
The possibility of finding non-pathogenic autoantibodies has been previously 
suggested with respect to VGCCs (Lennon, 1994). It is possible that intracytoplasmic 
components of ion channels which are normally inaccessible to antibodies might be 
rendered accessible in vitro by solubilisation, but not be candidates for antigenicity in 
vivo. If this were the case, we might however expect to find a proportion of all patient 
groups, including negative controls with similar positive results. 
The serum levels of anti-VGKC autoantibodies in the 2 positive STC patients were 
comparable with those in acquired neuromyotonia (NMT) (Shilito et al., 1995; Hart et 
al., 1997), a condition of the peripheral nervous system characterised by 
hyperexcitability of motor nerves that results in continuous muscle fibre activity 
(myokymia), muscle cramps and weakness (Isaacs, 196 1). Antibodies to VGKCs have 
been detected in over 50% of cases, using immunoprecipitation of VGKCs extracted 
fTom the human brain, and labelled, as in this study with 1251_a-dendrotoxin (Shilito et 
al., 1995; Hart et al., 1997). In these assays, no healthy control had a comparable 
positive result. It is also of interest that both positive patients were from the same, 
smaller AOIST sub-group with a very similar gastrointestinal physiological 
phenotype (rectal hyposensation, upper GI problems / dysmotility), and that positives 
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were not observed in other STC patient sub-groups. It has been noted that such a 
distribution would be unlikely to occur by chance alone. 
The single VGCC N-type positive serum had a titre of over 200pM, a level 
comparable only with LEMS patients in a previous large study (Lennon et al., 1995). 
In this seminal work, 47 healthy controls all had serum levels of antibody <20pM 
(Lennon et al., 1995), only I/ 28 scleroderma patients had a positive serum at a level 
of only 45pM, and 90 patients with SCLC without paraneoplasia had approximately 
20% positivity, but only at a median level of 67pM. Such a high level of antibody has 
therefore only been reported in disease states where it has been assumed that such 
antibodies are of pathogenic significance. Low positive titres of anti-P/Q-type VGCC 
antibodies (e. g. approx. IOOpM), similar to those observed in the 4/ 10 IP patients in 
this study, have been demonstrated in patients with a variety of other paraneoplastic 
syndromes. For instance, levels were comparable with 70 patients with paraneoplastic 
encephalomyeloneuropathies in a study where only a single healthy control had a 
positive serum of 59pM (Lennon et al., 1995). These autoantibody levels, whilst 
lower than LEMS serum levels, might therefore still be of significance. The 
distribution of all 4 positives to this group would be extremely unlikely by chance 
alone. 
Finally, pathogenic antibodies whilst present, might be secondary to as yet 
undiagnosed neoplasia. On the basis of the ages, general medical health, non-smoking 
status, and relatively long follow-up of the patients in this study, this hypothesis 
seems unlikely. 
If antibodies to ion channels detected in this study are a real finding of pathogenic 
significance, how might they lead to the observed phenotypes (STC and IP)? With 
respect to the VGKC autoantibodies, it is of interest that neither STC patient had CNS 
or PNS symptoms or signs, even on detailed testing. Similarly, gastrointestinal 
syniptoms are not a recognised feature of neuromyotonia. VGKCs are the most 
heterogeneous of the family of voltage-gated cation channels (Pongs, 1993). At least 
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six shaker-related VGKC (x-subunits have been isolated from human brain, each 
encoded by a different gene (Pongs, 1993). A functional VGKC consists of 4 
transmembrane u-subunits that combine as homomultimeric or heteromultimeric 
tetramers (Wang et al., 1993) to interact with intracellular B-subunits, which are 
thought to form a tetramer (Rettig et al., 1994). Different toxins from a variety of 
species block particular types of Ký channel (Castle et al., 1989). oc-dendrotoxin has a 
selective action on VGKCs, but like other toxins can bind a number of subtypes of 
VGKC. It is therefore possible that the antibodies demonstrated in STC and 
neuromyotonia have different VGKC subtype binding properties and therefore 
clinical effects, although the receptors themselves all bind to labelled (x-dendrotoxin. 
Mice injected with plasma or IgG from patients with neuromyotonia show increased 
quantal release of neurotransmitter at the neuromuscular junction, consistent with the 
idea that antibodies against VGKCs lead to increased nerve excitability and 
consequent prolongation of the action potential at the nerve terminal (Shilito et al., 
1995). Such excitability, was it to occur in the gut, might produce a reinforcement of 
colonic contractions but a decrease in "purposeful" propulsive activity leading to an 
overall decrease in transit. This would thus mimic the putative constipating 
physiological effects of opiates (Frantzides et al., 1992), which lead to STC (Kaufinan 
et al., 1988) (see 1.6.5). 
Approximately 30-50% of patients with LEMS have anti-N-type VGCC antibodies, 
compared to the majority who have anti-P/Q-type (Lennon et al., 1995). Although the 
majority of patients with paraneoplastic syndromes who have anti-N-type also have 
anti-P/Q-type antibodies, some patients have an isolated high-titre autoantibody to N- 
type VGCCs (Lennon et al., 1995). At one time, it was thought that N-type VGCCs 
might preferentially mediate postganglionic autonomic rather than somatic 
transmission (Herning et al., 1988). However, more recent correlative clinical 
evidence (O'Suilleabhain et al., 1998), and the results of experimental serum transfer 
experiments (Waterman et al., 1997) do not now support this hypothesis. The 
significance of the anti-N-type autoantibody in the single STC patient, like the role of 
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N-type channels in LEMS, remains unclear. Anti-P/Q VGCC autoantibodies are 
thought to be of greater significance in disruption of postganglionic autonomic 
transmission (Waterman et al., 1997), and such autoimmunity therefore remains a 
possible mechanism for the pathogenesis of the IP phenotype in the 4 patients with 
positive sera. It has been noted that autonomic deficits are a common finding in such 
patients (Camilleri & Fealey, 1990; Bharucha et al., 1993; Camilleri et al., 1993). 
The origin of antibodies, in the absence of neoplasia, in the patients described has not 
been addressed by this study. Antibodies to antigens in SCLC and other 
paraneoplastic syndromes are thought to be due to an immune reaction to abherrantly 
expressed proteins on the malignant cell surface (Dalmau et al., 1995). However, only 
about 20% of cases of NMT have an associated SCLC or thymoma, and the majority 
(80%) of cases occur without evidence of neoplasia (Newsom-Davis & Mills, 1993). 
Similarly, approximately 40% of LEMS have no detectable neoplasm (O'Neill et al., 
1988). There is now a considerable body of experimental work suggesting that 
inimunomodulation of enteric neuromuscular function, possibly as a consequence of 
clinical or subclinical enteric infection, may have an aetiological role in intestinal 
dysmotility (see review: Collins, 1996). Similarly, there is human epidemiological 
evidence that cases of adult-onset dysmotility (especially IBS) can follow enteric 
infection (Lindberg et al., 1999). Recent histological studies suggest that 
inflammation affecting the myenteric plexus, although generally less marked than in 
established cases of autoantibody-mediated plexitis (Smith et al., 1997), may be 
present in these patients (Lindberg et al., 1999). Chagas' disease is an example of an 
infection leading to a humoral autoimmune response directed against enteric neurones 
which results in functional intestinal obstruction (Goin et al., 1999). As for viruses 
(Debinski et al., 1997), further evidence for infectious agents in the aetiopatho genesis 
of severe idiopathic human dysmotility should continue to be sought. 
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Conclusions 
Whatever the origin, this study suggests that anti-channel antibodies may have a role 
in some acquired gastrointestinal motility disorders. Whilst this study has 
demonstrated the presence of antibodies to VGCs, it has not proved their causal 
association with STC. The epitopes recognised by the antibodies require 
characterisation, and the distribution of target epitopes in the gut require 
demonstration. Passive serum transfer experimentation in a murine model could 
attempt to reproduce of the STC or IP phenotype. If acquired cases do indeed have an 
autoimmune channel-related aetiology, it will be of considerable interest to perform 
molecular genetic studies to test whether early-onset cases have a developmental, 
possibly congenital abnonnality of channel protein morphology. 
Many gastroenterologists typically associate ion channels with the generation and 
propagation of action potentials in cardiac myocytes or in neurones of the central and 
peripheral nervous systems, but it is important to note that such channels play an 
equally critical role in the functional biology of the gastrointestinal tract. Within the 
near future, channel blockers will be likely to be introduced as treatments for a variety 
of gut disorders (Lencer & Alper, 1999), including gastric and intestinal motility 
disorders (Hong et al., 1997), and it is expected that their role in disease causation, 
like that of the PNS and CNS channelopathies will soon be elucidated. 
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SMOOTH MUSCLE 
DEGENERATION WITH 
INCLUSION BODIES IN SLOW 
TRA NSI TC ONS TIPA TION 
8.1 INTRODUCTION 
Smooth muscle is the final effector of gastrointestinal motor activity, and loss of co- 
ordinated smooth muscular function may result in altered colonic motility. Recent 
advances have led to the recognition of some (albeit rare) underlying structural and 
morphological abnormalities of the smooth muscle of the gastrointestinal tract which 
may be primary or secondary. Primary myopathies are due to an innate abnormality in 
enteric muscle and can be congenital, or of early or late onset (see reviews by Smith 
& Milla, 1997; Martin et al., 1999) (Table 8.01). Secondary muscle disease can occur 
as part of a multisystem disease such as scleroderma, but can also complicate 
abdominal or pelvic radiotherapy. Unlike the secondary myopathies, the aetiology of 
most primary myopathies has not been elucidated, and the possibility that 
developmental morphogenic abnormalities could result from defective genetic control 
of the complex sequential events in gut development has been discussed in the 
introduction ý(1.6.1.2). 
Most reported primary and secondary myopathies are characterised by intestinal 
dilatation e. g. chronic idiopathic intestinal pseudoobstruction (CIIP), though some of 
these patients may present with constipation. Consistent myopathic findings have not 
been demonstrated by light microscopy in patients with STC (Park et al., 1995, 
Benson et al., 1992), and in-vitro physiological studies have had similarly conflicting 
results (Hoyle et al., 1992, Slater et al., 1997, Mitolo-Chieppa et al., 1999). 
Whilst one ultrastructural study has observed morphological changes in patients with 
STC (Benson et al., 1992), unlike cases of childhood pseudoobstruction, detailed 
ultrastructural. studies of smooth muscle have generally not been performed. 
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Table 8.01: Classification of enteric myopathies 
PRIMARY MYOPATHIES 
Congenital / Abnormal developmental (morphogenic) phenotypes 
Early-onset Focal absence of enteric muscle coats 
Segmental fusion of enteric muscle coats 
Presence of additional muscle coats 
Otherphenotypes 
Myopathy with autophagic activity 
Pink blush myopathy with nuclear crowding 
Contractile protein abnormality 
Myopathy with atrophy andfibrosis 
Late-onset Myopathies with atrophy andflibrosis 
Hollow visceral myopathies: sporadic and familial 
Degenerative leiomyopathy 
Autoimmune myopathy 
Inclusion body myopathies 
Polyglucosan body myopathy 
Mitochondrial Iciomyopathy 
SECONDARY MYOPATHIES 
Systemic disorders Desmin myopathy 
Muscular dystrophies 
Mitochondrial cytopathies 
Metabolic storage disorders 
Amyloidosis 
Progressive systemic sclerosis 
Other collagen vascular disorders 
Local disorders Obstructive / post-irradiation muscle failure 
[Modified with permission from Martin et al., 1999] 
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Morphological changes seen in intestinal myopathies include varying degrees of 
fibrosis, hypertrophy or atrophy of muscle fibres, vacuolation of myocytes (Schuffler 
et al., 1977, Martin et al., 1990, Smith & Milla, 1997), alteration in the 
immunohistochernical staining pattern of myocyte contractile proteins (Smith et al., 
1992), abnormal layering of the muscle (Smith & Milla, 1997), and the presence of 
intracellular inclusion bodies (Martin et al., 1990). 
Inclusion body myopathies 
In intestinal smooth muscle cells, inclusion bodies have been described in a variety of 
disorders including viral infection, adult polysaccharidosis (Peress et al., 1979), 
Lafora's disease (Harriman & Millar, 1955, Gambetti et al., 1971), and desmin 
myopathy (Ariza et al., 1995). Many of these disorders are systemic and the 
consequences of gut smooth muscle dysfunction are usually less clinically significant 
than failure of other involved organs. Specific to the gastrointestinal tract, a familial 
myopathy affecting the smooth muscle of the internal anal sphincter has been reported 
in a number of women who presented with proctalgia fugax, and hypertrophy of the 
internal sphincter (Kamm et al., 1991; Martin et al., 1992). The characteristic 
pathological features of this disorder were evident on periodic acid-Schiff (PAS) 
staining, when ovoid inclusion bodies, 2-30 ýLm in length, were demonstrated. These 
inclusion bodies resisted diastase predigestion, and had a similar staining profile 
(Diezel, 1956), and ultrastructural appearance (Ramsey, 1965) to the polyglucosan 
structures of corpora amylacea, seen as a usual feature in the ageing brain. Structurally 
similar polyglucosan bodies have also been described in intestinal smooth muscle 
cells of aged dogs, without apparent associated muscle dysfunction (Kamiya et al., 
1983). These were clearly evident on light microscopy with PAS staining, were 5-20 
ýtm in diameter, and were variably stained with other methods. Ultrastructural study 
revealed a filamentous composition, which was identical to previously reported 
Lafora bodies found in the CNS (Harriman & Millar, 1955). Such inclusions 
increased in number with age, and were found throughout the intestinal tract, although 
predominantly in the ileum and large intestine. In the human gut polyglucosan 
inclusions have been noted in small numbers of patients with intestinal 
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pseudoobstruction (Venislos et al., 1988; Fogel et al., 1993). 
Eosinophilic inclusion bodies evident on conventional staining have been described in 
the intestinal tract of diabetics with severe autonomic neuropathy (Duchen et al., 
1980; Moscoso et al., 1986). We had previously demonstrated similar inclusion 
bodies in a small number of patients with STC (Martin et al., 1999). These may result 
from smooth muscle cell injury, occurring as a secondary phenomenon to other 
processes such as denervation or faecal stasis, or may reflect a new primary pathology 
which is specific to STC. 
The aim of this study was to further explore the hypothesis that STC may be 
associated with the finding of inclusion bodies in gastrointestinal tissue. By the use of 
selected control populations with blinded analysis, we aimed to clarify whether these 
inclusions were a specific unique finding to idiopathic STC, reflecting a primary 
myopathic aetiology, or were a secondary response of smooth muscle cells to either 
denervation or other factors such as faecal stasis or laxative use. 
8.2 MATERIALS AND METHODS 
8.21 PA TIENTS 
Patients and controls were placed into one of six defined groups for inclusion in the 
study (Table 8.02). 
8.2.1.1 Slow transit constipation sub-groups 
Patients were defined as having STC by criteria discussed in chapter 2. These patients 
were further subdivided on the basis of clinical classification into those with 
idiopathic STC (chronic idiopathic and adult onset idiopathic STC i. e. CIST + 
AOIST), and those with post pelvic intervention STC (PIST) (see chapter 3). Other 
groups, i. e. C/PIST and NIST were excluded on the basis of the small number of 
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tissues available. 
Table 8.02: Subjects included in study by group 
Group Reason for inclusion N Age: med. Sex 
("model') (range) FIM 
------------------------------------------------------------------------------------------------------- 
Idiopathic STC Test patients 25 42 (24 - 73) 25 /0 
Post pelvic injury STC Extrinsic pelvic denervation 11 37 (28-54) 10/1 
Rectal evacuation disorder Faecal stasis / laxative use 5 42(25-47) 510 
Chagas' disease Acquired intrinsic denervation 6 64(57-69) 2/4 
Hirschsprung's disease Failure of innervation 10 0.5 (0.2-1.0) 3/7 
Nonnal controls Ageing 80 70 (20-92) mixed 
Idiopathic STCpatients (CIST and A OIST) 
Twenty five patients with idiopathic STC were studied. All were female, age 24 - 73, 
median 42 years. In all patients, constipation had arisen de-novo in childhood (n = 
15), adolescence (n = 6), or after the age of 20 (n = 4), and patients denied any effect 
of subsequent pelvic surgery or childbirth. 
Postpelvic intervention STCpatients (PIST) 
Eleven patients (10 female) with onset of constipation after pelvic intervention were 
studied; age 28 - 54, median 37 years. Constipation had followed pelvic surgery (n = 8, 
hysterectomy in 6), obstetric episode (n = 2), and blunt pelvic trauma (n = 1, male 
patient). In all cases, surgery had not directly affected the continuity of the bowel itself, 
and patients had had no preceding gastrointestinal symptoms. 
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8.2.1.2 Specific control groups 
Rectal evacuation disorders (RED) 
Patients with severe rectal evacuation disorders were included to control for the 
possible effects of chronic laxative use, and faecal stasis. All patients had normal 
transit studies. Five patients, all female were studied, age 25 - 47, median 42 years. 
The main diagnosis was prolapse in two, prolapse and rectocele in two, and non- 
relaxing pelvic floor in one. 
Chagas'disease 
These tissues were included as a control for the effects of acquired intrinsic 
denervation (Wood et al., 1982; Brandt de Oliveira et al., 1998). Six patients were 
studied, 2 female, age 57-69, median 64 years. Three patients had undergone colonic 
resection for megacolon, and 3 were obtained fresh at post-mortem examination of 
patients with fatal cardiomyopathy. Tissues for study were taken from a region of 
macroscopically undilated sigmoid colon in all cases. 
Hirschsprung's disease (HSCR) 
Tissue sections of mid-colon were taken from a series of patients with total colonic 
aganglionosis. These were included to control for the effects of congenital failure of 
innervation. Ten patients, 7 male, 3 female were included, age 0.2 - 1.0, median 0.5 
years. 
Normal controls 
Tissues included non-nal ileal and colonic tissue removed for the treatment of 
colorectal cancer (n = 75) and ileal and colonic tissue from patients with familial 
adenomatous, polyposis (FAP) (n =2). The latter, and a small number of ascending 
colonic tissues from patients with ileal Crohn's disease (n = 3) were included to help 
provide a comprehensive age range of normal control tissue. These tissues were only 
selected if the region of the colon was macroscopically normal, and the muscularis 
propria microscopically unaffected by the disease process. Ages ranged from 20 - 92 
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years, and were mixed equally for sex. 
8.2.2 ME THODS 
8.2.2.1 Tissue collection 
For all STC and RED patients, once the colon was removed, specimens were removed 
from the antimesenteric aspect of the colonic and / or ileal wall from inter-taenial 
portions. In patients undergoing subtotal colectomy, tissue specimens were taken from 
the terminal ileum (proximal resection margin), ascending colon (approximately 5 cm 
distal to the caecum), and sigmoid colon (approximately 5 cm proximal to the distal 
resection margin). When right or left hernicolectomy had been performed, similarly 
situated specimens were removed from the ileum and ascending colon or sigmoid 
colon respectively. Tissues from patients with RED were obtained at sigmoid 
colectomy or by biopsy from the site of sigmoid colonic conduit formation (Williams 
et al., 1994). Normal control (Ileal, ascending and sigmoid colonic) tissue, and 
Chagas' disease (sigmoid colonic) tissue was obtained from the archive of the Royal 
London Hospital, Dept. of Morbid Anatomy, and from Dr Ricardo Brandt de Oliveira 
(Ribeiro Preto, Brasil) respectively. The total number of tissues obtained from 
different sites by different procedures for each group is shown in Table 8.03. 
8.2.2.2 Histological methods 
All solutions and reagents used are shown in appendix 8.01. A summary of the 
processing of STC tissues is shown in appendix 8.02. The specimens used for this 
study were fixed for 24-3 6 hours in 10% formalin solution, and mounted in paraffin 
blocks by standard methodology. 
8.2.2.3 Light microscopy 
5 ýtm sections were cut in a longitudinal axis, collected on chrome-alum coated glass 
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slides, and stained with haematoxylin and eosin (H&E) (Appendix 8.03). Periodic 
acid-Schiff (PAS) preparations with and without diastase predigestion (stains for 
glycogen / glycoproteins) were made for all tissues (Appendix 8.03). 
Table 8.03: Tissues included in study by group 
Group Terminal Ascending Sigmoid Obtainedfrom 
Ileum colon colon 
--------------------------------- 
Idiopathic STC 
--------------- 
11 
------------------ 
18 
-------------- 
8 
----------------------- 
SC/R&LHC 
Post pelvic injury STC 4 4 7 SC/R. &LHC 
Rectal evacuation disorder 0 0 5 LHC / conduit 
Chagas' disease 0 0 6 CU, PM 
Hirschsprung's disease 0 0 10 Pull throughs 
Normal controls 40 50 20 R& LHC, AR, 
PC 
Key: SC = subtotal colectomy, R & LHC = right and left hemicolectomy, CU 
colonic resection unspecified, PM = post-mortem, AR = anterior resection, PC 
proctocolectomy. 
8.2.2.4 Blinding 
All slides were labelled with a department code, and were then distributed randomly 
to slide containers by someone not involved in the analysis. 
8.2.2.5 Qualitative and quantitative analysis 
Whole H&E and PAS sections were systematically analysed at a magnification of 
X125 or x250 by 2 observers using a double-headed Olympus BH2 microscope. The 
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presence, distribution and number of inclusion bodies were noted. Validation of 
findings between observers was assessed by further independently viewing 20 sections 
that had been picked at random, and comparing the findings. The area of the 
muscularis propria of each section was calculated using a Magiscan M29 imaging 
system (Applied Imaging International, Sunderland, UK) by a further observer who 
was not aware of the histological findings. The assessment of muscle area was 
validated by repetition, and a second observer with subsequent intra and inter- 
observer studies of 10 sections. The number of inclusions per mm 2 of muscularis 
externa was then calculated. 
8.2.2.6 Analysis of composition 
A panel of sections in which inclusion bodies were detected were used to establish 
their possible composition using further sections, routine stains, and 
immunohistochemistry (Table 8.03). Serial 4 ýtm sections were taken through 10 
inclusion bodies to further establish the 3 dimensional morphology on H&E staining. 
Additional routine histological stains included a range of trichrorne stains to 
demonstrate various connective tissue elements: Massons trichrome, PTAH, Picro- 
Mallory and Martius yellow crystal brilliant scarlet. Other stains were used to detect 
collagen: elastic van Gieson; myelin: Luxol fast blue; amyloid: Alcian blue and Congo 
red; and lipofuschins: Sudan black and long Ziehl-Neelson; (Appendix 8.03). 
Immunostaining was performed using a kit-based (Dako, Ely, Cambs, UK) indirect 
immunoperoxidase method (Appendix 8.04), with a variety of different antibodies to 
cytoskeletal and other cellular proteins (Table 8.04). Thermal or enzymatic antigen 
retrieval was used for some epitopes. The antibodies used had specificities against 
epitopes of actin, smooth muscle actin, vimentin, desmin (Smith & Milla, 1997), P- 
tubulin, amyloid precursor protein (APP) and ubiquitin (Mather et al., 1993). 
Immunostaining of neural elements was performed using antibodies to neurone 
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specific enolase (NSE), neurofilament 2FII, SIOO, and PGP 9.5 as described 
previously (Martin et al., 1990). 
Because no nuclear material was detected in the inclusions on serial sectioning, 
immunostaining using a cytoplasmic apoptotic marker (Annexin V, Chemicon Int. ) 
(Koopman et al., 1994) was subsequently performed on a further panel of sections. 
Annexin V is a calcium-dependent phospholipid binding protein that detects the 
apoptosis-associated translocation of phosphatidylsenne from the cytosol to the cell 
membrane, and had been previously used immunohistochernically to detect apoptosis 
of neuronal and smooth muscle cells (Giambanco et al., 1991). 
8.2.2.7 Statistical analysis 
Intra and inter observer limits of agreement were expressed as the mean and 95% CI 
of the differences, with the Wilcoxon signed rank test used to test the significance of 
effectiveness of pairing. The frequency of occurrence of inclusions was compared 
between STC and controls using Fisher's exact contingency calculation. The number 
of inclusions per unit area was compared between STC and controls using the Mann 
Whitney U-test. Because of the marked age effect observed, a further age-matched sub- 
group of controls (range 20 - 73 years, median 46) were selected (all patients in age 
range) from the total for comparison with the STC groups. 
8.3 RESULTS 
8.3.1 VALIDATION OF METHODOLOGY 
There was a high level of agreement between the 2 observers for the quantitation of 
inclusion bodies (mean difference =0 inclusions, 95% Cl: -1 to +1 inclusion, p< 
0.0001). Likewise, there was minimal intra-observer (mean difference =I mm 2,95% 
Cl: -2 to +4 mm. 
2, p -< 0.0001), or inter-observer error (mean difference =0 Min 2 
2 95% Cl: -2 to +2 mm ýp<0.0001) with r espect to the 
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estimation of area of muscularis propria by image analysis. 
Table 8.04: Routine and immunostaining. 
ROUTINESTAINS 
-------------------------------------------------- All tissues ----------------------------------- 
Haernatoxylin and eosin (H&E) 
PAS with and without diastase predigestion (PAS / D-PAS) 
--Panel of tissues with inclusions ---------------------- 
Alcian blue Martius yellow crystal brilliant scarlet (MSB) 
Congo red Picro-Mallory 
Elastic van gieson Phosphotungstic acid haematoxylin (PTAH) 
Luxol fast blue Sudan Black 
Long Ziehl-Neelson Toluidine Blue 
Masson Trichrome 
IMMUNOSTAINS 
Antibody Manufacturer Type Raised Raised 
Vimentin 
Desmin 
Actin 
Smooth muscle actin 
P-Ubiquitin 
P-Tubulin 
(x-amyloid 
precursor protein A4 
NSE 
PGP 9.5 
in against 
Retrieval 
methods 
Dako monoclonal mouse swine none 
Dako monoclonal mouse human none 
Dako monoclonal mouse human none 
Dako monoclonal mouse human none 
Dako polyclonal rabbit ubiquitin* trypsin 
Roche monoclonal mouse human none 
Roche monoclonal mouse human none 
Dako monoclonal 
Novocastra monoclonal 
mouse human none 
mouse human micowave 
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S100 Dako polyclonal rabbit cow trypsin 
Neurof flament 2F II Dako monoclonal mouse human none 
Annexin V Chemicon monoclonal mouse human citrate 
* affinity purified antibody (Mather et al., 1993) 
8.3.2 QUALITATIVE FINDINGS 
Inclusion bodies 
Inclusion bodies (described 8.3.4) were detected in ascending colonic, sigmoid 
colonic and ileal specimens from normal subjects. In both the colon and ileum, the 
ftequency of patients with inclusions increased with age (Figure 8.01a) . In patients 
classified as having idiopathic STC, inclusions were a more frequent finding 
compared with selected age matched normal subjects in the ileum (33% vs. 9%, n. s), 
the ascending colon (50% vs. 19%, p<0.05, Fisher's exact test), and sigmoid colon 
(43% vs. 20%, n. s) (Figure 8.02 a-c). In patients classified as having post pelvic 
intervention STC, inclusions were observed with a similar frequency to idiopathic 
STC patients within the ileum (25%) and ascending colon (50%) (Figure 8.02 a, b). 
They were however, a very frequent finding in the sigmoid colon (71 %) (Figure 8.02 
c). In the RED group, inclusions were seen in the sigmoid colon, but only with a 
frequency similar to age matched controls. (Figure 8.02 c). All of the small number of 
signioid colonic tissues studied from patients with Chagas' disease had inclusions 
(Figure 8.02 c). No inclusion bodies were observed in the HSCR colonic tissues. 
Other morphologicalfindings 
Morphological abnormalities of smooth muscle were observed in 4 idiopathic STC 
patients (fibrosis: 1, apoptosis: 2, degeneration of muscle cells: 2), and 2 post pelvic 
intervention STC patients (degenerating fibres, fibrosis). Chagas' tissues all had 
microscopic evidence of myenteric plexus damage, and 4/7 had mild to severe 
muscular degeneration, with multiple apoptotic and degenerate smooth muscle cells, 
and occasional lymphocytic infiltrates. 
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Figure 8.01: (a) Frequency of normal control subjects with inclusion bodies in the 
ascending (n == 50), and sigmold colon (n = 20) by age group. The bar chart shows an 
almost linear increase in frequency with increasing age. (b) Density of inclusions in 
colonic (n = 70) and ileal (n = 40) specimens from normal control subjects by age. 
With advancing age, the data appears to separate into 2 sub-populations. 
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Figure 8.02: Frequency of patients with inclusion bodies in study groups vs. age 
matched controls for (a) ileal, (b) ascending colonic, and (c) siginoid colonic tissue. 
An increased frequency of STC patients with inclusions was seen for all three tissues 
studied. The frequency was similar for idiopathic, and post pelvic intervention 
patients in the ileum and ascending colon, but was increased more for the latter group 
in the sigmold colon. 100% of Chagas' disease patients had siginoid inclusions, but 
no inclusions were seen in HSCR tissues, and no increase of inclusions over control 
frequency was seen in the RED group. 
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Microscopic evidence of melanosis coli was observed in 6 colonic specimens (9%) 
from normal subjects. There was no correlation with the finding of inclusion bodies, 
or with prolonged laxative use (I patient only), but this finding may however have 
reflected advancing age (median age of controls with melanosis 88 years). An 
increased incidence of melanosis compared to controls was seen in patients with 
idiopathic STC (n = 4,16%), in patients with post pelvic intervention STC (n = 3, 
30%), and was observed in one of the small number of isolated RED patients (20%). 
8.3.3 QUANTITATIVE FINDINGS 
Density 
In normal subjects, the number of inclusions per unit area appeared to increase with 
age with 2 sub-populations becoming apparent (Figure 8.01b). This distribution of the 
data set may reflect, at least in part, the increasing frequency of older patients with 
inclusions, rather than a true density-age relationship. 
The ranges, and mean density of inclusions in all groups are shown in Table 8.04. In 
idiopathic STC patients, the number of inclusions was very high in a small number of 
patients especially in the ascending colon, and the density of inclusions was therefore 
significantly higher as a whole than that seen in the normal control group (p < 0.001, 
Mann Whitney U-test) (Figure 8.03). The density of inclusions in other groups was 
not statistically greater than that of controls. 
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Figure 8.03: Number of inclusions per unit area "density" in the ascending colon of 
idiopathic STC patients, and controls. There was a significant difference between 
groups, p<0.00 1, Mann Whitney U-test. 
Distribution 
In normal subjects, 58% of inclusions were found in the longitudinal muscle layer, 
29% in the circular layer and 13% in the intermuscular plane adjacent to neural 
elements. In contrast, 192 (96%) of inclusions in idiopathic STC patients were found 
in the longitudinal muscle layer, with the remainder (only 4%) in the circular layer. In 
post pelvic intervention STC, 73% of inclusions were in the longitudinal muscle layer, 
with the remainder (27%) found adjacent to neuronal elements in the intennuscular 
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plane. A similar predominance of longitudinal layer inclusions (84%) was seen in the 
Chagas' disease patients. 
Table 8.05: Inclusions per total area of tissue studied (density) by group 
Tissue Group Total number of Number in Total area Density / mm' 
inclusions longitudinal layer (Mm) 
------------------------------------------------------------------------------------------------------- 
Ileum Idiopathic STC 8 8 503.8 0.016 
Post pelvic STC 6 5 116.5 0.051 
Controls 13 6 2229.7 0.006 
Ascending colon Idiopathic STC 181 173 811.9 0.223 
Post pelvic STC 3 3 166.8 0.018 
Controls 25 15* 2258.6 0.011 
Sigmoid colon Idiopathic STC 12 11 322.7 0.037 
Post pelvic STC 13 8t 377.6 0.034 
Controls 6 51 991.1 0.006 
RED 3 3 235.3 0.013 
Chagas disease 19 16 561.4 0.034 
HSCR 0 0 251.6 0 
perineural / im. plane = 4, circular muscle 6 
perineural im plane = 5, circular muscle =0 
perineural 1, circular muscle =0 
No formal study of serial sections was undertaken to establish whether inclusions 
were distributed continuously throughout the colon and ileum. However, in STC 
patients where tissues from more than one site were studied (n = 9), the majority (n = 
7,78%) had inclusions at all sites studied, with those having high densities of 
inclusions at one site, having similarly large numbers of inclusions at others. 
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8.3.4 ANALYSIS OF COMPOSITION 
On routine H&E staining, the inclusion bodies appeared amphophilic, being round or 
ovoid, approximately 4-22ýtm in diameter (Figure 8.04). Serial sections through 
inclusions revealed a homogeneous hyaline appearance without evidence of nuclear 
material. The inclusions were not stained with any of the tinctorial (except a faint pink 
stain with PTAH) or immunohistochemical methods used, despite the use of 
enthusiastic unmasking strategies. Unfortunately, the methodology used for the 
detection of apoptosis (Annexin V) (Giambanco et al, 1991) was not effective in 
demonstrating any staining, despite the use of unmasking strategies including those 
suggested by the manufacturer. Following enquiries with other groups, similar 
difficulties have been encountered, and the failure is likely to represent problems with 
the efficacy of the reagents rather than the technique used. It should however be noted 
that no specific positive controls were used for this immunostain. 
8.3.5 CLINICAL AND PHYSIOLOGICAL CHARACTERISTICS OF STC 
PA TIENTS WITH INCL USION B ODIES 
Clinical and physiological data for STC patients with or without inclusion bodies were 
reviewed to see if differences existed between these patients. Table 8.05 shows some 
of the main parameters that were reviewed. Differences existed in reported pre- 
operative bowel frequency, with patients having inclusions tending to less frequent 
bowel actions than patients without inclusions. However, this difference was not 
statistically significant overall (range 3-48, median 15 days vs. range 2-30, median 7 
days, p=0.08, Mann Whitney U-test). Patients with inclusions were significantly 
more likely to have disordered rectal evacuation on proctographic study (P = 0.02, 
Fisher's exact test). Whilst the outcome from colectomy appeared to be worse in the 
inclusion-positive group (increased incidence of recurrent constipation, diarrhoea or 
incontinence requiring subsequent ileostomy formation), further direct comparison 
was not made because of the heterogeneity of surgical procedures performed, variable 
follow-up, and lack of comparable prospective outcome data between patients. 
223 
P17D Piesis 2000 
(a) 
(C) 
(b) 
0 
ob, lb f& 
20ý, tm 
(d) 
20ýim 
Figure 8.04: H&E staining of inclusion bodies in (a) ascending colon of normal 
colon of STC control sub ect, aged 90 years (xIOO). (b) the ascending 
patient, aged 43 years (x 160), (c) the signioid colon (perineural) of a patient with 
post-pelvic intervention STC, aged 45 years (x 100), and (d) the signioid colon of 
a patient with Chaps' disease (x 100). L_ 
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Table 8.06: Clinical and physiological findings in STC patients with or without 
inclusion bodies 
No inclusions 
Total number of patients 19 
Age (years) 24-73 (median 46) 
Clinical findings 
Pre-op bowel freq. (days) 2-30 (median 7) 
Upper GI symptoms 64% 
Urinary symptoms 63% 
Psychiatric illness 27% 
Laxatives 94% 
Successful outcome from surgery 75% 
Length history (years) 3-50 
Physiological findings 
Anorectal manometry 
Rectal sensory abnormalities 
defaecatory problems on 
evacuation proctography 
Transit: isotope scintigraphy 
Abnormal small bowel motility 
*p=0.08, Mann Whitney U-test 
tp<0.02 chi square test 
8.4 DISCUSSION 
With inclusions 
17 
22-62 (median 40) 
3-48 (median 15)* 
69% 
44% 
45% 
83% 
38% 
3-48 
No differences in sphincter function 
45% 40% 
14% 58% 
No differences in pattern of transit delay 
50% 67% 
A high proportion of adults with STC had inclusion bodies present in both layers of 
the muscularis propria, particularly in the longitudinal layer, in the absence of other 
significant abnonnality. Inclusions with an identical appearance were also seen in 
normal subjects with ageing, in all the small number of patients studied with Chagas' 
disease, but never in patients with HSCR. Inclusions were more frequent in STC 
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patients than in age-matched controls, and were seen in STC patients whose 
symptoms had arisen either de-novo or following pelvic intervention. The large 
number of patients studied, blinded design and validated reproducibility of the 
findings suggest that these are a real finding which to our knowledge have not 
previously been reported in these patient groups. 
Duchen et al. (Duchen et al., 1980) reported a series of post mortem. findings in 
diabetic patients with autonomic neuropathy. These findings included the presence of 
eosinophilic rounded or club-shaped inclusion bodies within smooth muscle cells of 
the gastrointestinal and urinary tract which were evident on conventional staining. 
Moscoso et al. (Moscoso et al., 1986) further demonstrated a form of necrobiosis and 
atrophy of smooth muscle in diabetic autonomic gastropathy, defining "M" bodies 
which were thought to represent individual "transformed" smooth muscle cells. These 
bodies had a similar eosinophilic hyaline appearance to those visualised by Duchen, 
and measured 4-25 ýtm in diameter. 
The inclusion bodies visualised in our study were of an almost identical size range. 
had similar staining characteristics, and appeared morphologically identical to those 
demonstrated in these papers (Moscoso et al., 1986, Duchen et al., 1980). Taken 
together with our findings in the colon from patients with Chagas' disease, and in 
normal subjects with advancing age, it is possible that denervation may be the 
underlying cause of such smooth muscle changes. Degeneration, especially of certain 
subgroups of enteric neurones, has been shown with ageing in man and experimental 
animals (Gomes et al., 1997, Gabella et al., 1989), and is known to be a feature of 
Chagas' disease (Wood et al., 1982; Brandt de Oliveira et al., 1998; Goin et al., 
1999). This hypothesis is further supported by the finding of inclusions with a high 
frequency in patients with STC following pelvic surgery, injury or obstetric trauma 
(Roe et al., 1988; MacDonald et al., 1997). In such patients, it is generally believed, 
though not anatomically proven that the motility problem arises from extrinsic 
parasympathetic denervation as a result of in . ury to the nervi erigentes (Devroede et j 
al., 1979; Smith et al., 1990; Varma 1992; MacDonald et al., 1993) (1.5.4.4.1). The 
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finding of a decreasing frequency of inclusion bodies from caudad to cephalad 
(sigmoid > ascending colon > ileum) in the small number of these patients studied 
might reflect the distribution (Christensen, 1991) of the ascending colonic nerves. The 
finding of inclusion bodies in the ileum of idiopathic patients may concur with the 
upper gastrointestinal motor abnormalities, known to exist in these patients (Bassotti 
et al., 1996; Glia & Lindberg, 1997; Mollen et al., 1999), and which have similarly 
been demonstrated by studies included in this thesis (3.3.3.2). 
It is therefore possible that the inclusions seen in the de-novo (idiopathic) STC group 
similarly occur as a result of some form of denervation process. This hypothesis 
would concur with a large number of studies which have indicated that neuronal 
degeneration occurs in such patients (Krishnamurthy et al., 1985; Lincoln et al., 1992; 
Shouten et al., 1993; Porter et al., 1998) (1.5.3). Since the STC group were not of an 
age range where inclusions occurred with a high frequency in non-nal subjects, it is 
possible, though no direct evidence currently exists, that such patients might have a 
similar, but "accelerated" degenerative process to that seen with ageing. Although 
ageing alone does not appear to affect transit times (Towers et al., 1994), it may 
explain why constipation is a potential accompaniment of ageing (Whitehead et al., 
1989; Towers et al., 1994). 
It remains possible, although there is no published evidence to this effect, that 
inclusion bodies may represent a response to other mechanisms of smooth muscle 
injury, for instance laxative use or prolonged distension by faecal stasis. This 
hypothesis was not confirmed by our study, in which an albeit small number of RED 
patients who had a similarly chronic history of severe defaecatory symptoms and 
laxative use, did not have an increased incidence of inclusions compared to age- 
matched controls. In addition, there was no significant difference in laxative use 
between STC patients with or without inclusion bodies. There was some co-existence 
of inclusions with melanosis coli in the small number of STC patients with this 
additional finding, but not in controls. Our study, like recent others (Byers et al., 
1997) however failed to demonstrate that such mucosal pigmentation is specific to 
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patients using laxatives, since only one record of prolonged laxative use was seen in 
the 9% of normal control subjects with this finding. Since this group were generally of 
a markedly higher age than controls without melanosis, it may reflect age related 
colonic epithelial apoptosis as has been previously suggested (Byers et al., 1997). It 
has been noted that the commonly held belief that currently used laxatives damage the 
bowel is not supported by scientific evidence (1.6.6). 
It is not possible to say from this study whether the inclusions demonstrated are lying 
adjacent to, or replacing smooth muscle cells. The inclusions, like those shown 
previously (Duchen et al., 1980, Moscoso et aL, 1986) had a homogeneous hyaline 
appearance, and serial sectioning did not reveal nuclear or other components by light 
microscopy. In addition, it was not possible to stain the inclusions with a wide range 
of conventional stains including PAS (although there was some faint pink staining 
with PTAH), and they were non-immunoreactive for a wide range of structural 
elements, including a range of anti-cyto skeletal and stress protein antibodies. This is 
not unprecedented in the field of inclusion body pathology. Ubiquitinated inclusions 
in anterior hom cells in motor neurone disease are not demonstrated by any method 
other than anti-ubiquitin immunohistochemistry and the core constituent protein 
remains elusive (Mather et al., 1993). In this study, we failed to test whether such 
inclusions might represent some form of apoptotic degeneration of smooth muscle 
cells, and this remains a possibility. A simple origin therefore, from recognised 
cellular elements of the intracellular inclusion material in the colonic muscle has not 
been ascertained by this study, and necessary ultrastructural studies are in progress. 
Interestingly, we did not observe inclusion bodies of polyglucosan composition which 
have been elegantly and clearly demonstrated in aged dogs by Kamiya et al. (Kamiya 
et al., 1986). This group used dogs selected at random for autopsy. The genetic 
background of dogs tends to be less diverse than that of humans due to selective 
breeding. Such practices lead to a relatively high incidence of genetic disorders in 
inbred strains (Leighton, 1997, Wood & Lakhani, 1997). The differences in our 
findings in humans may relate to an inherited predisposition in dogs, albeit without an 
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accompanying motility dysfunction, although it is also conceivable that dietary 
differences may have a role. 
The significance of the very high proportion of inclusions in longitudinal muscle layer 
of idiopathic STC patients, in contrast to the more balanced distribution in controls is 
not clear, although this observation may reflect the greater ease of visualising 
inclusions in longitudinally cut fibres. It is known, however that electrical control 
activities exhibited by the longitudinal muscle layer are responsible for control of long 
duration, propagating contractions (Sarna, 1991; Sarna, 1993), and that in STC, 
propulsive contractions are reduced (Bassotti et al., 1988). The role of the longitudinal 
muscle layer in relation to spontaneous electrical activity is becoming increasingly 
established (Stevens et al., 1999). 
The clinical significance of the finding of inclusions in patients with STC cannot be 
judged from the design of this study. Comparison of patients with or without 
inclusions may suggest that patients with inclusion bodies are more likely to have a 
generalised intestinal disorder (GID), which is known to adversely effect outcome 
(Redmond et al., 1996). If this were the case, it might be desirable to ascertain this 
diagnosis prior to consideration for colectomy. Certainly the outcome of the patients 
with inclusions in this study was very poor, with a high rate of stoma formation for 
recurrent or continuing symptoms, or intractable diarrhoea. Laparoscopic biopsy 
allows full thickness colonic tissue to be studied, and has been performed safely at our 
institution for a small number of these patients (unpublished data of the authors), and 
in children with chronic constipation (Hutson et al., 1996). In one study patient, the 
finding of inclusion bodies on the laparoscopic biopsy of the sigmoid colon was 
confirmed by subsequent colectomy. The distribution throughout the bowel, and 
therefore positive predictive value of such a procedure has clearly not been addressed 
by this study. A positive impact of the finding of inclusions may be the relief felt by 
some patients to be given a defined structural abnormality as a potential explanation 
for their symptoms, which have often been attributed solely to a psychological 
disturbance. 
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9 
SUMMARYAND CONCLUSIONS 
9.1 CLINICAL AND PHYSIOLOGICAL HETEROGENEITY OF SLOW 
TRANSIT CONSTIPATION: DEFINING THE PROBLEM 
9.1.1 SUMMARY 
In order to perform further clinical, neurophysiological and aetiological studies of 
STC, a population of patients was defined. In total, 130 patients were included in the 
thesis for which extensive clinical and physiological data were collected and analysed. 
Distinct clinical sub-groups could be defined, based on age and mode of onset. These 
included some previously described sub-groups, such as chronic idiopathic STC 
(CIST) and STC following pelvic surgery or childbirth (PIST), but also 4 other sub- 
groups which included patients with other precipitating factors such as spinal injury. 
Physiological comparison of patients placed in such sub-groups revealed some 
similarities and differences. In particular, comparison of the 2 main sub-groups (CIST 
and PIST) demonstrated 3 important findings which were in contrast to previously 
published reports of smaller patient numbers. The pattern of transit is in fact similar in 
both groups i. e. predominantly (70%) generalised, the incidence of rectal evacuation 
disorder is significantly higher in patients with PIST (68% vs. 34%, p=0.04), and 
small bowel motility disturbances occur in both groups (overall, 48%). 
Such heterogeneity has implications for the perceived pathogenesis of STC and 
interpretation of variation in morphological and physiological studies. In addition, 
regardless of the effect of physiological differences, it is unclear what independent 
effect a variation in pathogenesis of STC might have on treatment outcome. The 
response to surgery might be expected to be different for diseases with diverse 
pathogenesis. Indeed, wide variation exists in the outcome of such patients following 
surgery. The classification system presented was used to select and clinically clarify 
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heterogeneity within patients selected for further studies in the thesis. 
9.1.2 CONCL USIONS 
1. Whilst the clinical end-point i. e. that of severe intractable constipation with slow 
colonic transit may be indistinguishable between patients wIth STC, the group is 
clinically heterogeneous. 
2. Some significant physiological differences are detectable between clinically 
defined sub-groups. 
3. The generally accepted supposition that STC patients with symptoms arising after 
pelvic surgery or childbirth have an isolated disturbance of rectosigmoid motility 
is incorrect. 
9.2 LINEAR DISCRIMINANT ANALYSIS OF SYMPTOMS IN PATIENTS 
WITH CHRONIC CONSTIPATION: VALIDATION OF A NEW 
SCORING SYSTEM (KESS) 
9.2.1 SUMMARY 
We assessed the ability of a new symptom scoring system (KESS) to assist in 
diagnosing constipation and to discriminate between the main patho-physiological 
sub-groups of patients, including those with STC. A structured symptom scoring 
questionnaire (11 questions) was completed by 71 chronically constipated patients, 
and by 20 asymptomatic controls. Linear discriminant analysis was used to assess the 
ability of different questionnaire symptoms to discriminate between these subgroups. 
The KESS total score delineated patients with constipation clearly from normals. 
Unlike previous studies utilising symptom questionnaires, the KESS questionnaire 
appeared to be able to discriminate between patho-physio logical sub-groups for the 
majority of patients with constipation (55%, C. I. 43% to 67%). Discriminant scores 
predicted patients with pure STC or RED better than patients with mixed 
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abnormalities. 
9.2.2 CONCL USIONS 
1. This new scoring system is a valid technique to assist in the diagnosis of 
constipation. 
2. This is the first study utilising appropriate statistical methodology to demonstrate 
a discriminatory ability of multiple symptoms in constipation. 
3. At present, symptom analysis does not adequately differentiate major patho- 
physiological sub-groups for use in clinical practice. 
9.3 SENSORY AND AUTONOMIC NEUROPATHY IN PATIENTS WITH 
SLOW TRANSIT CONSTIPATION 
9.3.1 SUMMARY 
Previous studies have suggested that some patients with STC have autonomic and 
sensory dysfunction, detectable by peripheral testing. These studies have utilized 
relatively small patient numbers, and limited types of tests. We performed a range of 
standard neurophysiological and selective quantitative tests of sensory and autonomic 
function in 41 STC patients, compared to positive and negative control populations. 
The results demonstrated that approximately half of patients had evidence of 
autonomic and / or small sensory fibre function, which was detectable in the lower 
limbs by quantitative testing, but not evident on clinical neurological examination. 
Whether such changes are causative in terms of the observed gut phenotype requires 
further investigation. The aetiology of neural dysfunction remains unclear. 
9.3.2 CONCL USIONS 
I- Quantitative tests provide evidence of a small fibre neuropathy in a proportion of 
patients with STC. 
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9.4 SCREENING OF PATIENTS WITH IDIOPATHIC SLOW TRANSIT 
CONSTIPATION FOR MUTATIONS OF THE RET PROTO- 
ONCOGENE AND GDNF 
9.4.1 SUMMARY 
The frequent onset in early childhood and history of constipation or Hirschsprung's 
disease (HSCR) in close family relatives (observed in the previous study) suggest that 
idiopathic STC could have a genetic basis. A number of germline mutations have 
been described in HSCR, including mutations of RET, and the gene encoding its 
ligand glial cell line-derived neurotrophic factor (GDNF). We screened a panel of 
chronic idiopathic STC patients, including 4 families in which there were relatives 
with HSCR, for RET and GDNF mutations previously identified in HSCR. The 
methodology was clearly validated by the use of positive controls, but although 
common sequence polymorphisms were demonstrated with comparable frequency to 
published data, no published or new mutation was seen in any of the exons of RET or 
GDNF. 
9.4.2 CONCL USIONS 
1. Unlike in Hirschsprung's disease, mutation of RET or GDNF is not a frequent 
cause of idiopathic STC. 
9.5 DETECTION OF AUTOANTIBODIES TO EXPRESSED NEURONAJL 
ION CHANNELS IN SLOW TRANSIT CONSTIPATION 
9.5.1 SUMMARY 
Disorders of ion channels (channelopathies) are being increasingly identified, and 
have been implicated in several acquired disorders of gut motility with or without 
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dysautonomia. We screened sera from 42 patients with STC for autoantibodies to a 
panel of neuronal ion channels using previously validated immunoprecipitation 
studies. Three patients had high serum levels of either anti-"native" voltage gated 
calcium (VGCC) or potassium channel (VGKC) autoantibodies. The 2 patients with 
anti-VGKC autoantibodies both had severe symptoms that arose de-novo in 
adulthood. In addition, 4/ 10 patients with intestinal pseudo-obstruction, included as a 
comparison group, had anti-VGCC autoantibodies. The significance of these findings, 
which were reproducible in blinded, independently performed assays, is unclear, 
especially since autoantibodies were only found in a small proportion of patients. In 
such patients, if autoantibodies are of pathogenic significance, it is possible that 
selective effects on enteric neurones might lead to the observed phenotype in STC. 
Future studies may demonstrate a causative mechanism for such autoantibodies. 
9.5.2 CONCL USIONS 
1. Anti-neuronal ion channel autoantibodies may have an as yet unrecognised role in 
the development of some acquired gastrointestinal motility disorders in a small 
proportion of patients. 
9.6 SMOOTH MUSCLE DEGENERATION WITH INCLUSION BODIES 
IN SLOW TRANSIT CONSTIPATION 
9.6.1 SUMMARY 
Myopathies, including those characterised by the finding of inclusion bodies, have 
been described in enteric disorders. We identified inclusions present in STC patients, 
and tested whether these were a primary or secondary finding using a systematic, 
blinded, dual observer qualitative and quantitative analysis of colonic and ileal tissue 
from patients with STC (n = 36) compared with selected control populations (n = 
10 1). Round or ovoid (4-22 Vtm diameter) amphophilic inclusions increased in normals 
with ageing (p < 0.02). Inclusions were a more frequent finding in patients with 
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idiopathic STC compared with age matched controls or patients with rectal evacuation 
disorders: ileum (33% vs. 9%), ascending (50% vs. 19%, p < 0.05), and signioid colon 
(43% vs. 20%), and were very frequent in the sigmoid (71%) of patients with STC 
arising after pelvic surgery. The number of inclusions per unit area was significantly 
higher in patients with STC (p < 0.00 1). Inclusions were found in all Chagas' patients, 
but not with aganglionosis. The inclusion bodies visualised in our study were of an 
almost identical size range, had similar staining characteristics, and appeared 
morphologically identical to those demonstrated in previous studies of gastrointestinal 
tissues from patients with severe diabetic autonomic neuropathy. It was not possible 
to determine inclusion body composition with a wide range of conventional or 
immunostains. 
9.6.2 CONCL USIONS 
1. An inclusion body myopathy is identifiable in patients with STC, and may arise 
secondary to denervation. 
2. The composition of such inclusion bodies remains elusive. 
9.7 CONCLUDING REMARKS 
The aetiology of STC remains elusive. This thesis supports the view that the key to its 
understanding lies with knowledge of the interrelationships of nerve and muscle. There 
will continue to be much controversy over the nature of the primary deficit, nerve or 
muscle failure, but it seems likely that both the functional and structural integrity of gut 
smooth muscle is dependent on neural (chemical and electrical) trophic support, and 
similarly, that the maintenance of nerve function is likely to be dependent on end organ 
neurotrophic support. The balance of form and function, support and dependence holds 
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the key to this disorder, and further studies could be directed to understanding ot. s 
balance in health in the gut, and its possible aberration in disorders of motility. Such 
further knowledge of the pathogenesis of the condition may allow more directed 
therapies aimed at the reversal of the disease process or processes themselves. 
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APPENDICES 
2.01 CONTROL AND COMPARISON GROUPS 
Type Chapter Study type Study subjects 
Negative controls 
Positive controls 
Specific comparison 
/ control groups 
4 Symptom analysis 
5 Neurophysiology 
7 Autoantibody assays 
8 Inclusion study 
5 Neurophysiology 
6 Mutation screening 
7 Autoantibody assays 
7 Autoantibody assays 
8 Inclusion study 
Healthy volunteers 
Healthy volunteers 
Healthy volunteers 
Neoplastic disease 
Diabetes mellitus, 
Multiple endocrine 
neoplasia and HSCR 
Neuromyotonia 
(Isaac's' syndrome) 
Lambert-Eaton myasthenic 
syndrome (LEMS) 
Myasthenia gravis (MG) 
Intestinal pseudoobstruction. 
Idiopathic megacolon 
Rectal evacuation disorder 
Chagas' disease 
Hirschsprung's disease 
Z02 DEMOGRAPHICDATA 
Age at presentation Median 39, range 13-79 years 
Sex Female 126, Male 4 (ratio 32: 1) (male = 3%) 
Race Caucasian 121, Asian 4, Afro-Caribbean 2, NK 3 
Geographical address Greater London 70, Essex 27, Other 18, NK 15 
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2.03 AGES OF SYMPTOM ONSET 
Range Number ofpatients 
Age I-5 14 
Age 6- 10 37 
Age 11 - 15 12 
Age 16 - 20 13 Median 12 years (range I- 68) 
Age > 20 41 
Not known 2 
Total 119* *II patients excluded (see text) 
2.04 MODE OF ONSETI PRECIPITATING EVENTS 
Mode of onset Number % total 
Idiopathic (no clear precipitating events) 84 64.6 
Sexual or physical abuse 2 
Gastroenteritis 2 
Viral infection I 
Minor anal trauma I 
Foreign travel I 
Obstetric episode 12 9.2 
Gynaecological or other pelvic surgery 11 8.5 
Idiopathic + subsequent pelvic event 11 8.5 
Neurological injury / disease 7 5.4 
Other (miscellaneous) 5 3.8 
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2.05 PRESENTING SYMPTOMS 
Frequency of bowel action 
(number of days between successive bowel 
actions based on mean of ranges given) 
median =8 days 
range =I- 49 days 
not known = 15 
Defaecatory symptoms Number of Total known % total 
patients 
--------------------------------------------------------------------------------------------------- 
Straining 102 112 89.3 
Time spent per attempt at 
defaecation >5 min 67 83 80.7 
Incomplete evacuation 97 102 95.1 
Unsuccessful evacuation 77 89 86.5 
Painful evacuation 62 75 82.7 
Stool consistency (hard / pellets) 88 99 88.9 
Incontinence 13 64 20.3 
Rectal prolapse (feeling of) 11 69 14.5 
Digitation: rectal / vaginal 26 108 24.1 
Bleeding per rectum 65 100 65.0 
Other gastrointestinal symptoms 
Abdominal pain 113 119 95.0 
Abdominal bloating 109 112 97.3 
Nausea / vomiting 49 93 52.7 
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2.06 MANAGEMENT 
Medical 
Agent used 
--------------------------- 
Laxatives 
Suppositories 
Enemas 
Prokinetics 
Number ofpatients Total known % Total 
-------------------------------------------------------------------------------------- 
108 120 90.0 
40 102 39.2 
29 102 28.4 
8 120 6.7 
Surgical 
Anorectal Procedures Number ofpatients (from total = 130) 
---------------------------------------------------------------------------------------------------- 
Anal stretch 3 
Lateral sphincterotomy I 
Rectal biopsy 4 
Rectocele repair 2 
Anterior and posterior repair I 
Rectopexy abdominal 5 
Delormes 1 
Colonic surgery 
Subtotal colectomy and ileorectal anastomosis 
Right hernicolectomy 
Left hemicolectomy 
Sigmoid colectomy 
Colonic conduit formation 
Stomaformation 
----------------------- 
Ileostomy 
Colostomy 
Other management 
------------------------------------------- 
15(12%) 
5 
6 (one with rectal reduction) 
3 
6 
------------------------------- 
primary 
--------------------------------------------------------- 
4 
Secondary 4 
primary 2 
--------------------------------------------------------------------------------------------------------------------- 
Botalinum injections 2 
Behavioural therapy (Biofeedback) 2 
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2.07 PERSONAL HISTORY 
Surgical history (NK = 15; total known = 115) Number 
Appendicectomy 13(11%) 
Cholecystectomy 5 
Hemia repair (s) 4 
Gastric surgery 2 
Other 3 
None 91 
Obstetric history (126 female, NK = 12; total known = 114) 
Total Instrumentation Caesarean 
section 
Parity 0 36 
1 14 1 1 
2 37 5 4 
3 14 0 4 
4 7 0 0 
>4 6 2 2 
total 114 8 11 
Gynaecological history (126 female, NK = 13; total known= 113) 
---------------------------------------------------- ---------------- ------------------------------- 
Disorders Number of Surgery Number of 
patients patients 
Endometriosis 5 Laparoscopy gynaecological 
Pelvic inflammatory disease 6 surgery 15 
Ovarian cystic disease 5 Dilatation and curettage 3 
Cervical carcinoma or CIN 111 3 Pelvic floor repair* 11 
Ectopic pregnancy 2 Ovarian surgery 5 
Uterine or bladder prolapse 5 Hysterectomy 38(34%) 
Fibroids 14 Cervical surgery 3 
Infertility treatment 2 
Total 37(33%) 64(57%) 
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Psychiatric disorders (NK = 30; total known = 100) 
Depressive illness (unspec. )* 13 (13%) 
Schizophrenia 0 
Anxiety disorders 2 
Eating disorders (anorexia nervosa) I 
Behavioural problems (unspec. ) 2 
Psychoactive substance dependence 2 
Other 3 
None 77(77%) 
* includes: unipolar and bipolar (n = 1) illness, suicide; n=1, parasuicidal behaviour; n=2 
Past Medical History (NK = 17; total known = 113) 
Metabolic lEndocrine Thyroid disease (treated) 5 
Diabetes Mellitus 0 
Hypercalcaernia 0 
Obesity I 
Other 0 
Cardiorespiratory Asthma 2 
COPD 3 
Hypertension 5 
Cardiovascular other 4 
Neoplastic disease Benign breast disease 2 
Malignant melanoma (eye) 1* 
Pulmonary carcinoid 1* 
Neurological disease Epilepsy 3 
Migraine 2 
Multiple sclerosis 0 
CVA 0 
Spinal disease Spinal surgery (all) 9 
Vertebral fracture (all) 3 
Disc disease (all) 8 
Neoplasia (benign) I 
Abscess 2t 
Spina Bifida 
treated successfally, in remission at time of presentation 
Poff's disease (TB spine); n=1, pyogenic abscess; n=1. 
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2 08 DR UG HIS TOR Y 
(excluding laxatives; NK = 34; total known = 96) * 
Analgesia (all) 21(22%) 
Opiate containing medications 11 (11%) 
Non steroidal analgesia 3 
Antidepressants (all) 7 
Antianxiolytics 4 
HRT 8 
Inhalers for pulmonary disease 5 
Nil 52 
only commonest used medications shown 
both analgesic and anti-diarrhoeal use included 
2.09 FAMILYHISTORY 
(NK =39; total known =9 1) 
Constipation (any) 
Constipation (medical referral) 
Hirschsprung's disease 
Nil 
Autoirnmune & rheumatological 
39(43%) 
17(19%) 
4 
50(55%) 
(see CHAPTER 7) 
2 10 S YS TEMA TIC ENQ UIR Y 
Urological symptoms 
Frequency 
Dysuria 
Urgency 
Nocturia 
Incontinence (any) 
Total 
(NY, =51; total known = 79) 
19(24%) 
4 
9 
6 
15(19%) 
31(39%) 
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None 
Neurological symptoms 
Rheumatological symptoms 
48(61%) 
(see CHAPTER 4) 
(see CHAPTER 7) 
5.01 SOLUTIONS FOR INJECTION: 
Capsaicin was supplied (Sigma-Aldrich, Poole, Dorset, UK) as a colloidal mixture of 
0.05ýtg/10ýtl in Tween-80 and saline as described by Simone et al., (1989). 
Nicotine hydrogen tartrate (BDH Chemicals Ltd) was supplied via Guys Hospital 
Pharmacy in 2ml glass vials at a final concentration of 10ýLg/ml. 
Methacholine chloride solution was supplied in 2ml glass vials by Guys Hospital 
Pharmacy at a concentration of 100ýLg/ml. 
All solutions were stored at 4'C, and expiry dates checked before use. 
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5.02 RESULTS OF CONVENTIONAL NEVROPHYSIOLOGICAL TESTS AND 
NON-INVASIVE AUTONOMIC TESTS 
Routine neurophysiology 
STC DNI Controls * 
--------------- 
Median 
---------------- 
range 
--------- ---------- 
Median range Normal range 
SNCV 46.7 
-- 
38.6-70.0 
--------------- 
34.8 
-------------------- 
O. Ot - 47 
-------------------------------- 
> 42.5 
SNSAP 13.72. 4.8- 26.8 2.0 0.0- 13.4 > 7.8 
PNCV 49.3 40.7 -58.6 34.0 0.0- 43.9 > 44.0 
PNCAP 4.24 2.42 -10.6 4.08 0.0- 6.3 > 2.5 
PNDML 4.5 1.6- 10.9 2.7 0.0- 7.8 < 6.0 
Key: SNCV Sural nerve conduction velocity (m / sec) 
SNSAP Sural nerve sensory action potential (VtV) 
PNCV Peroneal nerve conduction velocity (in / sec) 
PNCAP Peroneal nerve compound action potential (gV) 
PNDML Peroneal nerve distal motor latency (msec) 
Dept. of Neurophysiology, Royal London Hospital control ranges for ages 
18-50 years (c/o Dr Peter Misra). 
t No response elicitable: value given as 0.0 
Non-invasive autonomic tests 
Median range Median 
- -------- -- 
range 
---------------------- 
Abnorrnal* 
-------- - --------------- 
RR 
---------------- 
32 
--------------------- 
8.4-66 
- -- - 
11.0 2.5-26.0 
- ------------ 
<10 
VAL 1.38 1.10-2.04 1.11 1.03-1.15 < 1.2 
BP tilt +4 0-+18 +4 -30-+ 15 > -30 
RR tilt 1.15 1.05-1.50 1.16 1.04-1.16 < 1.00 
Key: RR Heart-rate response to deep breathing (bpm difference) 
VAL Valsalva ratio (ratio) 
BP tilt Blood pressure response to standing using tilt-table (ratio) 
RR tilt Heart-rate response to standing using tilt-table (ratio) 
Control ranges from literature: (Ewing, 1988) 
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Values may be positive (increase in blood pressure), or 
negative (drop in blood pressure i. e. postural hypotension) 
5.03 FULL RESULTS OF QUANTITATIVE PERIPHERAL SENSORYAND 
AUTONOMIC TESTS 
STC DM Controls 
-------- -------- 
Median 
---------- 
range Median range 
-------------------------------- -- 
Median range 
LT 4 
- --------------- 
1-9 9 4-20 
------------ 
2 
------------- 
1-7 
VIB 8 3-20 31 14-50 7 5-11 
Cool 2.1 0.9-5.6 11.5 1.6-22.0 1.5 1.0-3.5 
Warm 4.2 2.0-12.1 17.0 3.5 - >18.0 3.2 1.4-5.1 
HeatPam 12.4 7.8 - >18 > 18 13.0 -> 18 12.0 7.7-16.1 
ARS 40 7-74 31 4-63 47 32-84 
DS 62 33-87 NP NP 62 35 -87 
ARV 75 24-240 15 6-97 77 44-140 
Key: LT Light touch threshold (no units) 
VIB Vibration threshold (Biosthesiometer units) 
Cool Cool threshold (OC) 
Warm Warm threshold ('C) 
HeatPa m Heat as pain threshold (OC) 
ARS Axon reflex sweating (gM-2 h-) 
DS Direct sweating (gM-2 h-') 
ARV Axon-reflex vasodilatation (flux units) 
NP Not performed 
No response within safety limit of test (>I 8'Q 
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6.01 SOLUTIONS AND BUFFERS 
TBE: 90rnM Tris-HCI, pH 8.0, 
90mM boric acid, 
2mM EDTA- made up as aI OX concentrate. 
TNE (I OX): I OOmM Tris buffer, 
I OmM EDTA, 
2M NaCl. 
Fon-namide stop solution: 98% deionised formamide, 
I OmM EDTA, pH 8.0, 
0.025% bromophenol blue, 
0.025% xylene sulphate. 
Loading buffer for agarose gels (I OX): 
Mutation detection enhancement (MDE) 
10% sucrose, 
0.025% bromophenol blue, 
0.025% xylene cyanol. 
Provided as gel solution (FMC bioproducts, Rockland, ME) 
6.02 PUREGENE 0 DNA ISOLATION 
Cell lysis 
1.6 ml of whole blood added to 50ml tube containing 18 ml of RBC lysis buffer (provided in kit). 
Invert to mix and incubate for 10 mins at room temperature. 
Centrifuge for 10 mins at 2000g. Remove supernatant leaving behind visible white pellet and small 
quantity of residual fluid. 
Vortex the tube to resuspend WBC in residual supernatant. 
Add 6 ml of cell lysis solution (in kit) to the tube, and pipette up and down to lyse cells. If cell 
clumps persist, incubate at 37'C until solution is homogenous. 
RNAase treatment 
1. Add 30ýd RNAase A solution (in kit) to the cell lysate. 
Mix the sample by inverting the tube 25 times and incubate at 371C for 15 mins. 
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Protein precipitation 
1. Cool sample to room temperature 
2. Add 2 ml of protein precipitation solution (in kit) to the cell lysate. 
3. Vortex vigorously at high speed for 20 seconds to mix the protein precipitation solution uniformly 
with the cell lysate. 
4. Centrifuge at 20OOg for 10 mins until the precipitated proteins forni a tight dark brown pellet. 
DNA precipitation 
1. Pour the supernatant containing the DNA into a clean 50 ml tube containing 6 ml 100% 
isopropanol. 
Mix the sample by inverting gently 50 times until the white threads of DNA forni a visible clump. 
Centrifuge at 20OOg for 3 mins. 
Pour off supernatant and drain tube. Add 6 ml of 70% ethanol. Invert the tube several tiMes to wash 
the DNA pellet. 
Centrifuge at 20OOg for I min. Carefully pour off the ethanol. Drain the tube and allow to air dry. 
DNA hydration 
1. Add 250ptl DNA hydration solution (in kit). 
2. Allow to rehydrate overnight at room temperature. 
3. Store at - 4'C. 
6.03 DNA SPECTOMETRY 
1. Make 100ml of Ix TNE in dH20(from 10 x TNE stock). 
2. Add 10ýd Hoechst dye stock (Pharmacia Biotech Inc., UK), shake to mix. 
3. Add 2 ml of diluted dye to a2 ml clean optical cuvette, dry exterior, and place in 
spectrometer and calibrate to zero. 
4. With a 2ptl pipette, add 2ptl of DNA standard (calf thymus DNA, I OOng/ml) 
(Pharmacia Biotech Inc., UK) to the cuvette, mix and dry exterior. 
5. Calibrate spectrometer to read 100 units. 
6. Repeat zero and 100 unit calibrations until stable. 
7. Repeat with 2ýtl test DNA and record reading Y. 
8. Calculate DNA concentration 'y'in ng / ml by: y=x/ 100. 
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6.04 TOUCHDOWNPCR PROTOCOLS 
Temperatures (Q & durations 
94 2min 
94 10 sec x+4 10 sec 72 1 Osec 
94 10 sec x+2 10 sec 
1 
72 1 Osec 
94 40 sec xI min 72 1 min 
72 10 min 
x == annealing temperature (below) 
No of cycles 
1 
3 
3 
35 
(denaturing) 
1 (final elongation) 
6.05 RET and GDNF PRIMER SEQUENCES AND CONDITIONS 
Gene Exon Primer Annealing temp ('C) 
RJET 
I F GCACCCGCCATCCAGACCC 60 
R GAGCCGGCGGCCGGCAGAAC 
2 F CCATATTCTCACCATCCCTC 50 
R AGTGTCAGCGGCTGTGATAA 
3 F GCCGATGCCCCCACAGACCT 56 
R AAGACCAGCAGTAGCAGGCA 
4 F CCCTGTCTGCTTGGTGCG 56 
R GGACACTAAACCGACCGAG 
5 F ACTGACCAACGCCCTCTG 56 
R GCACCTCATTTCCTGGGGG 
6 F ATTGTTGTGCCCCTACCTG 56 
R CCCCAGACAGGCAATAGGTA 
7 F TCTACCCTCAGGCCATTACAG 56 
R GCTCCCAGACCCCGACCCT 
8 F TGGTGCTGTTCCCTGTCC 56 
R CCACCGGTGCCATCGCCCCT 
9 F AGTCTGCTGTGTGTCCTGTG 56 
R CCATGCCCTGATFAAACCCT 
10 F GGAGGCTGAGTGGGCTACG 56 
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R CTGGGAGGTGGTGGTGGTC 
11 F CCTCTGCGGTGCCAAGCCTC 56 
R CCTCGTCTGCCCAGCGTTG 
12 F GCCTTCTTCCTCCCCTGTCAT 50 
R GAGACTCCCCCAGGGGCACTGT 
13 F CTCTCTGTCTGAACTTGGGC 56 
R TCACCCTGCAGCTGGCCTTA 
14 F AAGACCCAAGCTGCCTGAC 56 
R GTGGTGGGTCAGGGTGTGG 
15 F GACTCGTGCTAT = CCTC 56 
R TATCTTTCCTAGGCTTCCCA 
16 F GTCTTTATTCCATCTTCTCT 56 
R TCTGTAACCTCCACCCCAAG 
17 F CACTGGTCCTTTCACTCTCT 56 
R GGGAGGGAATGCACACAGAT 
18 F TGTGGTGGGCTGTCCTTCTG 60 
R CTGGGGTGAGGCTGGAGTCT 
19 F TAGTTGTGGCACATGGCTTG 56 
R GAGAGGAAGGATAGTGCAGA 
20 F AGTTTTGGTTCTTCAGTGC 56 
R GACTTTCCATTCTCAGCAT 
Additionalfor sequencing 
2R TAAGGGCGGCTTGAGGAAGG 
4F TGTCTGCTTGGTGCGCAGGT 
R AGCACGCGCGGACAAGCAC 
GDNF 
F AAGTTATGGGATGTCGTGGC 56 
R AGTCACTGCTCAGCGCGAA 
2F CAAATATGCCAGAGGAT-fATC 52 
R TCAGATACATCCACACCTT-fT 
Additionalfor sequencing 
IF TGGGATGTCGTGGCTGT 
R AGTCACTGCTCAGCGCGAAGG 
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6.06 SSCP GEL CONSTITUENTS (2 CONDITIONS) 
1.0.8% MDE (for 150 ml total) 
60 ml 2x MDE, 
12 ml 10 x TBE, 
78 ml H20, 
800ýd 10% ammonium persulphate (APS), 
80ýtl TEMED (reaction initiation). 
2.0.8% MDE / 10% glycerol (for 150 ml total) 
60 ml 2x MDE, 
12 ml 10 x TBE, 
63 ml H20, 
15ml glycerol, 
800ýtl 10% ammonium persulphate (APS), 
80ýtl TEMED (reaction initiation). 
6.07 SIL VER STAINING PROTOCOL FOR MDE GELS 
1. Fix gels in a solution of 10% absolute ethanol / 0.5% acetic acid for 10 mins at 
room temperature. 
2. Stain with 0.1% silver nitrate for 10 mins at room temperature. 
3. Rinse gels with distilled water to remove excess silver solution. 
4. Develop with a solution 1.5% NaOH / 0.01% NaBH4 (sodium borohydride) 
0.048% formaldehyde for 20 mins at room temperature. 
5. Fix stain with a solution of 0.75% NaC03 for 10 mins at room temperature. 
6. Treat with 10% glycerol solution for 10- 15 mins prior to drying gels. 
7. Dry under vacuum for 90 mins at 80'C. 
305 
PhD ThesiS 2000 
6.08 PREPARATION OF DNA FOR SEQUENCING 
1. Add 80ýLl dH20to each reaction tube. 
2. Precipitate DNA by vortexing with a solution of 15ýd 2M sodium acetate, pH 4.6, 
I ýtl glycogen and 250ýLl ethanol. 
3. Store samples at -20'C for 60 mins. 
4. Centrifuge at maximum speed for 20 mins. 
5. Aspirate ethanol. 
6. Wash in 70% ethanol. 
7. Air dry DNA pellet. 
6.09 PREPARATION OFACRYLAMIDE SEQUENCING GELS 
1. To 40g of urea, add 25 ml of 8H20,12 ml of acrylamide, and Ig of amberlite 
(deionising) pellets. Stir until dissolved in a heated water bath. 
2. Filter 8 ml of TBE followed by the gel mix and allow to degas. 
3. Makeup 10%APS. 
4. To gel mix, add 400ýd of 10% APS and 45[tl of TEMED (reaction initiation). 
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7.01 PATIENTDETAILS 
Main historical data for STC patients 
Conditions N Description N 
Autoimmune disease II Personal history Ankylosing spondylitis I 
Psoriasis 2 
Family history only IDDM 5 
Hypothyroidism 3 
Hyperthyroidism I 
Rheumatoid arthritis 2 
Ankylosing spondylitis I 
Neurological disease 6 Personal history Traumatic or degenerative 
spinal conditions 5 
Epilepsy I 
Peripheral sensory neuropathy I 
Neoplastic disease 2 Personal history Carcinoid (treated) I 
Malignant melanoma (treated) I 
----------------------------------- 
Symptoms 
------------------------------- 
N Notes 
---------------------------------------- ---------- 
-------------------------------------------------------------------------------------------------------------------- 
Limb myalgia 5 pains in limb or limb girdle musculature 
Limb muscle weakness 3 investigations negative 
Limb arthralgia / arthritis 32 secondary to psoriatic arthropathy (hands only) 
I all rheumatological investigations: negative 
Distal parasthesias / numbness 64 hands only, 2 lower limb 
Urinary symptoms I frequency 7 
nocturia 2 
dysuria 2 
incontinence 6 
urgency 3 
retention I 
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Main demographic data for patients included in assay studies 
Group N Sex FIM age median duration of symptoms 
(range) 1years median (range) 1years 
CIST 22 23/0 41 (25-62) 29(17-47) 
PIST 10 10/0 30(26-55) 6(1-32) 
AOIST 10 10/0 38(26-52) 6(1-12) 
IP 10 3 52(27-64) 10(3-31) 
imc 4 1/3 32(29-39) 28(27-34) 
7.02 ASSAYREAGENTS 
All reagents were supplied by Sigma-Aldrich, Poole, Dorset, UK (Sigma), unless 
otherwise stated. 
Protease inhibitors 
PepstatM A 
Leupeptin 
Phenylmethylsulphonylflouride (PMSF) 
Detergents 
Triton X 100 (t-octylphenoxypýolyethoxyethanol) 
Digitonin (50% pure) 
P4265 
L2884 
P7626 
(9002.93-1) 
Calbiochem-Novabiochem Corp (San Diego, 
Califomia, USA) 
Acetylcholine receptor (AChR) extract from TE671 and CN21 cell lines and 
AChR additive (bovine serum) 
Both purchased from RSR Ltd., Cardiff, U. K. 
Sheep anti-human IgG 
Purchased from Dr Bemard Rees-Smith, Cardiff, UK 
Unlabelle toxins 
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Calcium channels 
Synthetic co-conotoxin GVIA (4161 -v) 
Synthetic (o-conotoxin MVIIC (4283-v) 
[Both purchased from Peptide Institute (European distributors, Scientific marketing, 189/191 High St, 
Barnet, Herts EN5 5SU). The toxins are received as lyophilised solids. They are reconstituted with 
distilled water at a concentration of lmg/ml and stored at -70'C until use. Each toxin is used at a 
concentration of IýLM (mol wt. synthetic co-conotoxin GVIA = 3161, synthetic (o-conotoxin MVIIC= 
2750)]. 
Potassium channels 
Synthetic a-dendrotoxin (a-DnTx) purchased from Latoxan (Valence, France) 
Muscle AChR-a-I channels 
6-Bungarotoxin (T3019) 
Labelled toxins 
Calcium channels 
1251_(O-conotoxin GVIA (I 251_(O -CgTx) purchased from Amersham International 
(IM217,10ýtCi, S. A. > 2000 Ci/mmol). 
125 1-(o-conotoxin MVIIC (1251_0 -CmTx) purchased from New England Nuclear Ltd, 
Mass, USA (5ýtCi, S. A. > 2000 Ci/mmol). 
Potassium channels 
1251_a-dendrotoxin (125 I-a-DnTx) purchased from Amersham Intemational 
MuscleAChR-a-I channels 
1251-cc-Bungarotoxin low specific activity 
(1251_(X-BnTx) purchased from Amersham 
intemational (IM 109) 
[The toxins are rece ituted with 
distilled water at a ived as lyophilised powder. They are reconst 
concentration of 0.05ýtCi/5ýd and aliquoted 
into 5ýXi amounts (0.5ml) and stored at -70'C until use]. 
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7.03 ASSAYBUFFERS 
1. Solubilisation buffer for brain membrane preparation and VGCC assay (SB) 
PH 7.4, stored at -20'C until use: 
25mM Tris-HCI 
5mM HEPES 
0.32M Sucrose 
2.15g 
1.19g for I litre 
0.32g 
Just before use, add protease inhibitors: 
Pepstatin final concentration I ptM 
Leupeptin final concentration 2ýM 
PMSF final concentration 0.1 ptM 
2.4% digitonin in SB 
Digitonin purchased is 50% pure. Therefore the solution is made up to 8%: 1.6g 
digitonin in 20ml SB. This "solution" is left overnight at 4'C before use. There is a lot 
of insoluble material remaining; before use in the assay an aliquot must be 
microfuged: 13,000rpm /5 min and clear supernatant removed for subsequent use. 
3. IM NaCl in SB 5.84g NaCl in 100ml SB 
4.2% Digitonin in solubilisation buffer for VGKC extraction only (DTX) 
20mM Tris 
I OOmM NaCl 
5mM KCI 
Natural pH -= 
10.0, therefore add HCI to pH 7.12 
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To 2ml (will be 2.5 ml when 500ýtl membranes added), add digitonin 0.05g (50%) 
to give final concentration of 2% (active concentration: 1%). 
2. Incubate in waterbath at 37'C for 15 min. 
Just before use, add protease inhibitor: PMSF: 5ýtl of OAM in propan-2-ol (final 
concentration 0.2mM). 
5. Incubation buffer (IB) (for VGCC assay only) 
0.1 % digitonin in 20mM phosphate buffer pH 7.4, stored at 41C 
500pl digitonin 4% 
17.5 MI dH20 
2ml 0.2M Phosphate 
6. Washing buffer (WB syn. PTX) 
0.1% Triton X 100 in 20mM phosphate buffer pH 7.4, stored at 4'C 
7.04 BRAIN-MEMBRANE PREPARATION 
The protocol is identical whether using human (frontal or cerebellar tissue) or rabbit 
tissue, and is a common step to both calcium and potassium channel assays. To 
prepare membranes from rabbit brain, 2-3 cm 3 sections of cerebellum were added 
immediately post-mortem to 20 ml of ice-cold buffer (25mM Tris-hydrochloric acid 
[HCI], 5mM HEPES, containing 0.32M sucrose, 2[tM leupeptin, IýiM pepstatin, 
0.1 mM phenylmethylsulfonylfluoride [PMSF]). The sections were homogenised and 
centrifuged. The supernatants were removed, recentrifuged, and the pellets 
resuspended at a final protein concentration of 20 to 25 mg/ml and stored at -70'C. 
1. Tissue removed as soon as possible post-mortem, cut into small pieces and 
dropped into liquid nitrogen. Then stored at -70'C until use. 
2. Take 'x' gram of cerebellum, and make up with ice cold SB (with protease 
inhibitors added immediately before use) to 6-8 x volume of Y. 
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3. Homogenise using a Polytron Homogeniser (PTIO-35, Kinematica GmbH, Littau, 
Switzerland). Full speed 3x 10 sec, resting on ice in-between. 
4. Spin 1000rpm (50g) / 10 min (Beckman J2-2t centrifuge). 
5. Harvest supernatant. 
6. Spin 13,000rpm (10,000g) / 10 min (Beckman J2-21 centrifuge). 
7. Resuspend pellet in a volume of SB equivalent to original brain tissue weight. 
8. Aliquot in 500ýtl amounts. Then store at -70'C until use. 
Z 05 PREPARA TION OF CHANNEL EXTRA CTS 
Voltage-gated calcium channel (VGCC) extract preparation 
(made in batchesfor storage before subsequent use) 
1. Defrost aliquots of brain-membrane preparation. 
2. Add 700ýtl SB (with fresh protease inhibitors), vortex, spin 13,000rpm / 5min 
(bench-top Eppendorf centrifuge), discard supernatant. 
3. Add I ml SB, vortex, spin 13,000rpm /5 min, discard supernatant. 
4. To the pellet (approx. 200[d), add: 
IM NaCl in SB loogl 
SB 200ýtl 
4% digitonin in SB 500[tl 
therefore the final solution will be 2% digitonin, 0.1 M NaCl 
5. Rotate I h) 4'C. 
6. Spin 13,000rpm / 15 min. 
7. Remove supernatant as source of VGCs; store at -701C. 
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Voltage-gated potassium channel (VGKC) extract preparation 
(madefteshfor immediate use) 
1. Defrost aliquots of brain-membrane preparation. 
2. Add stepwise (2 x 250ýtl) to 2ml DTX (with fresh protease inhibitor), mix gently 
with pipette (I :5 dilution) (total volume 2.5ml: see above). 
3. Incubate 37'C for 15 min. 
4. Spin 13,000rpm / 15min (bench-top Eppendorf centrifuge). 
5. Harvest the supernatant (VGKC extract) and store on wet ice until use. 
7.06 VGCC j"DIOIMMUNOASSA yS USING 125j. 0). CoNO TOXIN M VIIC 
125 125j, ( I-ct)-CmTx) TO LABEL CEREBELLAR EXTRACTS OR 
CONO TOXIN G VIA (25, ct)-CgTx) TO LABEL FRONTAL CORTICAL 
EXTRA CTS 
1. Defrost extracts on wet ice. 
2. If not perfonned previously, carry out a total (labelled toxin only) and a non 
specific binding study (in the presence of excess unlabelled "cold" toxin). See 
appendix 7.11 
3. In a 7ml bijou, add 25ýil IB to 5ýtl extract (1251_(o -CmTx: cerebellar extract) or 
20[d 1B to 10[d extract (1251_0 -CgTx: frontal extract), i. e. to a total of 30ýtl per 
sample, multiplied by the total number of samples to be tested in assay. 
i. e. 
1251_C0 
-CmTx: for 50 samples = 250ýtl extract + 1.25ml 1B 
1251_(o 
-CgTx for 50 samples = 500ýd extract + 1.00ml IB 
4. Defrost 1.0ýtCi aliquots of either 
1251_(O 
-conotoxin, make up each aliquot with 
500ýtl IB, spin 13,000rpm /5 min. 
5. Add 5 finol of either 
1251_0 
-conotoxin per sample, usually 6-10 ýLl / sample: see 
appendix 7.12 for calculation. 
6. Make up total volume / sample to 50ýtl with 1B. i. e. 30ýd + 6-10ýtl (above) + 20- 
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(6-1 0)ýtl. This is the labelled extract preparation. 
7. Incubate 2h at 4'C on wet ice. 
8. Dilute I Oýtl test sera I/ 10 with IB, vortex, spin 13,000rpm /5 min. 
9. Add 25[d of supernatant from each sample of diluted serum to 50ýtl of labelled 
extract, vortex, and incubate overnight at 40C. 
10. Add 125ýtl of I/5 diluted sheep anti-human IgG (diluted in PTX) to each sample 
(not microfuged) 
11. Incubate Ih at 4'C. 
12. Add Iml PTX, mix gently, spin at 13,000rpm /5 min (Bench-top Eppendorf 
centrifuge). 
13. Remove supernatant by suction, wash pellet twice in Iml PTX. 
[N. B if large number of samples, perform steps 12 and 13 stepwise in sets to prevent 
time dependent dissociation of complexes into PTX]. 
14. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra 11 auto-gamma, Meriden 8, CT, USA). 
15. Calculate final binding of labelled extract in pM /I using algorithm (Appendix 
7.09) 
7.07 VGKC RADIOIMMUNOASSAY USING 
125, 
a-DENDROTOXIN 
ý25, a 
DNTX) TO LABEL CEREBELLAR EXTRACTS 
1. Label freshly made VGKC extract (above). Calculate total amount required (50ptl 
x number of samples), and mix gently with pipette: 
ýd VGKC extract 
[il PTX 
X/ 10 1251_(x-DnTx 
2. Incubate at room temp for 15 min. 
3. Transfer to Eppendorfs, and microfuge 13,000rpm /5 min before use. 
4. Dilute 25ýd patient sera 1/ 10 with PTX, vortex, spin 13,000rpm/ 5 min. 
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5. Add 50ýtl of supematant from each sample of diluted serum to 50ýd of labelled 
extract, vortex, and incubate overnight at 4C. 
6. Add 250ýtl of I/6 diluted sheep anti-human IgG (diluted in PTX) to each sample 
(not microfaged) 
7. Incubate I hat room temp. 
8. Add lml PTX, vortex, spin at 13,000rpm /5 min (Bench-top Eppendorf 
centnifuge). 
9. Remove supernatant by suction, wash pellet twice in I ml PTX. 
[N. B if large number of samples, perform steps 12 and 13 stepwise in sets to prevent 
time dependent dissociation of complexes into PTX]. 
10. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra 11 auto-gamma, Meriden 9, CT, USA). 
125, 7.08 MUSCLE AChR RECEPTOR ASSAY USING , týZBVNGAROT0XJN 
125 ( I-eý-BuTx) 
1. Add one part RSR CN21 extract to one part RSR TE671 extract and note the 
volume. 
2. To the known volume add the RSR AChR "additive" at the current dilution and 
mix. (e. g. lot RE2 uses 16541 per ml of undiluted extract). 
3. Leave at 4'C for 30 min. 
4. Centrifuge 10,000 rpm at 4'C for 30 min. 
5. Collect and measure the supernatant. 
6. Dilute the supernatant 1: 6 with PTX. 
7. Dilute the 125 -a-bungarotoxin (BuTx) 1: 10 with PTX in a sarstedt tube. 
8. To two eppendorf tubes pipette I Oýd of diluted BuTx each. 
9. Count on gamma camera. 
10. Calculate the required volume of diluted BuTx to label the extract at Ix 106 
counts per ml AChR extract. Divide the mean counts from the I Oýtl counted tubes 
by 10. Then divide Ix 106 by this figure. This will give the volume in ýtl of 
315 
PhD Thesis 2000 
diluted BuTx needed per ml of AChR extract. 
11. Add the required volume of BuTx, mix and leave for a minimum of 10 min 
(ideally more than Ih) before use. 
11. Dilute 25ýd patient sera I/ 10 with PTX, vortex, spin 13,000rpm /5 min. 
12. Add 50ýil / 1041 of the serum dilution to 2 further tubes for each sample (i. e. 2 
rows). 
13. Add 50ýil labelled extract to both rows of tubes, mix, and incubate overnight at 
4'C. 
14. Add 250ýtl diluted sheep anti-human IgG (1: 8 in PTX) to all tubes containing 50ýtl 
diluted sera and 75ýtl to those tubes containing 10ýLl diluted sera. 
15. Leave for Ih at room temp. 
16. Add 800[il / 40OVtl of PTX, mix gently, spin at 13,000rpm /5 min (Bench-top 
U- 
Eppendorf centrifuge). 
17. Remove supernatant by suction, wash pellet twice in further PTX. 
18. Remove excess liquid. Count pellet on automatic gamma counter for I minute 
(Canberra Packard Cobra 11 auto-gamma, Meriden 8, CT, USA). 
7.09 CONVERSION OF OBSERVED COUNTS TO CONCENTRATIONS OF 
ANTIBODY 
Final concentrations of antibody are expressed as pmol /I serum (i. e. pM). 
1. VGCC assays (P/Q and N-type) 
Conversion is dependent on isotope decay. The conversion factor (K) may be 
calculated from a further variable Q) which is date dependent, and taken 
from the 
decay table (below), and the volume of serum used (2.5ýtl for all assays), where: 
K == X (fmol cpm-1) / 2.5ý11 
The final concentrations of antibody are then calculated, where: 
[ab] = (observed cpm - mean control cpm) .K 
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DECAY TABLE (see appendix 7.09) 
S. A. (Ci/mmol 1 cpm -1mol 5 IMOI-Cpm DAYS S. A. (Ci/mmol I cpm-lmol 5 fmol-cpm 
2572 0.000219 22839 21 - T5 6-7 0.000359i 13915 
-28 2556 0.000220 22697 22 -1548 0.000364 13746 
-27 2539 0.000222 
-- 
22546 23 1530 0.000368: 8 -6 
-26 2522 0.000223 22395 24 -1512 - 
2505 0.000225 22244 25 1-495 - 0.000377! 13276 
.; 
24 2488 0,000226 22093 26 1478 0.00038 ýP, -'- -- - -Tý-j'- 25 
-23 ý 2473 
/. 2458 
0.000228 
0.000229 
21960 
21827 
27 
28 
1461 
-1444 
0.0003 1297 
0.000390 12823 
-21 2433 0.000231 21605 29' 1428, 0.000394 - 12681 
-20 2414 0.000233 21436 30 1412 0.0003 12539 
-19, 2396 0.000235 21276 31 1395 0.00040 123 
-18 2378 0.000237 21117 32 1378 0.0004091 12237 
-17 2359 0.000239 2094' ] 33 1362 0-00041311 - -12095 
2340 0.000241 20779 34 1346 0.000418i 11952 
-15 2320 0.000243 20602 35 1331 0-0004-23 [- -118-19 
-14 2300 0.000245 20424 36 1316 0.000428 11686 
-13 2280 0.000247 20246 37 1301 0.0004331 1-1553 
-12 2260 0.000249 20069 38 1286 0.0004381 11420 
2240 0.000251 19891 39r 1271 0.0004431 11286 
-10 2220 0.00025.4 19714 40 1256 0.0004481 11153 1 
1 
--9 
2199 0.0002ý-6 1 9ý27 41 1242 0.000453 11029 
-8 2178 0.000259 19341 42, 1228 . 
0.004590 10905 
-7 2156 0.0002ý1 19145 43 1214 0.000464 10780 
-6 2134 0.000264 18950 44 1200 0.000469 1065Q 
-5 1 2112 0.000267 18755 45 1186 0.000475 10532 
20PO 0.000269 18559 46 1172 0.000480 10407 
-3 2068 0.000272 18364 47 1158 0.000486 10283 
-2 2046 0.000275 18168 48 1144 0.000492 10159 
2023 0.000278 17964 49 1131 0.0004981 10043 
2000 0.000281 1 17760 50 1118 0.0005041 9928 
1977 0.0002851 17556 51 1105 0.0005101 9812 
2 1 1'954 0.0002881 17352 52 1092 0.0005161 9697 
3 1 1932 ; 0.0002911 17156 53 1080 0.000521 1 9590 
4 1 1910 0.000295 16961 54 1068 0.000527 1 9484 
51 1888 1 0.0002ý5 16765 55 1055 0.000534 1 9368 
- - 61 1866 0.000302 16570 56 1042 0.000540 53 ! 92 
7 1,1844 0.000305, 16375 57 1030 0.000547 1 9146 
8 1822 1 0.0003Q9i 16179 58 1018 0.000553 
19 40 
9 1801 0.00031 3 15991. 59 1007 0.000559 i 8942 
10 1780 0.000316 15806 60 996 0.000565 
1 8844 
12 
1760 
1740 
Q. 000320 
0.000324 
15629 
15451 
61 
62 
984 
972 
0.0005721 8738 
0.000579i 8631 
13ý 
141 
17 
1700 
0.000327 
0.000331 
15274 
15096 
63 
64 
961 
950 
0.0005861 8534 
0.0005931 8436 
15 1680 0.000335 14918 65 939 0.060600i 
8338 
16 1660 
-16-4-1 
1622 
0.000339 
0.0-00343 
0.500347 
14741 
ý-14-572 
14403 
66 
-67 
68 
928 
----91-8 
908 
0.000607t__ 8241 
0.000613i 8152 
0.0006201 8063 806ý 
01 Z)z 
19i 1604; 0.000351 14244 
063ý51 zol 1586 14084 
69 
70 
8971 0.000628 7965 6' 
7 68 ý66! 0.6666ý6i'-'- 868 
1 
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e. g. on day - 15 
K=0.000243 (fmol cpm-1) / 2.5ýil 
K=0.243 (pmol cpm-1) / 2.5 1 
K=0.0972 (pmol cpm- 1 1- 1) 
and: [ab] = (observed cpm - mean control cpm) - 0.0972 
2. VGKC and AChR assays 
Conversion factor = 0.1 (not isotope date dependent). Therefore final concentration = (observed cpm - 
mean control cpm) * 0,1 
7.11 TOTAL AND NON-SPECIFIC BINDING CURVES FOR VGCC 
RADIOIMMUNOASSAY. 
1. Perform this every 2 months. 
2. Calculate a quantitative precipitation curve for known strongly positive (LEMS) 
and known negative (healthy control) sera. Total binding is calculated by using 
increasing serum concentrations in the presence of labelled toxin only, and non- 
specific binding, by repeating the assay at each serum concentration in the 
presence of excess unlabelled toxin. The specific binding is calculated at each 
point by subtracting the non-specific binding from the total binding. 
,q 
125j. 
a 7.12 CALCULATION OF VOLUME EQUIVALENT OF 5fMOL I- 
CONOTOXINS 
1. Count actual omission in cpm of I Optl of either diluted 
1251_C0 
-conotoxin. 
2. Find "expected count" using decay table (see below) and knowledge of the time 
period since preparation by the manufacturer (Amersham, UK). N. B "minus" days 
are a nuance of the decay curve and manufacture. 
3. Calculate the volume (x) equal to 5frnol by using the equation: 
acraal cpm / 10 ýLl expected cpm /x 
i. e. on day - 23, if the observed count 
for 10ýtl is 37,000 cpm, then: 
37,000 / 10 = 21,960 / 
and x=6 ýil (I S. D. 
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8.01 SOL UTIONS AND REA GENTS 
All reagents were supplied by MERCK (BDH) Chemicals, Poole, Dorset, UK (not 
stated) or Sigma-Aldrich, Poole, Dorset, UK (Sigma). Stept-ABC kit was supplied by 
DAKO, Ely, Cambridge, UK (kit code K0377). 
Ethanol is absolute unless otherwise stated. IMS = 100% industrial methylated spirits. 
General 
Acid Alcohol 
Scott's Tap Water Substitute 
Fixative and differentiator 
Hotchkiss Periodic Acid 
Hotchkiss Reducing Rinse 
Routine Dyes 
Gill's Haematoxylin 
300ml dH20, 
700ml IMS, 
lOn-d conc. hydrochloric acid. 
(added to 990ml of the above) 
2g potassium hydrocarbonate, 
20g magnesium sulphate, 
I OOOrfll CIH20, 
99rnI 95% ethanol, 
3ml glacial acetic acid. 
0.4g periodic acid, 
5ml 0.2M sodium acetate, 
I Oml dH20, 
35n-il ethanol. 
lg potassium iodide, 
Ig sodium thiosulphate, 
20ml CIH205 
30ml ethanol, 
Iml IM HCl. 
IL dHA 
625ml ethylene glycol, 
I Og haematoxylin, 
Ig sodium iodate, 
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176g aluminium sulphate, 
50ml glacial acetic acid, 
825ml dH20- 
Weigert's haematoxylin 1g haernatoxylin, 
100ml ethanol, 
4ml 30% ferric chloride, 
I OOn'1I CIH20) 
I rnl hydrochloric acid. 
1% Eosin Ig cosin Y, 
100ml dH20- 
Schiff s Reagent Ig basic fuchsin, 
50ml IM hydrochloric acid, 
Ig anhydrous sodium metabisulphate, 
200ml dH20. 
Celestine blue Ig solochrome prune, 
0.5n-d conc. hydrochloric acid, 
100 ml 2.5% iron alum, 
14ml glycerol. 
Alcian blue pH 0.2 - 1% Alcian Blue in 10% sulphuric acid. 
pH 1.0 -I% Alcian Blue Mi 0.1 M hydrochloric acid. 
pH 2.5 - 1% Alcian Blue in 3% acetic acid. 
Congored 0.5g Congo red, 
50ml ethanol, 
50ml dH20- 
Congo red differentiator 0.2g potassium hydroxide, 
100ml 50% ethanol. 
Van Gieson solution 100ml saturated aqueous picric acid, 
10 nil 1% aqueous acid fuchsin. 
Ponceau fuchsin 0.7g Ponceau 2R, 
0.35g acid fachsm, 
Iml glacial acetic acid, 
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Sudan black solution 
Toluidine blue 
Immunohistochemistry 
Endogenous peroxidase 
block (0.3%) 
Antibody diluent 
100ml dH20. 
Saturated Sudan black B (in 70% alcohol). 
Ig toluidine blue, 
Ig sodium tetraborate, 
I 00ml dH20- 
Iml 30% hydrogen peroxide, 
99ml 100% methanol, 
Sodium chloride 4.1 
Tris 0.3g, 
Bovine albumin 0.2g (Sigma), 
Sodium azide 0.2g, 
IM HCI 2ml, 
Casein 50ul (Sigma), 
dH20 500ml. 
Shake well, and adjust to pH 7.6 with 0.1 M sodium hydroxide 
0.05M Tris buffered 
saline pH 7.6 
Sodium chloride 8.76g, 
Tris 6.06g, 
IM HCI 3 6ml, 
dH20 800MI- 
Leave to stand for I hour, and then adjust to pH 7.6 with IM HCI. Make up to IL with dH2() 
Stept-avidin-biotin- complex 
Solution (Strept-ABC) (DAKO) 
Diaminobenzidine 
tetrachloride (DAB) 
solution 
TBS 5ml, 
Solution A&B: I drop. 
0.05M Tris buffered salMe pH 7.6: 10ml, 
DAB 6mg (Sigma), 
Fresh 3% hydrogen peroxide 0.1 ml. 
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Antigen retrieval 
Citrate buffer working solution Citrate buffer stock I 00ml (see below), 
dH20 900MI- 
Place into the large straining trough an, d mix thoroughly with a magnetic stirrer. Whilst still on the 
stirrer, pH to exactly 6.0 with IM sodium hydoxide. 
Citrate buffer stock 
store at 4'C. 
EDTA buffer working solution 
Citric acid 7.56g, 
Trisodium citrate 47.56g, 
CIH20 2000ml. 
EDTA buffer stock I 00ml (see below), 
dH20 900ML- 
Place into the large straining trough and mix thoroughly with a magnetic stirrer. Whilst stirring, pH to 
exactly 8.0 with 1M sodium hydoxide. 
EDTA buffer stock EDTA 3.7g, 
d1420 IOOOMI- 
8.02 S TC TISS UE PR 0 CESSING PR 0 TO COL 
E, - I urfreshly obtained colonic or ileal tissues: 
1. Serosa and pericolic fat +/- any faecal residue removed. 
2. Full thickness sections taken for fixation overnight in: 
a. 10% formal saline. 
b. Zamboni fixative. 
c. Bouin's fixative. 
d. 4% parafon-naldehyde. 
e. Glutaraldehyde for EM. 
3. Full thickness sections embedded fresh in OCT compound (Tissue-Tek, Sakura 
Finetek, Torrance, CA, USA), using liquid nitrogen-cooled isopentane. 
4. Full thickness section frozen fresh in liquid nitrogen. 
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5. Tissue layer separated into mucosa and muscularis propria components and: 
a. Small sections weighed and frozen fresh in liquid nitrogen 
b. Small sections extracted as protocol for future neurotrophin assay studies 
[details not included in thesis, although performed by author] - 
8.03 H&E AND PAS ROUTINE STAINING 
H&E 
I. Dewax section in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Rehydrate in dH20- 
4. Stain in Gill's haernatoxylin for 20 minutes. 
5. Wash in tap water for 5 minutes (Scott's tap water substitute followed by a rinse in tap water may 
be used instead of washing in water. 
6. Differentiate in 1% acid alcohol. 
7. Wash in tap water for 5 minutes. 
8. Stain in eosin for 3 minutes. 
9. Differentiate in tap water. 
10. Blot. 
11. Dehydrate rapidly In IMS x 2. 
12. Clear in xylene x 2. 
13. Mount in Canada balsam. 
PAS 
1. Dewax section in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Treat with Hotchkiss periodic acid solution for 5 minutes. 
4. Wash well in 70% ethanol. 
5. Treat with Hotchkiss reducing rinse for 30 seconds. 
6. Wash well in 70% ethanol. 
7. Stain in Schiff s reagent for 10 - 30 minutes (dependent on the batch of Schiffs reagent in use). 
8. Wash in tap water for 10 minutes. 
9. Stain nuclei in celestine blue for 1 minute. 
10. Wash in tap water for 5 minutes. 
11. Differentiate if required in 1% acid alcohol 
12. Wash in tap water for 5 minutes. 
13. Rehydrate in IMS then xylene x 2. 
14. Mount in Canada balsam 
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D-PAS 
1. Dewax in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Wash with dH20. 
4. Incubate with 0.1% aqueous malt diastase (BDH) at 37'C for 30 minutes. 
5. Repeat as from step 2 of PAS protocol, 
8.04 OTHER ROUTINE STAINING METHODS 
ALCIAN BLUE 
1. Dewax in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Wash with dH20- 
4. Stain in Alcian blue for 30 minutes. 
5. Wash in tap water for 10 minutes. 
6. If required, lightly counterstain in filtered I% aqueous neutral red for I minute. 
7. Blot sections. 
8. Rehydrate in IMS then xylene x 2. 
9. Mount in Canada balsam. 
CONGO RED 
1. Dewax Sections in xylene x 2. 
2. Remove xylene, with IMS x 2. 
3. Stain in Gill's haernatoxylin for 15 minutes. 
4. Wash in tap water for 5 minutes. 
5. Differentiate in 1% acid alcohol. 
6. Wash in tap water for 5 minutes. 
7. Rinse in 70% alcohol. 
8. Stain in filtered Congo red in a coplin jar for 15 minutes. 
9. Blot. 
10. Differentiate in Congo red differentiator. 
11. Wash in tap water for 5 minutes. 
12. Rehydrate in IMS then xylene x 2. 
13. Mount in Canada Balsam. 
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ELASTIC VAN GIESON 
I. Dewax section in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Rehydrate in dH20- 
4. Stain in Weigert's iron haematoxylin solution for 30 minutes. 
5. Wash in tap water for 5 minutes. 
6. Differentiate in I% acid alcohol. 
7. Wash in tap water for 5 minutes. 
8. Stain in van Gieson solution for 3 minutes. 
9. Blot. 
10. Rehydrate in IMS then xylene x 2. 
11. Mount in Canada balsam. 
MASSONS TRICHROME 
I. Dewax sections in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Stain in Weigert's haernatoxylin for 10 minutes. 
4. Wash in tap water for 5 minutes. 
5. Differentiate in I% acid alcohol. 
6. Wash in tap water for 5 minutes. 
7. Stain in Ponceau fuchsin for 10 minutes. 
8. Rinse in dH20, 
9. Differentiate in 1% phosphotungstic acid. 
10. Counterstain progressively in 2% light green. 
11. Rinse in dH20- 
12. Rehydrate in IMS then xylene x 2. 
13. Mount in Canada balsam. 
Phosphotungstic acid haematoxylin (PTAH) 
I Dewax section in xylene x 2. 
2. Remove xylene with IMS x 2. 
3. Treat with 0.25% aqueous potassium permanganate solution for 5 minutes. 
4. Wash in tap water for 5 minutes. 
5. Bleach with 5% aqueous oxalic acid solution. 
6. Wash in tap water for 5 minutes. 
7. Stain in PTAH solution for 12 - 24 hr at room temperature. 
8. Wash in dH20- 
9. Rehydrate in IMS then xylene x 2. 
10. Mount in Canada balsam 
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SUDAN BLACK 
1. Paraffin sections to 70% alcohol. 
2. Stain overnight at room temperature in sudan black solution. 
I Wash in tap water for 5 minutes. 
4. Wash out excess background in 70% alcohol. 
5. Wash in tap water for 5 minutes. 
6. Mount in aqueous mountant. 
TOLUDINE BLUE 
I- Fix in acetic acid for I minute. 
2. Stain in toluidine blue for I minute. 
3. Wash briefly in tap water. 
4. Rinse in ethanol. 
5. Differentiate in acetic alcohol, 
6. Rinse in ethanol. 
7. Clear in xylene 
8. Mount in Canada balsam 
8.04 IMMUNOHISTOCHEMICAL STAINING PROTOCOL USING DAKO 
STREPT-ABC 
1. Dewax (xylene) and rehydrate sections in 2 changes 100% IMS. 
2. Incubate endogenous peroxidase block for 15 minutes. 
3. Wash sections in tap water for 2 minutes. 
4. If antigen retrieval is required (below), go to appropriate procedure. 
5. Transfer to tap water and wash for 2 minutes. 
6. Soak sections in at least 2 changes of TBS for 3 minutes. 
7. Dry carefully around the sections and encircle with PAP (DAKO) pen. 
8. Apply blocking serum for 20 mins: 
polyclonal antibodies: normal swine serum 1: 5 in antibody diluent. 
monoclonal antibodies: normal rabbit serum 1: 5 in antibody diluent. 
9. Drain blocking serum. 
10. Apply primary antibody at the appropriate dilution in antibody diluent for 60 
minutes (antibody diluent only to negative control sections). 
11. Rinse section twice in TBS 
12. Wipe around the sections, and apply secondary antibody for 30 minutes: 
326 
CH-Knowles 
- polyclonal antibodies: biotinylated swine anti-rabbit 1: 200 in antibody diluent. 
- monoclonal antibodies: biotinylated rabbit anti-mouse 1: 200 in antibody diluent. 
13. Make up the Stept avidin-biotin complex solution (Strept-ABC). Vortex, and 
allow to complex for at least 30 minutes before use. 
14. Rinse section twice in TBS 
15. Apply Strept-AIBC for 30 minutes 
16. Rinse section twice in TBS 
17. Apply filtered DAB solution for approximately 10 minutes (examine positive 
control slide for progress of development) 
18. Rinse section twice in TBS 
19. Counterstain (usually Gill's haematoxylin) if necessary 
20. Dehydrate and mount. 
8.05 ANTIGEN RETRIEVAL 
Microwave retrieval 
1. Place sections into black plastic staining rack leaving a gap between the slides. 
2. Place rack into a large glass staining trough containing exactly I 000ml of the 
appropriate buffer. 
3. Cover the trough with cling film and make several holes in the cling film. 
4. Place the trough in the microwave and run at full power for 18 minutes. 
5. With care, remove trough from microwave. 
6. Carefully remove cling film. 
7. Leave sections to stand in the hot buffer for 5 minutes. 
8. Return to original technique (stage 5 of IHC protocol 8.04). 
Trypsin retrieval 
1. Place one empty coplin jar and one filled with dH20in a waterbath at 37T. 
2. Add 0.1 g Trypsin to I 00ml of 0.1 % calcium chloride and mix. 
3. Adjust to pH 7.8 with 0.1 M sodium hydroxide. 
4. Place sections in the preheated dH20 at 3 7'C for I Omins. 
5. Bring trypsin solution to 37T using a hot plate stirrer (do not overheat). 
6. Pour trypsin into the preheated coplin jar. 
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7. Place sections into the trypsin solution at 37T for the appropriate time. 
8. Return to original technique (stage 5 of lHC protocol 8.04). 
Pronase retrieval 
1. Microwave in citrate buffer (above). 
2. Leave sections to stand in the hot buffer for 5 mins. 
3. Wash briefly in dH20. 
4. Treat with Pronase (Protease XIV, Sigma) in PBS pH 7.4. 
5. Return to original technique (stage 5 of IHC protocol 8.04). 
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